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Q U I L L  O N  S C A L P E L  This section
provides a medium through which Canadian 
surgeons can declare themselves, briefly and in­
formally, on the day-to-day affairs of surgery.
MODERN TREATMENT OF BONE TUMOURS
Our understanding of bone tumours has 
shown a steady increase and consequently 
our ability to treat them rationally and 
successfully has made noteworthy progress 
as is indicated by the series of papers from 
the fourth annual conference on the clinical 
application of basic sciences that appear in 
this issue of the journal. During the early 
days of modern surgery, the management of 
bone tumours was hampered by lack of 
knowledge. The clinical, radiologic and 
microscopic criteria that were developed 
and the various tumour entities that were 
delineated just before and after World War 
II resolved much of the previous confusion 
and made possible a satisfactory classifica­
tion of bone tumours that provides a basis 
for investigators and clinicians to communi­
cate their results to one another. The classi­
fication presented by K. K. Unni in this 
issue (page 504) is the one generally ac­
cepted and it is not likely to be appreciably 
modified in the future.
Progress has also been made in under­
standing the etiology of some of the malig­
nant tumours of the osseous system. It has 
been recognized for some time that ionizing 
radiation can cause malignant disease. Trau­
ma as an etiologic factor has long been 
suggested by the clinical history of some 
cases and experimental work now indicates 
that a viral etiology is not outside the realm 
of possibility. However, it must be recog­
nized that the experimental work that has 
been carried out so far is important more 
because of its future promise than for any 
actual assistance it has been to the patient 
suffering from malignant disease. The 
existence of experimental models has pro­
vided a more solid foundation for the modern 
approach to therapy by permitting the estab­
lishment of controlled situations that would 
not be possible in clinical practice.
A better understanding of the host re­
sponse to tumours has provided exciting and 
convincing evidence that there are indeed 
defence mechanisms for the destruction of 
tumours or the limitation of their growth. 
This had been suggested many years ago and 
now appears to be established as fact. Once 
more there can be hope that a better under­
standing of these processes will allow more 
rational manipulation of the natural defences 
and perhaps better therapeutic results.
Finally, the combination of newer meth­
ods of therapy, immunologic and chemothe­
rapeutic, together with aggressive surgical 
resection and often replacement with either 
custom-made parts or allografts, give hopes 
for the future. Surgical extirpation of malig­
nant tissue remains the best means of cure. 
Aggressive surgery for metastases combined 
with chemotherapy to prevent the develop­
ment of further spread of the tumour has 
in some centres obtained gratifying results. 
Where surgical ablation of the tumour would 
otherwise lead to unacceptable loss of func­
tion of a limb, replacement with a prosthe­
sis or a graft has also given early promise.
Several facts have become apparent in 
assessing the present status of the manage­
ment of bone tumours. In the first place, 
such tumours are rare. If real progress is to 
be made in their management, regionaliza­
tion of facilities must be accepted in order 
that sophisticated therapy can be made 
available to all. This is the only way in 
which meaningful data can be obtained 
about the results of therapy. Secondly, it is 
nO longer possible for one individual to 
supply the total management of all aspects 
of bone tumours. A multidisciplinary ap-
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proach is mandatory in order to bring the 
greatest expertise to each individual pa­
tient. Finally, it must not be forgotten that 
the quality of life of the survivor after he 
has received treatment for cancer is of great 
importance. This area is frequently neglected 
and must be taken into account in order 
that the patient and his medical team may 
make rational decisions.
The papers published in this issue pre­
sent many aspects of the status of present- 
day therapy of some selected tumours. It is 
hoped that future work will give us a better 
understanding of the etiology of not only 
malignant disease but some of the lesions of 
the musculoskeletal system that are called
GLIMPSES OF SURGICAL HISTORY: R FOR RELIGION AND ROYALTY
DAVID A. E. SHEPHARD
In his caves and forest haunts, primitive man 
attributed disease to human possession by 
demons. The remedy was to cast out the evil 
spirit through the agency of the good — 
priests and kings. Thus were early medicine 
and surgery shaped by RELIGION and 
R O Y A L T Y .
In Babylon and ancient Egypt priests and 
physicians were as one; temples served the sick 
as well as God. But the priest-physicians served 
medicine in another way: they kept alight the 
lamp of medical learning in the corridors of 
time, which were swept by the winds of magic. 
In time, however, it was the religious view 
that disease reflected divine purpose, with the 
intellectual emphasis solely on theological 
matters, that made the lamp flame weakly. 
Until scientific learning was accepted as fruit­
ful, heretics and heathens kept the lamp 
aburning. Today, hospital chaplains are there­
fore welcome cohealers with surgeons and 
other physicians.
Kings and emperors were healers too: the 
“royal touch” for scrofula demonstrated one 
aspect of the divine right of kings —  though 
the father of English surgery, Richard Wise­
man (1622-76), showed what mere mortal 
surgeons could do for citizens who did not 
have the benefit o f the royal touch. William
tumours but are actually quite different from 
lesions of other parts of the body. A second 
hope is that we may be able to form a true 
assessment of the effects of the types of 
therapy described in the following articles, 
both on the tumour and on the individual. 
Only time will tell whether aggressive sur­
gical resection accompanied by replacement 
of the resected part will give long-term 
satisfactory results.
R. L. Cruess, m d , frcs[c]
Professor and chairman,
Division of orthopedic surgery,
McGill University,
Montreal, PQ.
I ll of England, too, was aware that the royal 
touch had suggestive rather than divine 
powers: to the few citizens he did touch he 
expressed the good advice, “God grant you 
better health and more sense,”
Royal rulers have influenced medicine and 
surgery in various ways. Some Chinese em­
perors were investigators as well as editors 
and authors. Shen Nung, about 3000 BC, 
was one such: he experimented on himself 
with drugs and poisons and compiled The 
Great Herbal, an English edition of which was 
published as recently as 1911. Hwang Ti, about 
2500 BC, wrote the Nei Ching, in which he 
stated that “all the blood in the body is under 
the control of the heart.. . . The blood current 
flows continuously in a circle and never stops.” 
In the West, kings and queens supported 
medicine by patronizing the medical profes­
sion: the first royal medical college was 
formed in 1551, after Henry VIII had granted 
letters patent to Thomas Linacre. The sur­
geons’ royal college in England was formed 
in 1800, the Company of Barber Surgeons in 
1540.
But monarchs, who were also mortals, 
needed medical care. Thus we find expressions 
such as a la reine attached to anesthesia. And  
no doubt Simpson, when anesthetizing Queen 
Victoria, called on the double powers of reli­
gion and royalty to help him in his courtly 
task —  and the queen herself on her own re­
markable powers.
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S E L F - A S S E S S M E N T
SESAP II QUESTION
609. The roentgenogram shown above demonstrates changes in the distal end of the 
femur of an 18-year-old girl. A diagnosis is established by biopsy.
If there is no evidence of distant metastases, the treatment of choice for this patient is
(A) hemipelvectomy
(B) disarticulation of the hip
(C) irradiation and chemotherapy
(D) irradiation followed by midthigh amputation
(E) midthigh amputation alone
For this incomplete statement select the one completion that is BEST from those noted 
above.
For the critique of Item 609 see page 575 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Syllabus: 
Surgical Education and Self-assessment Program No. 2.)
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MODERN CONCEPTS OF BONE TUMOUR TREATMENT
INTRODUCTION
H. K. UHTHOFF, MD, FRCS[C]* and J. E. HARRIS, MD, FRCP[C], FACPt
R e c e n t  progress in the diagnosis and treat­
ment of malignant tumours of bone has 
markedly improved the prognosis in disease 
once thought to be fatal, especially in 
younger persons. It is not so long ago that 
surgical intervention was considered by 
many to be practically futile, and survival 
of a patient for more than 5 years was 
grounds for doubting the original diagnosis.
Better treatment can be achieved only 
through a clear understanding of the basic 
principles involved, and therefore the divi­
sion of orthopedic surgery, University of 
Ottawa, in collaboration with the service 
of oncology and in association with the 
Royal College of Physicians and Surgeons 
of Canada, organized in May 1977 an ap­
plied basic science course entitled “Modern 
Concepts of Bone Tumor Treatment”.
An outstanding faculty of internationally 
known experts came to Ottawa to discuss 
refined methods of diagnosis and diverse 
modalities of treatment. It became clear 
from their presentations that in treating pa­
tients with malignant disease a multidisci­
plinary approach is mandatory. This pro­
duces results so gratifying that for the first
*Chief, department of orthopedic surgery, Otta­
wa General Hospital, Ottawa, Ont.
tDirector, laboratory of immunloogy, Ottawa 
General Hospital.
Reprint requests to: Dr. H. K. Uhthoff, Chief, 
department of orthopedic surgery, Ottawa General 
Hospital, Ottawa, Ont. K IN  5C8.
time one dares to speak about cure of ma­
lignant bone tumours. Moreover, when 
surgery is indicated, the use of prostheses 
makes it possible to avoid the mutilation 
that once would have resulted from exten­
sive resection of tissue. In large part these 
advances have been made possible through 
early postsurgical intervention with new 
programs of adjuvant chemotherapy. The 
introduction into clinical use of agents such 
as doxorubicin (Adrianmycin) and the grow­
ing experience with high-dose methotrexate 
therapy followed by citrovorum factor 
rescue have provided effective treatment in 
patients who have minimal residual disease 
following surgical resection of bone tu­
mours. For the first time, too, beneficial 
chemotherapy has become available for pa­
tients with bone tumours who have disse­
minated disease. The influence of these wel­
come developments is becoming evident in 
the increased duration of disease-free in­
tervals and prolongation in patients’ survival. 
This new and exciting area in the treatment 
of cancer by chemical agents is considered 
in detail in the papers that follow. New in­
sights into the etiology and immunology of 
bone tumours and their possible application 
to future programs of chemotherapy or 
chemoimmunotherapy also receive attention.
We are grateful to all the participants in 
the symposium for their outstanding con­
tributions and to the coeditors of the Cana­
dian Journal of Surgery for enabling us to 
publish many of the papers presented.
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BONE SARCOMAS: ETIOLOGY AND IMMUNOLOGY*
JOSEPH G. SINKOVICS, MD, FACP,t HARIKISHAN THOTA, PhD,t JIMMY 
J. ROMERO, BS and RUTH WALDINGER, RN
The etiology of skeletal sarcomas is found in 
exogenous agents (irradiation, oncornavirus) act­
ing in a peculiar setting of host factors. Patients 
with skeletal sarcomas react immunologically to 
autologous and allogeneic sarcoma cells, but 
reactors can be found among the healthy persons 
with or without exposure to patients with sar­
comas. Various modalities of immunotherapy are 
available to increase the patient's immune reac­
tivities in general or to sarcoma cells in partic­
ular, but immunotherapy of skeletal sarcomas 
has not yet brought about clear-cut and sub­
stantial benefits in addition to or beyond the re­
sults of conventional treatment.
L'etiologie des sarcomes du squelette se re- 
trouve dans certains agents exogenes (irradia­
tion, virus oncorna) agissant a I'interieur d’un 
ensemble particulier de facteurs endogenes. Les 
patients souffrant de sarcome du squelette rea- 
gissent immunologiquement a des cellules sar- 
comateuses autologues et allogenetiques, mais 
les repondants peuvent etre retrouves parmi les 
personnes saines, avec ou sans contact avec 
des patients atteints de sarcome. Divers modes 
d'immunotherapie sont disponibles pour aug- 
menter chez le patient la reponse immunologi- 
que non specifique, ou specifique aux cellules 
sarcomateuses en particulier, mais I’immuno- 
therapie des sarcomes du squelette n'a pas 
encore procure de benefices evidents ou subs- 
tantiels, ajoutes ou superieurs aux resultats du 
traitement conventionnel.
T he etiology of skeletal sarcomas profound­
ly influences the immunology of the host- 
tumour relationship. If these tumours are
*From the section of clinical tumor virology and 
immunology, department of medicine, The Uni­
versity of Texas System Cancer Center, M. D. 
Anderson Hospital and Tumor Institute, Houston, 
TX.
Supported by the Kelsey-Leary Foundation of 
Houston and by Biomedical Research grant no. 
RR511-14, allot. BR-04.
Presented at the conference “Modern Concepts 
of Bone Tumor Treatment”, Ottawa, Ont., Mav 
12 and 13, 1977.
tInvited guest lecturer of the Royal College of 
Physicians and Surgeons of Canada.
t Deceased.
^ P ™ 1; requests to: Dr. J. G. Sinkovics, Section 
ot clinical tumor virology and immunology, de- 
partment of medicine, M. D. Anderson Hospital 
and lumor Institute, Houston, TX 77030, USA.
induced by viruses in man (as they are in 
mice) it should be possible to identify cross- 
reactive sarcoma-specific antigens and to 
use these to monitor the host’s immune 
reaction to the tumour, quantitate the tu­
mour burden and offer a prognosis for the 
disease. Such antigens may also be useful 
for immunotherapy.
E tiology
Overlapping Features of Sarcomas
Tumours originating in the mesenchymal 
cells of osseous or cartilaginous structures 
cannot be regarded as distinct from sar­
comas originating in soft tissues. These 
tumours exhibit overlapping features as the 
undifferentiated mesenchymal cells of ori­
gin reach various degrees of differentiation 
towards connective tissue (fibroblasts), fat 
tissue (lipocytes), muscle (striated and 
smooth muscle myocytes), and cartilage and 
bone (chondrocytes and osteocytes). Two 
examples of this overlap are osteocytic and 
chondrocytic tumours originating in soft 
tissues1"5 and chondrocytic elements in 
metastatic soft tissue sarcomas such as cys- 
tosarcoma phylloides.4
Induction by Radiation
The etiology of sarcomas is unknown. 
Trauma is often recorded as preceding sar- 
comagenesis. Since bone infarcts have been 
shown to give rise to osteogenic sarcomas in 
man,5 trauma cannot be dismissed as a 
possible etiologic factor in the development 
of sarcomas. On the other hand, one may 
surmise that trauma is coincidental and that 
subclinical sarcoma existed before the in­
jury.
The best documented physical factor in 
sarcomagenesis in man, especially in the 
etiology of osteogenic sarcoma, is ionizing 
radiation either in the form of bone-seeking 
radionuclides or external irradiation.5' 6 
Numerous reports of radiation-induced sar­
comagenesis in man have been published. 
In some, massive doses of irradiation 
(13 000 rad for retinoblastoma), in others
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minimal doses of irradiation (800 rad for 
bursitis)7 resulted in the later development 
of osteogenic sarcoma. Postirradiation osteo­
genic sarcomas originate in extraosseous tis­
sues: in the peritoneum and abdominal 
cavity after radiotherapy for colonic, uterine 
cervical or ovarian carcinoma;8* '*’ and at 
the base of the brain (suprasellar) after ra­
diotherapy for pituitary tumours.10 The de­
velopment of true osteogenic sarcoma may 
follow successful radiotherapy for Ewing’s 
sarcoma.11 Therapeutic irradiation can also 
give rise to chondrosarcomas.12* 13
Host Factors
The most remarkable host factors influ­
encing sarcomagenesis in man are von 
Recklinghausen’s disease, Paget’s disease, 
Albright’s syndrome, Ollier’s disease and 
Maffucci’s syndrome.14* 13 The association 
of osteogenic sarcoma with Paget’s disease 
is remarkable. The incidence of osteogenic 
sarcoma in the general population of West­
ern countries occurs in two peaks: the first 
occurs in the 2nd decade, the second in 
more advanced age groups. The second peak 
of incidence may be correlated with Paget’s 
disease. In Japan, where the incidence of 
Paget’s disease is very low, the second peak 
of osteogenic sarcoma is absent.14 Paget’s 
disease has recently been attributed to a 
slow virus infection inasmuch as possible 
subviral structures were observed in the 
nuclei and cytoplasm of osteoclasts from 
patients with osteitis deformans.10 Paget’s 
disease alone has been considered to be a 
malignant disease of osteoclasts17 and it is 
somewhat responsive to treatment with 
mithramycin, actinomycin D and, sympto­
matically, to salmon calcitonin. Chondro­
sarcomas frequently arise from enchon- 
dromas of Ollier’s disease.13 However, the 
most important factors in sarcomagenesis 
may be viral and immunologic.
Oncornaviruses
Oncornaviral etiology for human sarco­
mas (including osteogenic sarcoma) may be 
considered on the basis of a number of ex­
perimental data. The most important of 
these are the phenomena of antigenic con­
version and focus formation.18-20 When 
cell-free filtrates of human sarcomas are
inoculated into cultures of normal human 
fibroblasts, some of these fibroblasts begin 
to express new antigens that were not pre­
sent in uninoculated fibroblasts; these anti­
gens react in immunofluorescence tests with 
antisera directed towards human sarcoma 
cells. Furthermore, some of the inoculated 
fibroblasts undergo a change in their growth 
pattern and relation to neighbouring cells; 
these “transformed” fibroblasts assume a 
rounded shape and pile up on each other, 
disregarding contact inhibition and thus 
growing in foci.21 These changes can be 
explained best by the transfer from sarcoma 
cells to the fibroblasts of an oncogenic viral 
genome. Genome fragments of oncornavi­
ruses have been actually demonstrated in hu­
man sarcoma cells,22 but a fully character­
ized virus strain has not been isolated from 
human sarcomas. The sighting of oncor­
navirus particles or possible subviral struc­
tures23 in an occasional sarcoma cell or in 
a tissue culture cell line derived therefrom 
is the weakest argument for viral etiology 
in so far as nononcogenic endogenous on­
cornaviruses also exist in both normal and 
tumorous tissues.
Strong supporting evidence for the on­
cornaviral etiology for human sarcomas (in­
cluding osteogenic sarcoma) comes from the 
animal world. Not only avian species carry 
well-known oncogenic viruses, but small 
mammals, New World monkeys and apes 
also yield well-characterized oncogenic on­
cornaviruses; most of these viruses cause 
leukemias and lymphomas, but true oncor­
navirus-induced soft tissue and skeletal 
sarcomas have been identified in mice, rats 
and lagothrix (woolly) monkeys. Most of 
the sarcomagenic viruses of animals are in­
complete and cannot code for the synthesis 
of the viral envelope in the host cells. There­
fore, although the viral genome is present 
in the host cell, no mature virions are 
formed; that is, most of these sarcomas are 
nonproducers of virus. Coinfection with 
leukemia viruses contributes the viral ge­
nome fragment necessary for the synthesis 
of viral envelopes. Host cells coinfected with 
sarcoma and leukemogenic oncornaviruses 
release fully mature, enveloped sarcomagenic 
viruses. Among the attempts to apply this 
principle for the rescue of a hidden human
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sarcoma virus, one of the most remarkable 
is the inoculation of cultured human sar­
coma cells with human leukemia cells. In­
teresting cell transformations and antigenic 
changes occur in these cultures, 24 but 
neither the visualization nor the isolation or 
identification of a human sarcoma virus has 
so far been accomplished.
Other evidence for the possible viral 
etiology of human sarcomas derives from ex­
periments in hamsters. The incidence of 
“spontaneous” osteogenic sarcomas in most 
hamster colonies is exceedingly low. How­
ever, after the inoculation of filtrates from 
human osteogenic sarcomas, several ham­
sters developed osteogenic sarcomas. 25 Sera 
from patients with osteogenic sarcoma re­
acted immunologically with the hamster 
osteogenic sarcomas; thus it can be implied 
that these tumours were induced by a hu­
man osteogenic sarcoma virus. 26
I mmunology and Immunotherapy
Immune Assays Claimed to be Tumour-
Specific
A strong argument for the immunosur- 
veillance of the host against tumour cells is 
to be found in the increased incidence of 
leukemias, lymphomas and some other tu­
mours in naturally immunodefective indi­
viduals or in immunosuppressed recipients 
of organ transplants. With the exception of 
Kaposi’s sarcoma, sarcomas are not among 
those tumours whose incidence has been 
recorded as increasing in immunoincompe- 
tent individuals. Nevertheless, strong evi­
dence for both antibody- and cell-mediated 
immune reactions against both soft tissue 
and skeletal sarcomas in man has been do­
cumented. The antibody-mediated reactions 
are immunofluorescence,15’ 18’ 27- 2S com­
plement fixation with soluble sarcoma an­
tigens,31’ 32 agglutination of erythrocytes 
coated with a soluble osteogenic sarcoma 
antigen33 and potentiation or blocking of 
lymphocyte-mediated cytotoxicity.20’ 21> 34 
The cell-mediated reactions are lymphocyte 
proliferation in response to exposure to sar­
coma cell membranes or soluble sarcoma 
antigens, 33"35 lymphocyte- or macrophage- 
mediated cytotoxicity15’ 20’ 34’ 36 and re­
lease of migration inhibitory factor after
exposure of lymphocytes to sarcoma anti­
gens. 37 However, the question of what the 
human sarcoma-associated antigens are is 
still unresolved and controversial. Are these 
antigens truly cross-reactive? And to what 
extent? Among soft tissue sarcomas only? 
Among soft tissue and skeletal sarcomas 
with the exception of Ewing’s sarcoma? And 
what is the meaning of the immune reactions 
to these antigens in clinical terms? That is, 
can these immune reactions be intensified 
by immunotherapy to the benefit of the 
host? The existence of virus-related or 
virally coded human sarcoma antigen has 
not so far been proved; instead, a wide re­
activity to Forssman and embryonic anti­
gens expressed by human sarcoma cells has 
been demonstrated in the general popula­
tion and in patients with various tumours, 
among them soft tissue and skeletal sar­
comas. 38"40 The reactivity of healthy in­
dividuals exposed to sarcoma-bearing pa­
tients is most conspicuous. 41'43 The exist­
ence of a unique soluble osteogenic sarcoma 
antigen has been demonstrated by absorbed 
xenoantisera: antisera were produced in 
rabbits immunized with extracts of human 
osteogenic sarcoma; and it was demon­
strated that the sera, after extensive absorp­
tion with normal tissues, reacted with osteo­
genic sarcoma extracts in vitro and with 
osteogenic sarcoma cells in vivo, 44
General Immunocompetence
The general immunocompetence of pa­
tients with sarcomas can be assessed in vivo 
by skin tests to various recall antigens and 
to primary antigens, such as dinitrochloro- 
benzene (DNCB) or keyhole limpet hemo- 
cyanin, and in vitro by antibody or by lym- 
phocyte-blastogenic response to various anti­
gens. It has been claimed that primary skin 
sensitization to DNCB correlates with 
clinical stage and prognosis, 45 but patients 
with advanced melanomas or sarcomas may 
retain their ability to react to this primary 
antigen or to recall skin test antigens.46’ 47 
Patients with soft tissue sarcomas yielded 
lymphocytes reactive to phytohemagglutinin 
(PHA); however, reactivity to concanavalin 
A has been claimed to be reduced.48' 40 
The immune reactivity of patients with 
osteogenic sarcoma still remains controver-
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sial. One group50 has claimed that the lym­
phocytes of these patients cannot distinguish 
autologous osteogenic sarcoma cells from 
normal fibroblasts, but reactivity to PHA is 
intact. Another group51 detected a profound 
defect in the reactivity of lymphocytes from 
patients with osteogenic sarcoma to PHA; 
the lymphocytes of patients with soft tissue 
sarcomas reacted normally.51 These “non­
specific tests” failed to correlate with the 
clinical course of 50 patients with soft tissue 
and skeletal sarcomas, but lymphocyte- 
mediated cytotoxicity as expressed against 
cultured allogeneic sarcoma cells correlated 
well with the patients’ clinical course.47
Experience with a Cytotoxicity Assay
Immunologic studies of human tumours 
had a difficult beginning in our laboratories. 
The results of lymphocyte-mediated cyto­
toxicity assays, set against primary cultures 
or early passages of sarcoma cells during 
the second half of the 1960s were disap­
pointing. Primary and early cultures con­
tained too many fibroblast-like cells that 
grew out well even when cytotoxicity to­
wards small numbers of presumably neo­
plastic cells was noticed. Thus the overall 
view of the cultures did not express whether 
or not cytotoxicity occurred.52 In one 
study53 some preparations of lymphocytes 
were found to be nonselectively cytotoxic 
against a battery of different tumour cells 
(this report contains the earliest description 
of nonselectively cytotoxic human lympho­
cytes). Though only a few healthy lympho­
cyte donors were tested, reactors were found 
among them.54 However, when, in 1968, a 
patient with chondrosarcoma was found who 
repeatedly yielded lymphocytes highly and 
selectively cytotoxic to autologous tumour 
cells but not to autologous fibroblasts,15- 55 
it became possible to design an assay, first 
in a Leighton tube and later in Lab Tek 
chamber/slide cultures that quantitatively 
measured lymphocyte-mediated cytotoxicity 
against established human tumour cell lines; 
this assay also measured serum factors 
synergistic with (potentiating), or antago­
nistic to (blocking), cytotoxic lympho­
cytes.20, 30, 34 The interpretation of re­
sults obtained with this assay was difficult, 
because extensive cross-reactions between 
unrelated human tumour cell lines56 and
reactivity to human tumour cells in healthy 
persons57 were also found. These nonse- 
lective immune reactions may be mediated 
by “natural killer cells” or may be the re­
sult of true tumour immunity that is unex­
pectedly prevalent in the human population 
on account of frequent exposure to tumour 
viruses of low pathogenicity or frequent re­
jection of incipient subclinical tumours. 
Since these immune reactions were meas­
ured against established allogeneic human 
tumour cell lines, more trivial explanations, 
such as immune reactivity to HLA, blood 
group, Forssman, embryonic and bovine 
protein antigens expressed by the target 
tumour cells, are also possible. The overall 
reactivity of patients with sarcomas, how­
ever, was more frequent and stronger to­
wards cultured sarcoma cells than towards 
cultured carcinoma cells.58
Correlation of lymphocyte-mediated cy­
totoxicity and its blocking or potentiation by 
serum factors with the clinical course of the 
patients was not always clear. Excellent 
correlation was found in a few selected pa­
tients, among them a patient with chondro- 
blastic osteogenic sarcoma,59 and another 
with a small round cell tumour with high 
glycogen content (this tumour was first 
thought to be a rhabdomyosarcoma, but was 
established later to be an extraosseous 
Ewing’s sarcoma).20 In other patients con­
tradistinctions between the clinical course 
and the cytotoxicity assay were evident.60 
These could be attributed, among other 
factors not clearly understood, to the growth 
of sarcomas without the expression of 
tumour antigens in the immunoreactive hu­
man host.60
Tables I to III present a review of our 
limited experience with lymphocyte-me­
diated cytotoxicity assays as applied to the 
evaluation of patients with bone sarcomas. 
In these tabulations cytotoxicity measured 
against carcinoma, melanoma, soft tissue 
sarcoma, chondrosarcoma and Ewing’s sar­
coma cell lines is expressed. These human 
tumour cell lines, which were established in 
our laboratories, have been described pre­
viously.30, 54, 61 Unfortunately these pa­
tients were not extensively tested against a 
bona fide osteogenic sarcoma cell line for 
the following reasons: cell line no. 2322 
established in our laboratory was believed
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to have been derived from a patient with 
chondroblastic osteogenic sarcoma; several 
patients were tested against this cell line. 
However, the tissue diagnosis in this case 
was later revised to chondrosarcoma grade 
3 (i.e., a tumour with numerous mitotic 
figures). Accordingly, patients tested against 
this cell line are listed in Tables I to III as 
tested against chondrosarcoma (including 
another bona fide chondrosarcoma cell line 
of ours, no. 2454). An alleged human os­
teogenic sarcoma cell line obtained from an­
other laboratory was briefly introduced in 
our assay system but was found to be con­
taminated with mycoplasma and therefore 
its use was discontinued (results obtained 
with this cell line are omitted from Tables 
I to III). Thus, these assays lack data ob­
tained with osteogenic sarcoma target cells, 
so that the interpretations offered should be 
viewed as preliminary and incomplete. Pa­
tients with chondrosarcoma (Table I) ap­
peared to retain lymphocyte-mediated cy­
totoxicity towards carcinoma cells not dif­
ferent from the degree of cytotoxicity ex­
pressed by healthy donors.57 Strong cyto­
toxicity towards soft tissue and chondrosar­
coma cells was expressed equally well.
Table II contains similar data; many pa­
tients with osteogenic sarcoma retained lym­
phocytes cytotoxic to carcinoma cells at 
about the same level as that observed in 
healthy individuals57 and though there is no 
clear distinction, based on lymphocyte-me­
diated cytotoxicity, between soft tissue and 
chondrosarcoma target cells, strong reactions 
(I reactions) were more numerous against 
chondrosarcoma than against soft tissue 
sarcoma cells.
Table III suggests that patients with 
Ewing’s sarcoma form a unique group. 
Lymphocyte-mediated cytoxicity was over­
whelming towards our established Ewing’s 
sarcoma cell line no. 1846;30 reactivity to­
wards carcinoma cell lines was weak and 
towards soft tissue and chondrosarcoma 
cell lines was moderate. These data appear 
to be in agreement with the existence of at 
least one common human sarcoma antigen 
(among many sarcoma-associated antigens) 
and warrant the immunologic separation of 
Ewing’s sarcoma from the classic bone sar-
TABLE I.—Cytotoxic Lymphocytes of 21 P atients with Chondrosarcoma
Cytotoxicity mediated, by
Lymphocytes Serum and lymphocytes
Target tumour cells St-0 i /
i +  1 /
no. blood 
samples 
tested CTX, % Sl-0 i I
i +  1/
no. blood 
samples 
tested CTX, %
Carcinoma/malignant melano­
ma cell lines........................... 17 6 3 9/26 35 14 5 7 12/26 46
Soft tissue sarcoma cell lines. . 3 2 5 7/10 70 2 4 3 7/9 78
Chondrosarcoma cell lines. . . . 6 10 10 20/26 77 6 6 14 20/26 77
St = stimulatory to growth of target cells; O = growth of target cells neither inhibited (<  25%) nor sti­
mulated (<  25%); i = inhibition of growth (cytotoxicity), 25-50%; I =  inhibition of growth (cytotoxicity) 
> 51%; CTX = cytotoxicity.
TABLE II.—Cytotoxic Lymphocytes of 19 P atients with Osteogenic Sarcoma
Cytotoxicity mediated by
Lymphocytes* Serum and lymphocytes
i + 1 / ' i + I /
no. blood no. blood
Target tumour cells St-0 i I
samples
tested CTX,  % St-0 i /
samples
tested CTX,  %
Carcinoma/malignant melano­
ma cell lines........................... 10 7 1 8/18 44 11 4 5 9/20 45
Soft tissue sarcoma cell lines. . 2 4 2 6/8 75 1 4 2 6/7 86
Chondrosarcoma cell lines . . . . 9 5 15 20/29 69 8 5 15 20/28 71
*For abbreviations, see Table I.
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TABLE III.—Cytotoxic Lymphocytes of 14 Patients with Ewing’s Sarcoma
Cytotoxicity mediated by
Lymphocytes* Serum and lymphocytes
i +  / /  i +  / /
no. blood no. blood
samples samples
Target tumour cells St-0 i / tested CTX, % St-0 i I tested CTX,  %
Carcinoma/malignant melano­
ma cell lines........................... 14 3 0 3/17 18 12 4 1 5/17 29
Soft tissue sarcoma cell lines. . 6 0 4 4/10 40 4 2 4 6/10 60
Chondrosarcoma cell lines. . . . 6 3 2 5/11 45 5 4 2 6/11 54
Ewing’s sarcoma cell lines....... 0 3 6 9/9 100 1 2 7 9/10 90
*For abbreviations, see Table I.
TABLE IV.—Immune R eactions of a Patient with Chondroblastic Osteogenic Sarcoma to Cul­
tured Sarcoma (Sc) and Carcinoma (Cc) Cell L ines
Target cell
lines tested % reduction Significance
------------------Attacker No. of of target (Student’s
Sample Type No. cells tests cells, mean t test)
a ................................................... Sc 3 L 11 47 a vs. c, P  <  0.05
b ................................................... Sc 3 S eL  11 57
c ...................................................  Cc 1 L 5 12
d ................................................... Cc 1 S eL  5 24
e ...................................................  Sc 2 Ly 8 0 e vs. g, P <  0.05
f .................................................... Sc 2 Se Ly 8 54
g ................................................... Cc 1 Ly 3 —33*
h ................................................... Cc 1 Se Ly 3 10
“Growth stimulation instead of inhibition.
L = leukocytes, Ly =  lymphocytes; Se = serum.
comas (chondrosarcoma and osteogenic 
sarcomas).
Table IV summarizes the results of 
serially performed assays with the leukocytes 
and lymphocytes obtained from a patient 
with chondroblastic osteogenic sarcoma 
who had an unusually long clinical 
course.r’4' 59 The leukocytes or lympho­
cytes of this patient reacted against sarcoma 
cells better than against carcinoma cells; the 
patient’s lymphocytes stimulated the growth 
of carcinoma cells. Despite immune reac­
tions displayed toward sarcoma cells and 
despite the intensification of these immune 
reactions after immunotherapy,”’4 this pa­
tient succumbed to recurrent and metastatic 
disease. The same fate befell a similar pa­
tient whose sarcoma-directed immune re­
actions increased after immunotherapy but 
failed to arrest clinical progression of the 
disease.62 In a young girl with osteogenic 
sarcoma metastatic to the lungs, sarcoma 
cells were distinguished from carcinoma 
cells by the in vitro assay, and serum factors 
potentiating lymphocyte-mediated cytotox­
icity towards bone sarcoma cells were evi­
dent; despite this favourable reaction pattern 
she succumbed to advancing disease resist­
ant to doxorubicin (Adriamycin) (Table V). 
Table VI summarizes the test results in two 
elderly men with metastatic chondrosarco­
ma. In one patient chondrosarcoma and 
carcinoma cells were clearly distinguished, 
whereas in the other the reaction to chon­
drosarcoma and carcinoma cells in the in 
vitro assay was equal- Despite advancing
TABLE V.— Immune Reactions of a P atient 
with Osteogenic Sarcoma to Cultured Sarcoma 
and Carcinoma Cell L ines
Target cell 
lines tested
Attacker
cells*
% reduction of 
target cells, 
mean
Osteogenic and
chondrosarcoma. . . . . L 83
Se L 73
Ly 14
Se Ly 41
Squamous carcinoma. . . L 36
Se L 44
Ly — 17f
Se Ly 10
*For abbreviations, see Table IV.
(Growth stimulation instead of inhibition.
500 THE CANADIAN JOURNAL OF SURGERY Vol. 20
disease their lymphocytes exercised good 
cytotoxic function towards allogeneic cells 
in vitro. Patients with Ewing’s sarcoma 
appeared to react vigorously towards soft 
tissue sarcoma cells. In 1972 one patient 
with a primary tumour in the right foot 
metastatic to lungs and skull entered com­
plete remission after radiotherapy and 
chemotherapy with vincristine, cyclophos­
phamide and actinomycin D, but in 1973 
recurrent disease was resistant to doxoru­
bicin and dimethyl-triazeno-imidazole car­
boxamide. The leukocytes and lymphocytes 
of this patient were highly reactive towards 
various soft tissue sarcoma cells (Table VII) 
but not towards carcinoma cells; a serum 
factor potentiating lymphocyte-mediated cy­
totoxicity toward sarcoma cells was opera­
tional. Another young man with Ewing’s 
sarcoma also yielded leukocytes or lym­
phocytes reactive to sarcoma cells (including 
Ewing’s sarcoma cell line no. 1846) but not 
to a squamous carcinoma cell line. A serum 
factor blocking lymphocyte-mediated cyto­
toxicity towards the sarcoma cell lines was 
demonstrated in correlation with progressive 
disease (Table VII).
Similar immune reactions were detected 
in family members of patients with skeletal 
sarcomas, including Ewing’s sarcoma; four 
families were studied (Kay HD, Thota H, 
Sinkovics JG: Unpublished data). However, 
some healthy blood donors also displayed 
such reactions.57 One patient with Paget’s 
disease reacted vigorously to cultured os­
teogenic sarcoma cells, and one patient with
a giant cell tumour of the lumbar vertebrae 
that became malignant after radiotherapy 
and excision displayed a complete lack of 
reactivity towards osseous and soft tissue 
sarcoma cells (Kay HD, Thota H, Sinkovics 
JG: Unpublished data).
In conclusion, antibody- and cell-medi­
ated immune reactions both in autologous 
and allogeneic settings are evident in pa­
tients with skeletal sarcomas, but the rela­
tion of these immune reactions to the pa­
tients’ clinical course is unclear. Similar im­
mune reactions are also detectable in 
healthy individuals with or without known 
contact with sarcoma-bearing patients.
Immunotherapy
Immunotherapy in patients with skeletal 
sarcomas has not been rewarding, but it 
holds promise for further development. The 
following modalities of immunotherapy 
have been applied: nonspecific immuno- 
stimulation with Coley’s toxin for Ewing’s 
sarcoma and osteogenic sarcoma;63 active 
tumour-specific immunization with x-irra- 
diated tumour cells64 or tumour cell ly­
sates65' 66 for osteogenic sarcoma in parti­
cular; adoptive immunization with lympho­
cyte transfer from donors who rejected a 
transplanted tumour allogeneic to the tu­
mour donor;67 transfer factor68’ 60 and in­
terferon.70 Anecdotal case histories strongly 
suggest that nonspecific immunostimulation, 
especially with endotoxin-containing pre­
parations, may be marginally beneficial in 
the treatment of sarcomas in general,63
TABLE VI.'—Immune Reactions of T wo Patients (W and B) with Chondrosarcoma to Cultured 
Sarcoma (Sc) and Carcinoma (Cc) Cell L ines
Target tumour 
cells tested
Attacker
cells*
No. of 
tests
% reduction 
of target 
cells, 
mean
Significance 
(Student’s 
t test)Sample Type No.
a ................................... ................ Sc 4 L 6 W 69 a vs. c, P < 0.01
B 90
b ................................. ................ Sc 4 Se L 6 W 51 
B 98
Sc 1 Ly 1 B 71
c ................................. ................  Cc 2 L 4 W 22 
B 89
d ................................. ................ Cc 2 SeL 3 W 39 
B 97
Cc 1 Ly 1 B 47
*For abbreviations, see Table IV.
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TABLE VII.— Immune Reactions of Two Patients (W and J) with E wing’s Sarcoma to Cultured 
Sarcoma (Sc) and Carcinoma (Cc) Cell L ines
Sample
Target tumour 
cells tested
Attacker
cells*
No. of 
tests
% reduction 
of target 
cells, 
mean
Significance 
(iStudent’s 
t test)Type No.
a ................................. ................  Sc 4 L 12 W 58 a vs. c, P < 0.001
J 78 a vs. e, P < 0.01
b ................................. ................  Sc 4 Se L 11 W 52 b vs, f, P < 0.001
J 83
c ................................. 4 Ly 10 W 18 c vs, d, P <  0.01
J 41
d ................................. ................  Sc 4 Se Ly 8 W 48 d vs, h, P < 0.05
J 18
e ................................. ................  Sq Cc 1 L 7 W 29 e vs. g, P < 0.02
J 19
t .................................. ................  Sq Cc 1 Se L 6 W -1 0 f
J 26
e.................................. ................ Sq Cc 1 Ly 5 w 0
J 4
h ................................. ................  Sq Cc 1 Se Ly 4 w -7 5 f
J 4
Ov Cc 1 L 1 w 14
Ov Cc 1 Se L 1 w 13
Ov Cc 1 Ly 1 w 2
Ov Cc 1 Se Ly 1 w 3
*For abbreviations, see Table IV. Sq Cc = squamous carcinoma; Ov Cc = ovarian carcinoma. 
tGrowth stimulation instead of inhibition.
but tumour-specific immunotherapy with or 
without nonspecific immunization has so 
far failed to alter significantly the course 
of skeletal sarcomas. 64  This is in contrast 
with modest success claimed in the chemo- 
immunotherapy71 and immunotherapy72  of 
soft tissue sarcomas. Transfer factor appears 
to have some effect in the suppression of 
pulmonary micrometastases of osteogenic 
sarcoma, but it is controversial whether this 
effect is tumour-specific. One group08  
claims osteogenic sarcoma-specificity of 
their transfer factor preparations, whereas 
others0'-’ failed to confirm osteogenic sarco­
ma-specificity in the effects of transfer fac­
tor. Early results for the suppression of 
subclinical micrometastases of osteogenic 
sarcoma by large doses of human interferon 
are also promising, 70 but a precise com­
parison of treated and untreated groups of 
patients as to prognostic factors (tissue sub- 
types of osteogenic sarcomas; locations of 
primary tumours both in the bone, that is
whether intramedullary or parosteal, and in 
the skeleton, for example, whether prox­
imal or distal, extremity or torso) is needed 
before final conclusions can be accepted.
The authors thank Mr. Jerry Cabiness for his 
assistance in the lymphocyte-mediated immune
assays.
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CLASSIFICATION OF BONE TUMOURS*
KR1SHNAN K. UNNI, MB, BSt
Primary tumours of bone can be classified con­
veniently into distinct groups based on the ap­
pearance of the tumour cell, or its product, or 
both. Almost all the groups have benign and 
malignant counterparts. However, malignant bone 
tumours usually do not arise from benign tu­
mours. Although the cell of origin in many 
tumours is unknown, the classification described 
in this paper refers to well-defined clinicopatho- 
logic entities, so that the behaviour of a given 
tumour can be anticipated. This classification 
is accepted the world over and provides a “com­
mon language” for those who treat patients with 
bone tumours.
Les tumeurs osseuses primaires peuvent etre 
commodement classifies en groupes distincts 
a partir de la morphologie de la cellule tumorale 
ou de son produit, ou des deux. Presque tous 
les groupes ont des contreparties benignes ou 
malignes. Toutefois, les tumeurs osseuses ma- 
lignes n'originent habituellement pas d'une tu- 
meur benigne. Bien que la cellule d’origine de 
plusieurs tumeurs demeure inconnue, la classi­
fication decrite dans cet article couvre des 
entites clinicopathologiques bien definies, de 
sorte que le comportement d'une tumeur don- 
nee puisse-t-etre anticipe. Cette classification 
est acceptee universellement et elle offre une 
“langue commune” a ceux qui traitent des pa­
tients atteints de tumeurs osseuses.
The classification of bone tumours used at 
the Mayo Clinic1 is essentially the same as 
the one proposed by Lichtenstein,2 and the 
one adopted by the World Health Organiza­
tion8 and used by the Armed Forces Insti­
tute of Pathology.4 The classification is 
based on the cytologic characteristics of the 
tumour cells, or the product of the tumour
*From the department of surgical pathology, 
Mayo Clinic and Mayo Foundation, Rochester, 
MN.
Presented at the conference “Modern Concepts of 
Bone Tumor Treatment”, Ottawa, Ont., May 12 
and 13, 1977.
1'Consultant, department of surgical pathology, 
Mayo Clinic and Mayo Foundation; instructor in 
pathology, Mayo medical school, Rochester, MN.
Reprint requests to: Dr. K. K. Unni, Department 
of surgical pathology, Mayo Clinic and Mayo 
Foundation, Rochester, MN 55901, USA.
cells, or both (Table I). Although the cell 
of origin of a given bone tumour cannot al­
ways be determined, the classification re­
fers to well-defined clinicopathologic en­
tities and is both practical and comprehen­
sible. This does not mean that malignant 
tumours arise from their benign counter­
parts; they hardly ever do.
H em atopoietic  T umours
Tumours of bone-marrow origin are the 
most common bone tumours in our files. 
Myeloma predominates, but does not usual­
ly require surgical intervention. A patient 
with a “solitary” myeloma may survive for 
several years without disseminated disease.5 
Malignant lymphoma, like myeloma, may 
originate in bone or may be part of a dis­
seminated process. This differentiation is 
clinically important because the probability 
of survival for patients with “primary” lym­
phoma of bone is approximately twice that 
for patients with a similar bone tumour and 
disseminated disease.6
It is usually easy to make a histologic 
diagnosis of myeloma based on the charac­
teristics of the cell. Abundant blue cyto­
plasm and an eccentrically situated nucleus 
with clumped chromatin are the main fea­
tures. Malignant lymphoma usually has a 
mixed cell population, consisting of reti­
culum cells (histiocytes) and lymphocytes in 
different stages of maturation.
C hondrogenic T umours
Osteochondroma, which usually arises in 
the metaphyseal region of long bones, is 
characterized by a stalk made up of bone 
covered by a cartilage cap. Like the epi­
physeal plate the cartilage cap has cells 
arranged longitudinally. The cartilage cells 
“mature” towards the stalk to produce bone. 
Enchondroma is seldom treated surgically 
because it is rarely symptomatic. Most en- 
chondromas requiring surgery are in the 
small bones of the hands and feet, where 
they often produce pathologic fracture. Ty­
pically, they have a benign radiologic ap­
pearance.
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TABLE I.—Classification of Bone T umours by H istologic T ype
Type Benign Malignant
Hematopoietic — Myeloma
Malignant lymphoma
Chondrogenic Osteochondroma 
Enchondroma 
Chondroblastoma 
Chondromyxoid fibroma
Chondrosarcoma
Primary
Secondary
Dedifferentiated
Mesenchymal
Osteogenic Osteoid osteoma 
Osteoblastoma
Osteogenic sarcoma 
Conventional 
Osteoblastic 
Chondroblastic 
Fibroblastic 
Telangiectatic 
Well-differentiated 
Parosteal 
Periosteal
Unknown origin Benign giant cell tumour 
Benign (fibrous) 
histiocytoma
Malignant giant cell tumour 
Ewing’s tumour 
Adamantinoma 
Malignant (fibrous) 
histiocytoma
Fibrogenic Fibroma Fibrosarcoma
Desmoplastic fibroma
Notochordal — Chordoma
Vascular Hemangioma Hemangioendothelioma
Hemangiopericytoma
Lipogenic Lipoma Liposarcoma
Neurogenic Neurilemmoma Neurofibrosarcoma
The cells are arranged in small clusters 
within lacunar spaces. The chondrocyte has 
a small inconspicuous nucleus; double-nu­
cleated cells are uncommon.
Chondroblastoma occurs characteristical­
ly in the epiphyseal areas of young persons 
and is characterized by mononuclear cells 
with a sprinkling of benign giant cells. Chon­
droblastomas are differentiated from benign 
giant cell tumours by the presence of islands 
of cartilage or of peculiar “guttate” calci­
fication between the tumour cells.
Chondromyxoid fibroma, which is prob­
ably related to chondroblastoma, occurs 
typically on the metaphyseal side of the epi­
physeal plate and, radiologically, has a 
benign appearance. Histologically, the le­
sion is tabulated and has a chondroid or 
myxoid background. Within this background 
are stellate-shaped cells. The cells are more 
tightly packed towards the periphery of the 
lobules.
Chondrosarcoma is the most common 
malignant tumour of the chondrogenic 
group. It is predominant in adults and is 
usually situated in the metaphysis where it 
arises from within the medullary cavity. 
Generally, the radiologic appearance sug­
gests erosion at the endosteal surface of 
bone. Well differentiated chondrosarcomas 
can be extremely difficult to differentiate 
from enchondromas. Chondrosarcomas are 
more cellular than enchondromas. The 
nuclei are larger than normal, and double- 
nucleated cells are prominent. The poorly 
differentiated chondrosarcoma is relatively 
easy to diagnose histologically because of 
the presence of bizarre nuclei and many 
double-nucleated cells. Secondary chondro­
sarcomas are those that arise within a pre­
existing benign condition, most commonly 
within an osteochondroma. The true in­
cidence of malignant change in an osteo­
chondroma is difficult to assess, but is
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diagnosed on the basis of increased thick­
ness of the cartilage cap (particularly in an 
adult) and cytologic changes of malignancy 
in the cartilage cap.
Dedifferentiated chondrosarcoma is a 
well-recognized entity.7 Generally it devel­
ops in adults in the axial skeleton. It con­
sists of a well-differentiated chondrosar­
coma, usually situated within the medullary 
cavity, and a highly undifferentiated spindle 
cell tumour that may have the characteristics 
of either a fibrosarcoma or an osteogenic 
sarcoma.
Mesenchymal chondrosarcoma is charac­
terized by islands of cartilage that appear 
benign, interspersed with a highly malignant 
small cell tumour reminiscent of Ewing’s 
tumour or malignant lymphoma, or some­
times of a hemangiopericytoma. The lesion 
may occur within the bone or in soft tis­
sues. Most patients with mesenchymal chon­
drosarcoma die of metastatic disease; how­
ever, the clinical course may be unpredict­
able, and patients occasionally survive for 
20 years from the time of diagnosis.®
O steo g en ic  T umours
Osteoid osteoma and osteoblastoma are 
the prototypes of benign osteoid-producing 
tumours. They resemble each other his­
tologically, having a nidus of irregular in­
terconnecting bony trabeculae with inter­
vening osteoblastic activity. The osteoid 
osteoma characteristically produces pain, 
particularly at night, that is relieved by ace- 
tylsalicylic acid. Osteoblastoma may or may 
not produce such symptoms. Osteoid oste­
oma occurs predominantly in the long bones. 
An area of sclerosis usually surrounds the 
nidus. The osteoblastoma tends to occur in 
the axial skeleton and may not be asso­
ciated with reactive sclerosis. A benign 
osteoblastic lesion is called “osteoid oste­
oma” if it measures less than 1.0 cm in 
greatest dimension and is called “osteo­
blastoma” if it measures more than 2 cm.9
Osteogenic sarcoma is the malignant 
counterpart of osteoid-producing tumours 
of bone. Intramedullary osteogenic sarcoma 
usually originates in the metaphyseal region 
of the long bones in adolescents; it is parti­
cularly common in the lower end of the 
femur. The lesion is an anaplastic tumour
of high-grade malignancy with a great po­
tential for metastasis. Osteogenic osteosar­
coma can be classified conveniently into 
osteoblastic, chondroblastic and fibroblastic 
varieties, depending on the predominant dif­
ferentiation of the tumour matrix.10 The 
osteoblastic form has a malignant spindle 
cell stroma, with fine, lacelike osteoid be­
tween the spindle cells. The chondroblastic 
form has a predominantly cartilaginous 
matrix, with spindle cells towards the peri­
phery of cartilage lobules where osteoid, 
sometimes in small amounts, is common. 
The fibroblastic form consists of spindle 
cells with a small amount of osteoid.
In addition to these three varieties of 
osteogenic sarcoma there are several well- 
defined clinicopathologic entities. Some of 
these, such as the osteogenic sarcoma pre­
sent in Paget’s disease of bone and osteosar­
comas that arise after irradiation of bone, 
differ from conventional osteogenic sarcoma 
only because of the clinical setting. How­
ever, osteogenic sarcoma of the jaw differs 
from conventional osteogenic sarcoma be­
cause it occurs in an older age group and 
is less likely to be associated with distant 
metastases; patients usually die of recurrent 
tumour.
The telangiectatic type of osteogenic sar­
coma is a purely lytic, highly destructive 
lesion found in young people. Grossly, the 
lesion appears as a blood-filled space. His­
tologically, it contains septa separating 
blood-filled spaces, such as those present in 
aneurysmal bone cysts. Benign giant cells 
are usually abundant. However, the cells 
forming the septa are highly malignant; 
these septal cells contain pleomorphic nu­
clei and abnormal mitotic figures. It is im­
portant to recognize this form of osteogenic 
sarcoma as a distinct variety for two rea­
sons. First, the lesion is sometimes mistaken 
for a benign lesion, and second, the prog­
nosis seems to be worse than that in con­
ventional osteogenic sarcoma.11
Another distinct type of intramedullary 
osteogenic sarcoma is the well-differentiated 
form. Radiologically, the lesion appears to 
be relatively nonaggressive. However, close 
sciutiny reveals foci with a destructive 
tendency; in this way the lesion may be dif­
ferentiated from fibrous dysplasia. Histolo­
gically, the lesion is well differentiated. Spin-
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die cells of varying size and shape contain 
hyperchromatic nuclei and usually produce 
a large amount of collagen. Mitotic figures 
are difficult to find and osteoid production 
may be minimal or abundant. The tumour 
has a low potential for metastasis, but cure 
is never attained by incomplete excision.
In addition to osteogenic sarcoma of 
high-grade malignancy, two distinct types 
of osteogenic sarcoma —  parosteal and 
periosteal — may occur on the surface of 
bones.
Parosteal osteogenic sarcoma has been a 
well-recognized entity for some time.12 The 
lesion usually occurs in adults and involves 
the lower end of the femur posteriorly. Ra- 
diologically, it appears to be heavily ossified 
and is attached to the underlying bone by 
a broad base. Involvement of the underly­
ing medullary canal should be eliminated ra- 
diologically and grossly before parosteal 
osteosarcoma can be diagnosed. Histolo­
gically, the lesion is extremely well differ­
entiated, having a spindle cell stroma of 
well-differentiated cells. Mitotic figures are 
difficult to find. The lesion usually produces 
large amounts of osteoid, forming almost 
normal bony trabeculae. It has minimal 
metastatic potential, but is locally aggressive 
and, if treated inadequately, will recur.
Periosteal osteogenic sarcoma develops 
in young persons and usually involves the 
upper tibial metaphysis. Radiologically, a 
small radiolucent mass is visualized with 
bony spicules radiating perpendicularly from 
the underlying bone.13 As in parosteal os­
teogenic sarcoma, involvement of the under­
lying bone marrow has to be eliminated be­
fore periosteal osteogenic sarcoma can be 
diagnosed. Histologically, the lesion is 
moderately undifferentiated and is often 
predominantly chondroblastic. It has a 
higher metastatic potential than the paro­
steal type. However, the prognosis seems to 
be better than that in conventional osteo­
genic sarcoma.
T u m o u r s  o f  U n k n o w n  O rigin
Benign giant cell tumour usually occurs 
in adults. Radiologically, it appears to be 
purely lytic arising at the end of bone and 
extending into the articular cartilage; it is 
a lytic destructive lesion and may be mis­
taken for a malignant tumour. Histological­
ly, giant cell tumours are highly distinctive; 
they consist of a combination of mononu­
clear stromal cells and benign giant cells 
scattered evenly throughout the tumour. 
The nucleus of the giant cell resembles that 
of the mononuclear cell and it may be dif­
ficult to differentiate one cell from the other. 
Mitotic figures within the stromal cell may 
be abundant; however, the cells lack atypia.
We have found that it is not possible to 
anticipate biologic behaviour by grading 
benign giant cell tumours according to the 
appearance of the stromal cells. A malignant 
giant cell tumour is defined as a sarcoma 
arising in a portion of the bone that pre­
viously contained a benign giant cell tu­
mour. The malignant tumour usually appears 
several years after a benign tumour has 
been treated. There often is a history of 
prior irradiation to a benign tumour.
Ewing’s tumour is the commonest malig­
nant bone tumour of unknown origin. It 
occurs most frequently in young children, 
but has been noted in all age groups. The 
lesion may occur in any portion of the bone, 
but the shaft of the bone is usually involved. 
Histologically, the tumour is characterized 
by a monotonous proliferation of small 
round cells. The nuclei have a “ground- 
glass’’ appearance, and the cytoplasmic bor­
ders of the cells are indistinct. The individual 
cells lack pleomorphism.
A positive periodic acid-Schiff (PAS) 
stain has been described as the most im­
portant criterion for the diagnosis of Ewing’s 
tumour.14 However, a positive PAS stain 
merely indicates the presence of glycogen 
within the cytoplasm of tumour cells and, 
although a positive result is useful for the 
diagnosis of Ewing’s tumour, a negative re­
sult does not preclude the diagnosis. Rarely, 
a Ewing’s tumour that in all other aspects 
is typical has cells with a greater degree of 
pleomorphism that are two to three times 
the size considered usual in classic cases. 
These have been referred to as large cell 
Ewing’s tumours. They constitute 5 to 10%  
of all Ewing’s tumours. It appears that this 
distinction between a classic Ewing’s tu­
mour and a large cell Ewing’s tumour has 
no clinical significance.
Adamantinoma is also considered a tu-
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mour in which the cell of origin is unknown. 
Histologically, the lesion resembles the clas­
sic ameloblastoma of jaw bone, having epi­
thelioid-appearing cells in clusters distri­
buted within a spindle cell stroma. Gen­
erally the lesion occurs in adults; it tends 
to involve the tibia. Usually adamantinoma 
occurs in the midportion of the shaft and 
involves a large segment of bone. The 
tumour is locally aggressive, but has limited 
metatastic potential.
Malignant fibrous histiocytoma15 has 
been a common designation for bone tu­
mours in recent years. The exact status of 
such a tumour is obscure because many 
osteogenic sarcomas and fibrosarcomas con­
tain zones that resemble this entity. Never­
theless, a few malignant tumours and even 
a few benign neoplasms of bone possess the 
features assigned to this tumour.
F ibrogenic T umours
Fibroma is a term used by most radio­
logists to denote a lesion that is situated 
in the metaphysis of long bones in young 
persons- When the lesion is small and in­
volves only the cortex, the term “fibrous 
cortical defect” is used. Histologically, both 
the fibroma and the fibrous cortical defect 
show loosely arranged spindle cells with a 
scattering of benign giant cells; foam cells, 
in addition, are not uncommon. The spindle 
cells characteristically are arranged in a 
“storiform” pattern. The small lesions heal 
as the skeleton achieves maturity. Desmo­
plastic fibromas, which are locally aggres­
sive fibrogenic lesions occurring within the 
bone, are rare. They have small spindle cells 
with an abundant collagen stroma. In this 
respect, they resemble desmoid tumours 
of soft tissues.
Fibrosarcoma is the malignant counter­
part of the fibrogenic tumour. It is an un­
common tumour and develops predominant­
ly in young adults. Cytologically, the lesion 
has spindle cells with varying degrees of 
atypia; they produce large or small amounts 
of collagen. Fibrosarcomas may be well 
differentiated or poorly differentiated and 
the clinical behaviour can be predicted from 
the cytologic appearance.
Notochordal Tumours
Chordoma arises from the remnants of
the notochord within the spinal column. We 
know of no benign tumours of notochordal 
origin. About two thirds of chordomas oc­
cur in the sacral region, almost one third 
occur in the region of the clivus, and the 
remainder are distributed along the rest of 
the spinal column.
Chordomas are lobulated tumours with 
a chondroid or myxoid background. The 
cells are round or spindle shaped and are 
arranged in a single file within the myxoid 
stroma. Some of the cells have abundant mu­
coid cytoplasm and are called physaliphor- 
ous cells. Some chordomas are associated 
with large amounts of low-grade chondrosar­
coma, and such tumours are referred to as 
“chondroid chordomas”. Surprisingly, chon­
droid chordomas have a better prognosis 
than do conventional chordomas.
Vascular T umours
Hemangioma is rarely treated by surgery. 
It usually is found incidentally at autopsy. 
In the skull, particularly, the lesion tends 
to produce a “sunburst” radiologic appear­
ance.
Hemangioendothelioma is another malig­
nant vascular tumour. It may be well differ­
entiated or poorly differentiated. Histolo­
gically, this tumour is diagnosed by the 
presence of vascular spaces, which are 
usually anastomosing. The vascular spaces 
are lined by abundant endothelial cells with 
atypical nuclei, which are large and of irreg­
ular shape. The poorly differentiated heman­
gioendothelioma may have large areas of 
spindle cell tumour and may be difficult to 
differentiate from fibrosarcoma. In approx­
imately one third of cases, hemangioendo­
theliomas involve multiple bones, usually 
of the same limb.10
Hemangiopericytoma is composed of 
small spindle cells arranged in clusters 
around vascular spaces. The lesion is an 
extremely rare primary tumour of bone; 
little is known about its biologic behaviour.
L ipogenic and N eurogenic T umours
These are uncommon primary bone le­
sions. The only ones in our files at the 
Mayo Clinic are the benign lipomas and 
neurilemmomas.
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C o n c l u s i o n
As can be seen from our classification, 
the cell of origin of some of these tumours 
is uncertain. For the others, we assume the 
cell of origin from the histologic appearance 
of the cells or from the tumour cell product.
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MALIGNANT TUMOURS OF BONE: CLINICAL ASPECTS 
AND NATURAL COURSE*
CRAWFORD J. CAMPBELL, MD, FACS
An accurate pathological diagnosis must be made 
prior to treatment of a primary malignant bone 
tumour. Consideration must be given to the 
clinical and radiologic aspects as well as the 
histology. Both benign and malignant tumours 
occur more frequently in certain decades. A 
search should be made for precursor lesions 
such as Paget's disease. The presenting mani­
festations of pain, a mass and dysfunction are 
not specific for tumours. Laboratory tests may 
be helpful, especially in distinguishing tumours 
from infections and metabolic diseases. Metas­
tasis is usually via the blood stream to the lungs 
and bones. The low survival rate following 
amputation for osteosarcoma and radiation 
therapy for Ewing's sarcoma has been improved 
by chemotherapy. The lower-grade tumours such 
as aggressive giant cell tumour and low-grade 
chondrosarcoma can often be treated success­
fully by resection and insertion of an autograft, 
an allograft or a metallic implant.
Un diagnostic pathologique precis doit etre 
rendu avant d'entreprendre le traitement d'une 
tumeur osseuse maligne primaire. On doit con- 
siderer les aspects cliniques et radiologiques 
aussi bien que histologiques. Les tumeurs aussi 
bien malignes que benignes surviennent plus 
frequemment au cours de certaines decades de 
la vie. On devrait faire la recherche de certai­
nes lesions precurseurs telles que la maladie 
de Paget. Les symptdmes tels que la douleur, 
une masse ou un dysfonctionnement ne sont 
pas specifiques aux tumeurs. Les epreuves de 
laboratoire peuvent etre utiles, principalement 
pour distinguer les tumeurs des infections et 
des maladies metaboliques. Les metastases 
essaiment habituellement par la circulation san­
guine vers les poumons et les os. Le faible 
taux de survie suite a I'amputation pour un 
osteosarcome ou a I'irradiation pour un sarcome 
d'Ewing a ete ameliore par la chimiotherapie. 
Les tumeurs devolution lente telles que la tu­
meur agressive a cellules geantes et le chon- 
drosarcome devolution lente peuvent souvent 
etre traitees avec succes par resection et in-
*From the orthopedic surgical service of the 
Massachusetts General Hospital, department of 
orthopedic surgery, Harvard Medical School.
Presented at the conference “Modern Concepts of 
Bone Tumor Treatment”, Ottawa. Ont., Mav 12. 
13, 1977.
Reprint requests to: Dr. C. Campbell, Massachu­
setts General Hospital, Boston, Mass. 02114 USA.
sertion d'une autogreffe, d’une aliogreffe ou 
d’un implant metallique.
A n accurate pathological diagnosis in a case 
of bone tumour can be made only after a 
careful consideration of the clinical aspects 
and radiologic and histologic features. The 
purpose of this paper is to describe some of 
the clinical manifestations that have caused 
the patient to seek medical aid, and those 
that the primary physician may expect to 
find. The patient usually complains of pain, 
a mass, or dysfunction, of short or long dura­
tion. Some lesions are found fortuitously on 
examination for a nonrelated complaint.
The age of the patient is important, since 
both benign and malignant tumours usually 
occur more frequently in certain decades 
(Table I). Since many systemic diseases, 
such as inflammatory, metabolic, hemato­
poietic and metastatic disease may cause 
bone or joint pain, extremely careful history­
taking and physical examination are man­
datory.
The history of an injury, or relation to 
athletic activity, may lead to the discovery 
of a stress fracture or focus of myositis ossi­
ficans. Finding the cause of the pain, which 
is the most common presenting complaint, 
can be a real challenge. Bone pain may vary 
greatly in intensity and nature, from sharp 
and well localized to dull and aching or 
throbbing, and it is often worse at night. 
The pain may appear to arise from the 
neighbouring joints. However, none of these 
features is specific for tumours. Great care 
should be taken to look for a deep-seated 
mass and to note the range of motion of 
joints, the function of muscles and tendons 
and the status of the neurologic and vascu­
lar structures. The primary care physician 
has to judge which of his patients requires 
radiologic study and other tests. A good rule 
to follow is that persistent pain involving 
the skeletal system calls for radiologic exam­
ination; obviously the location of the pain 
will determine the area to be investigated.
In taking the history, making the exam­
ination and in further investigations, the
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TABLE I.—Presenting Symptoms and Signs in M ore Common Bone Sarcomas
Tumour
Peak
incidence,
decade
Most
common
location Pain* Mass* Functionf
Biochemistry
investigation
recommended
Duration of 
symptoms, 
mo
Osteogenic
sarcoma 2 About knee + ± ± Serum alkaline 
phosphatase 
(usually elevated)
<  6
Juxtacortical 
osteogenic sarcoma 3, 4 Distal end of 
femur (posterior) + + ± _ > 6
Chondrosarcoma 4-6 Trunk; proximal 
ends of femur 
and humerus
+ ± ± — > 6
Fibrosarcoma 2-4 About knee + ± ± — Often >  6
Ewing’s sarcoma 2 Pelvis; humerus; 
femur
+ ± ± Urinary vanillyl­
mandelic acid 
(VMA) and/or 
catecholamines (to 
rule out neuro­
blastoma)
Often >  6
Reticulum cell 
sarcoma 3-6 Trunk; pelvis; 
femur; humerus
+ ± ± Urinary VMA 
and/or catechola­
mines (to rule out 
neuroblastoma)
> 6
Giant cell tumour 3, 4 Epiphyseal end 
of long bone; 
about knee
+ ± ± Serum calcium and 
alkaline phospha­
tase (to rule out 
hyperparathyroid 
osteoclastoma)
> 6
* +  = present; ±  may or may not be present, 
f ±  = may or may not be limited.
physician should search for precursor le­
sions. It has been well documented that 
osteogenic sarcoma, fibrosarcoma and, less 
commonly, chondrosarcoma and giant cell 
tumour occur in association with Paget’s 
disease of bone, that they may occur after 
irradiation and that they can develop in 
fibrous dysplasia, osteogenesis imperfecta, 
the margins of infarcts, bone cysts and 
draining sinuses.1!' Chondrosarcoma can 
develop in any benign tumour of cartilage. 
1. 4, o - i  1
The routine laboratory tests are usually 
not helpful. Determination of serum calcium 
and phosphatase values may aid in the dif­
ferential diagnosis of some tumours from 
hyperparathyroidism, Paget’s disease and 
metastatic carcinoma. Measurement of the 
serum and urinary protein concentrations is 
necessary if myeloma is suspected, and the 
concentrations of urinary vanillylmandelic 
' acid or catecholamines, or both, are usually
elevated in metastatic neuroblastoma. He­
matologic investigation, which should in­
clude study of the bone marrow, or biopsy 
is essential in myeloma, neuroblastoma, leu­
kemia and malignant lymphomas. The biopsy 
should be planned carefully so that a repre­
sentative sampling of the tissue of the tu­
mour is obtained. Before making a diagnosis 
the pathologist must take into consideration 
the clinical and radiologic findings.
Treatment of these malignant tumours 
consists of ablation or destruction of the 
primary growth, radiation therapy (in 
Ewing’s and reticulum cell sarcoma), chemo­
therapy (in Ewing’s sarcoma and osteogenic 
sarcoma) and careful follow-up (Table II).
If amputation is necessary an attempt to 
mitigate the psychologic impact on the pa­
tient and his family by tactful discussion 
beforehand is essential. Every effort should 
be made to provide immediately a weight­
bearing prosthesis for the lower limb to
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TABLE II.—General M anagement of M ore Common Malignant T umours of Bone, Sites of
Metastases and Prognosis
T umour Preferred treatment
Most common 
metastases
5-year survival, 
approximate, %
Osteogenic sarcoma Surgical ablation; with Lung, bones 15
chemotherapy 45
Juxtacortical osteogenic Surgical ablation (occasionally Lung 50 +
sarcoma chemotherapy)
Chondrosarcoma Surgical ablation Lung (often late) 50
Fibrosarcoma Surgical ablation Lung 15
Ewing’s sarcoma Radiation (lesion); with Lung, bones 5
chemotherapy 50
Reticulum cell sarcoma Radiation; chemotherapy Lymph nodes, 40
bone, lung (20 at 10 yr)
Giant cell tumour Surgical resection; radiation Lung 95
TABLE I I I —Guideline for F ollow-up of M alignant T umours of Bone.
For first 2 yr
For bone For systemic Annually
Procedure Every mo. Every 3 mo. pain symptoms for life
Chest
Radiography..............................
Whole lung tomography or
X
computed tomography......... X  X X X
System review................................... X  X X X
Physical examination....................... X  X X X
Bone
Radiography............................. X
Isotope scanning....................... X
Study of lymph nodes and liver . . .  
Ancillary tests (as indicated)..........
X
X
permit early ambulation. The physician and 
the paramedical personnel should adopt a 
positive approach and hopeful outlook.
Although most bone tumours metastasize 
through the blood stream, some, such as 
reticulum cell sarcoma, may spread to the 
lymph nodes. If metastases occur, they usual­
ly do so within 2 years, but in the case of 
some tumours, such as chondrosarcoma, the 
interval may be prolonged to many years. 
There is evidence that chemotherapy in os­
teogenic sarcoma and Ewing’s sarcoma may 
delay the development of metastases.
The results of pulmonary resection in 
osteogenic sarcoma and giant cell tumour 
have been sufficiently successful prior to the 
use of chemotherapy to warrant great care 
in the search for metastases to the lung.12 
The evidence strongly suggests that chemo­
therapy may lengthen the time before the 
appearance of metastases and reduce their 
number. Spanos and colleagues13 reported 
a 5-year survival rate of 28% in their pa­
tients with metastatic osteogenic sarcoma 
who were treated by pulmonary resection; 
they suggested that posteroanterior stereo­
scopic views of the chest be obtained every 
month and whole lung tomograms every 
3 months. Computed tomography is a more 
sensitive test for early metastasis than lung 
tomography and might very well replace it 
in the 3-month follow-up check.
Every physician who treats patients with 
bone tumours should have a protocol to be 
followed in each case. My guideline for 
follow-up is shown in Table III.
The need for correlation with radiologic 
study and an appropriate biopsy is obvious
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if an accurate diagnosis is to be made in 
cases of bone tumour. Ablation of the 
primary tumour and appropriate chemo­
therapy must be followed by careful re­
habilitation and thorough follow-up for the 
duration of the life of the patient.
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SURGICAL MANAGEMENT OF MALIGNANT BONE TUMOURS*
THEODORE R. MILLER, MD, FACSt
The evolution of treatment for osteogenic sarco­
ma at the Memorial Sloan-Kettering Cancer Cen­
ter is reviewed. The possible control of micro- 
metastases by chemotherapy and the excision 
of macrometastases at single or multiple tho­
racotomies by the thoracic surgeon have added 
greatly to the salvage rate of this tumour. Inten­
sive chemotherapy has made possible en bloc 
resection of bones involved by tumour, with 
preservation of the limb. Despite advances, how­
ever, amputation or en bloc resection is still 
necessary to control the primary tumour.
Kettering Cancer Center. Le controle des mi- 
crometastases rendu possible par la chimiothe- 
rapie, et I'excision des macrometastases lors 
de thoracotomies simples ou multiples par le 
chirurgien thoracique, ont grandement ameliore 
le taux de survie de cette tumeur. Une chimio- 
therapie intensive a rendu possible la resection 
en bloc de I’os atteint, tout en permettant de 
conserver le membre. Toutefois, en depit des 
progres, I’amputation ou la resection en bloc 
sont encore necessaires pour controler la tu­
meur primaire.
On passe en revue revolution du traitement du 
sarcome osteogene pratique au Memorial Sloan-
K
*Presented at the conference “Modern Concepts 
of Bone Tumor Treatment”, Ottawa, Ont., May 
12 and 13, 1977.
t Senior attending surgeon, bone tumor service, 
Memorial Sloan-Kettering Cancer Center, New 
York, and clinical professor of surgery, Cornell 
University medical college, New York, NY.
Reprint requests to: Dr. T. R. Miller, 137 E 
36th St., New York, NY 10016, USA.
T he  eventual elimination of cancer will come 
from its prevention, not from its treatment. 
At present we can only attempt to control 
the disease once it has developed. Treat­
ment is in a constant state of change, just 
as the art of surgery is steadily improving. 
In spite of occasional retreats, as in the 
management of breast cancer, progress is 
definitely being made. The idea that a small 
cancer requires a lesser operation than a
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large cancer can be defended, but still can­
not be applied to most tumours.
The magnitude of the problem in osteo­
genic sarcoma and in Ewing’s sarcoma stems 
from the fact that only 203 cases of osteo­
genic sarcoma and 86 cases of Ewing’s sar­
coma occur annually in the United States. 
The scarcity of material makes it difficult to 
accumulate any large series of cases.
A review of past experience is always 
helpful in rationalizing our present ap­
proaches and in enabling us to look with a 
clear and open mind into the future. I shall 
attempt to review briefly the history of the 
clinical management of the malignant bone 
tumours at Memorial Sloan-Kettering Can­
cer Center over the past 50 years, and bring 
that experience up to date with a descrip­
tion of our present concept of management.
The late William B. Coley was the first 
chief of the bone tumour service at our in­
stitution, and was probably one of the earli­
est physicians to practise immunotherapy. 
At a time when amputation was the only 
effective method of treatment, he admin­
istered toxins of a mixture of organisms in 
increasing doses to the patient postoperative- 
ly in an effort to improve the salvage rate. 
The value of this agent (Coley’s toxin) has 
not always been recognized and has even 
been condemned by some prestigious organ­
izations as a “quack approach to cancer 
therapy” . Prompted by our more recent in­
terest in immunotherapy, a review of some 
of his case histories shows that this treat­
ment had definite value. Reticulum cell sar­
coma responded well to this form of the­
rapy. Since the immunotherapeutic concept 
became popular there has been widespread 
experimentation with the use of Bacillus 
parvum and bacille Calmette Guerin. Coley’s 
toxin fell into disuse around 1940 and the 
only treatment again remained surgical abla­
tion with the rather poor salvage rate of 16 
to 18% for the osteogenic sarcomas and 7 
to 9% for Ewing’s sarcoma.
No treatment of any tumour, and in par­
ticular a bone tumour, can be evaluated un­
less it is based on accurate pathological 
diagnosis. The refinements in this field with 
the use of histochemistry and electro-micro­
scopy have been followed with great interest 
by those entrusted with the management of
this group of tumours. Aspiration biopsy 
can be accurate in 85% of cases provided 
the aspirator furnishes the pathologist with 
a clot. Surgical biopsy, however, is some­
times necessary for accurate classification. 
The belief that biopsy should be done be­
tween tourniquets has long since been aban­
doned, since it has been shown that most 
cancer patients have free-floating malignant 
cells in the blood stream.
Many attempts have been made to grade 
bone tumours, from the viewpoints of both 
histology and morbid anatomy. This group 
of tumours tends to disseminate through the 
blood vascular system so that the usual 
methods of staging are not applicable. These 
tumours rarely involve lymph nodes or the 
liver, except by contiguity; they metastasize 
to the lungs almost exclusively.
Other diagnostic methods such as angio­
graphy, xeroradiography and the study of 
alkaline phosphatase concentration in both 
the tumour and blood stream have all 
increased diagnostic refinement. Bone scan­
ning with radionuclides has been helpful in 
the earlier diagnosis in these tumours, which 
frequently give rise to pain before radiologic 
evidence is present.
An additional method, comparing the al­
kaline phosphatase concentration in the 
blood aspirated from a painful bony area 
with the concentration in peripheral blood, 
has been described by Woodard and Mar- 
cove.1 Blood taken from the tumour or 
from a suspected metastasis will have a 
much greater alkaline phosphatase concen­
tration than peripheral blood or normal 
bone.
While many of these tumours are radio­
sensitive, osteogenic sarcoma has never, in 
our experience, been cured by radiotherapy 
alone. From 1935 to 1941, 114 cases of 
osteogenic sarcoma were seen and 69 were 
treated with therapeutic doses of irradia­
tion.2 None was cured during this time. 
Various methods of altering the milieu in 
which the tumour was treated were at­
tempted. Diathermy was given in the pre­
treatment period to increase the circulation 
and hence the sensitivity of the tumour 
to irradiation. These tumours have been 
treated under conditions of hypoxia as well 
as hyperoxia, but still no cures were ob-
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tained. To date, in 1977, 1697 cases of 
osteogenic sarcoma have been seen at our 
institution and not one patient treated by 
irradiation alone has been cured.
In the early years, it was noted that ade­
quate amputation as treatment of the primary 
tumour was almost never followed by local 
recurrence, but in a series where subtro­
chanteric amputation was done for tumours 
of the lower femur, the salvage rate fell 
from 19% to a dismal 5% , owing to local 
recurrence and pulmonary metastases. The 
latter complication is the cause of death in 
this group of tumours. Resection of solitary 
pulmonary metastases from other tumours 
had been performed sporadically in those 
cases where a long interval had elapsed be­
tween the primary treatment and the appear­
ance of the metastasis. This produced an 
occasional cure. With the advances in anes­
thesia, a renewed interest in this approach 
has been vigorously pursued by Beattie and 
his staff with considerable success.:i r’ Mul­
tiple secondary lesions have been removed 
from one or both sides of the chest by wedge 
resection. It is interesting to note that the 
lymph nodes of the bronchial tree and me­
diastinum are rarely involved, and there­
fore subtending node dissections are not 
necessary in the thorax. Amputation alone 
has yielded a universal salvage rate in osteo­
genic sarcoma between 17 and 19%.8 The 
addition of surgical removal of pulmonary 
metastases has raised this figure to around 
35% .4
The use of therapeutic doses of radio­
therapy after the fashion of Sir Stanford 
Cade,-' followed by amputation after a suit­
able waiting period, seems only to be a meth­
od of identifying those patients with occult 
pulmonary metastases. Because of the fail­
ure of this method to demonstrate steriliza­
tion of the tumour in any of the amputated 
specimens, Higinbotham and colleagues 
began to administer necrotizing doses of ir­
radiation (1000 R daily to a total of 12 000 
to 14 000 R) to the tumour, making sure to 
protect the skin necessary for surgical flaps.7 
Amputation was done as soon as the pa­
tient began to show signs of toxicity from 
the necrosed tissue. Ninety-seven patients 
were treated in this fashion before the meth­
od was abandoned. There was no improve­
ment in salvage over early amputation, and
practically none of the tumours had been 
sterilized by this large dose of ionizing ra­
diation.
Cryotherapy, using liquid nitrogen to pro­
duce repeated freezing of the primary tu­
mour or metastasis, has been helpful in 
temporarily controlling pain and speed of 
growth. Conventional chemotherapy in vari­
ous forms has also been tried with little or 
no success. Both of these agents have been 
tried in the treatment of primary and second­
ary tumours.
In 1963, because of the failure of the 
above methods, Marcove and colleagues9’ 0 
and I started to use an autogenous tumour 
antigen after amputation of the tumour-bear­
ing bone. This was suggested by the observa­
tion that pulmonary metastases seemed to 
appear later in the course of the disease in 
those cases of osteogenic sarcoma in which 
there was a long interval between the ap­
pearance of symptoms and the amputation, 
as compared with those cases in which diag­
nosis was early and treatment prompt. This, 
combined with the fact that the parents and 
siblings of a child with osteogenic sarcoma 
often have antibodies against the child’s 
tumour, suggested an immunologic approach. 
Amputation was carried out as soon as the 
diagnosis was made, and tissue cultures were 
prepared using portions of the child’s tu­
mour. The cells were then harvested and 
inactivated, and three different types of 
antigen were made: (a) an ultraviolet cell- 
free extract (UV vaccine), (b) a gamma-irra­
diated suspension of cells from the culture 
(gamma vaccine) and (c) a gamma-irradiated 
suspension of cells from the tissue culture of 
the patient’s own tumour (TC vaccine). The 
last was prepared immediately before each 
administration of the antigen. The others 
were stored at -60°C until used. Each vac­
cine was given subcutaneously weekly for 
as long as possible, or until pulmonary me­
tastases appeared. All patients were younger 
than 21 years of age and had true osteogenic 
sarcoma originating in the distal femur. None 
had had evidence of metastases for at least 
8 weeks after amputation. Results were com­
pared with those from a retrospective series 
of patients fulfilling the same criteria, treated 
at our institution between 1945 and 1946. 
Of 12 patients who received the UV vac­
cine, metastases had not developed in 4, 5
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years or longer after the amputation, where­
as in the control group only 27 of 154 pa­
tients remained free of disease. A fifth pa­
tient who had resection of a solitary pul­
monary metastasis was free of disease 7 
years after amputation and 5 years after tho­
racotomy, giving an apparent cure rate of 
42% , compared with 17% in the control 
group. Of the five patients who received the 
TC vaccine, metastases had not developed 
in 4 in the follow-up period of 20 to 31 
months. Survival times up to 3 years in sev­
eral of the vaccine-treated patients who 
eventually died of their tumour reflect a 
slower progression of the disease due to 
enhanced immunity. In the gamma-vaccine 
group, 15 of 17 patients had metastases be­
fore 21 months after amputation and their 
course was much the same as in the control 
series.
During this period of experimentation 
with tumour antigens (1963 to 1970), the 
reports appeared of the remarkable results 
of chemotherapy with high-dose metho­
trexate and citrovorum factor rescue. We 
then began to use these agents. Chemothe­
rapy in osteogenic sarcoma, because of the 
necessarily high dosage, requires consider­
able expertise to prevent an inordinately 
high morbidity and mortality, particularly in 
patients who are treated prophylactically.
During these years, occasional attempts 
at en bloc resection have been made in low- 
grade osteogenic sarcomas such as the par- 
osteal type and in low-grade chondrosarco­
mas confined locally. These attempts have 
met with some success. Marcove,8’ 0 with 
increasing boldness, has extended the indi­
cations and operative techniques for en bloc 
resection with prosthetic replacement and 
preservation of the limb. This method, com­
bined with high-dose methotrexate chemo­
therapy to control the micrometastases and 
with the removal of multiple secondaries 
in the lungs by thoracic surgeons, has shown 
great promise in increasing the salvage rate 
among these unfortunate young people.
During the last 3Vi years, Marcove8'10 
has performed this type of surgery on 59 pa­
tients. Of these, 21 had total femoral re­
section with replacement involving the hip 
joint and knee. Twenty of these femoral 
resections were performed for osteogenic 
sarcoma of the lower femur. Most of the
others were for chondrosarcoma or other 
benign and malignant tumours of the shoul­
der girdle, ordinarily requiring interscapulo- 
thoracic amputation. (The Tikhoff-Linberg 
amputation is useful for cases of tumour 
around the shoulder girdle.) The remainder 
of the 59 cases were chondrosarcomas of 
the upper femur or the fibula, and osteoge­
nic sarcoma and chondrosarcomas of the 
upper humerus.
The first total femoral resection was for 
chondrosarcoma and the patient subse­
quently died of pulmonary metastases.10 
The other 20 cases were of carefully se­
lected osteogenic sarcoma involving the 
distal femur. Of the 14 patients still living, 
13 are without disease and 11 of these 
still have the limb intact. Of the six who 
died, four died of pulmonary metastases 
after pulmonary resection, one died of 
pulmonary metastases after amputation 
for local recurrence in the limb, and one 
died after hemipelvectomy for metastases 
in the proximal lymph nodes. Of the 
nine patients who underwent amputation, 
two had local recurrence, three had severe 
infection requiring amputation (two of these 
had had heavy irradiation before the femoral 
resection) and two required amputation be­
cause of fracture of the metallic prosthesis. 
One patient, although free of disease, re­
quested amputation because the preserved 
limb did not come up to his expectations. 
One other patient had an amputation be­
cause of recurrence in the local lymph 
nodes.10
En bloc resection must still be regarded 
as experimental and great caution should be 
used in selecting the cases: (a) the tumour 
must be confined to the bone or soft tissue 
involvement must be minimal; (b) the pa­
tient must receive prophylactic chemotherapy 
for 6 weeks before the operation and must 
resume chemotherapy as soon as the wound 
is healed;11 and (c) the patient must agree 
to amputation in case of failure. In evaluat­
ing the results it should be noted that the 
leg tends to be stiff, with little or no flexion 
at the hip, but somewhat more at the knee. 
The patient must wear a stiff-leg brace post- 
operatively, and while the leg is good in 
appearance its function and sensation are 
impaired.
In summary, chemotherapy and pulmo-
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nary resection, in addition to amputation 
and en bloc resection, seem to have ex­
tended the lifespan of patients with osteo­
genic sarcoma. The salvage rate has been 
increased from 19 to 35%. It must be em­
phasized, however, that it is still necessary 
to amputate or resect the primary tumour en 
bloc. In order to achieve this degree of 
salvage the bulk of the thoracic metastases 
must be resected when present.
Ewing’s sarcoma, judged by our experi­
ence, presents largely a radiotherapeutic and 
chemotherapeutic problem, because the 
cases that we see in our clinic come to us 
late. However, amputation has a place in the 
management of Ewing’s sarcoma if the pa­
tient is seen early enough. Amputation is a 
safer method to relieve the body of the dis­
eased bone, since the late effects of radiation 
such as fracture, arrest of growth, and ra­
diation sarcoma are possible complications. 
The patient must be kept under careful con­
trol for the rest of his life. The late effects 
of chemotherapy are still not evident.
Fibrosarcoma of bone should be treated 
by amputation of the entire bone because the 
tumour tends to involve the whole marrow 
cavity. The concept of skip areas in osteo­
genic sarcoma has never been generally ac­
cepted; even so, it is our impression that 
anything less than total amputation of a 
tumour-bearing bone is inadequate. There 
has been a tendency in performing en bloc 
resection to amputate through a femur con­
taining an osteogenic sarcoma in its distal 
portion, and, with a prosthesis, conserve the 
ability to abduct the thigh.
In performing an amputation, we con­
sider that malignant tumours of the lower 
femur require hip-joint disarticulation; those 
of the upper femur, hemipelvectomy; those 
of the tibia and fibula, above-knee amputa­
tion; those of the bones of the forearm, up­
per-arm amputation; and those of the upper 
humerus, interscapulothoracic amputation.
We have had no experience with the use 
of the transfer factor or interferon, though 
it seems that these two modalities, if proved 
useful, would produce a minimal morbidity, 
comparable to our experience with tumour 
antigens.
The radicalism of treatment in chondro­
sarcoma depends upon the grading of the 
tumour. A grade 3 tumour (International 
Histological Classification12) should never 
be treated by en bloc resection, but grades 
1 and 2 may be treated by a lesser amputa­
tion or en bloc resection, or both- Large 
chondromatous tumours of the pelvis are 
almost always malignant and can rarely be 
treated by any measure short of hemipelvec­
tomy. As in osteogenic sarcoma of the 
pelvis, those lesions involving the wing of 
the ilium require a resection of the wing 
of the sacrum, since these tumours tend to 
cross the joint and recur in that location.
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PLACE OF RESECTION IN THE MANAGEMENT OF 
PRIMARY BONE TUMOURS*
CRAWFORD J. CAMPBELL, MD, FACS
A primary malignant sarcoma of bone in an ex­
tremity must be removed so that it will not recur 
locally. Amputation will accomplish this in most 
cases but a prosthesis is required. In carefully 
selected cases of malignant giant cell tumour, 
low-grade chondrosarcoma, low-grade fibrosar­
coma, parosteal osteogenic sarcoma and adam­
antinoma, resection with insertion of an auto­
graft, allograft or metallic implant has been 
successful. More recently implants have been 
used following resection of the more malignant 
tumours such as osteosarcoma, high-grade fibro­
sarcoma and high-grade chondrosarcoma, but 
further time is required to determine the prob­
lems secondary to chemotherapy, other compli­
cations, the length of time for rehabilitation, and 
the quality of life after this procedure as com­
pared with the more conventional amputation 
with early prosthetic fitting.
Un sarcome osseux malin primaire d'un mem- 
bre peut etre enleve de fagon a empecher une 
recidive locale. L’amputation peut accomplir 
ceci dans la plupart des cas mais une pro- 
these est requise. Dans certains cas soigneuse- 
ment choisis de tumeur maligne a cellules 
geantes, de chondrosarcome devolution iente, 
de fibrosarcome devolution Iente, de sarcome 
osteogenique parosteal et d'adamatinome, une 
resection avec insertion dene autogreffe, dene 
allogreffe ou den implant metallique a reussi. 
Plus recemment, des implants ont ete utilises 
a la suite de la resection de tumeurs plus mali- 
gnes telles que I’osteosarcome, le fibrosarcome 
devolution rapide et le chondrosarcome devo­
lution rapide, mais un plus long recul est requis 
pour determiner les problemes secondaires a 
la chimiotherapie, les autres complications inhe- 
rentes, le temps necessaire a la readaptation, 
et la qualite de la vie apres cette intervention 
comparativement a I'amputation plus conven- 
tionnelle avec ajustement d'une prothese.
*From the orthopedic surgical service of the 
Massachusetts General Hospital, department of 
orthopedic surgery, Harvard Medical School.
Presented at the conference “Modern Concepts of 
Bone Tumor Treatment”, Ottawa, Ont.. May 12 
13, 1977.
Reprint requests to: Dr. C. J. Campbell, Massa­
chusetts General Hospital, Boston, Mass. 02114
A blation by amputation has usually been 
considered the procedure of choice in some 
of the frankly malignant tumours of bone 
such as osteogenic sarcoma and the more 
malignant fibrosarcoma and chondrosar­
coma.1 On rare occasions when the patient 
or family will not permit amputation, re­
section without entering the tumour, as sug­
gested by Phemister- and Enneking,:i can 
give comparable results. Interest has been 
revived in resection rather than amputation, 
with consideration for the desire to “keep 
one’s own leg rather than wear a prosthe­
sis”. By meticulous attention to chemo­
therapy before and after the resection of 
some osteogenic sarcomas, spectacular re­
suits have been obtained. Metallic whole- 
bone implants have been inserted by Mar- 
cove and colleagues,4 metallic half-bone 
implants by Watts and colleagues (personal 
communication, 1977) and allografts by 
Mankin and colleagues.” These methods are 
actually in the experimental stages since 
much more information must be available 
before the morbidity, the degree of re­
habilitation and the quality of life following 
such formidable procedures can be com­
pared with what is possible after amputa­
tion with early prosthetic fitting.
On the other hand, some tumours of 
low-grade malignancy can be resected, so 
that the function of the limbs is preserved. 
Examples of these have been described by 
many a u th o r s .4"1# Some of the tumours 
in this category are giant cell tumour, low- 
grade chondrosarcoma, low-grade fibro­
sarcoma, parosteal osteogenic sarcoma, 
adamantinoma and, occasionally, aggressive 
recurrent benign lesions such as desmoplas­
tic fibroma, chondromyxoid fibroma and 
benign epiphyseal chondroblastoma. If a 
limb can be preserved with good function, 
such a result is usually worth the time and 
effort required. We believe that the follow­
ing principles enunciated by Phemister,® 
Ottolenghi14 and Henderson and Dahlinin 
should be observed:
1. An adequate biopsy specimen should
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Fig. lc
Fig. 1.—(a) Lytic lesion of distal end of radius 
in 3 3-year-old man, who had had several episodes 
of pain following minor trauma. Cortex is pene­
trated medially and dorsally. Biopsy showed giant 
cell tumour, (b) Fifteen months after curettage 
and bone grafting there is massive recurrence with 
invasion of soft tissue. Pathological examination 
showed giant cell sarcoma, (c) Four years after 
reconstruction with 20-cm tibial autograft. Graft 
has firmly united to navicular and lunate bones. 
Sixteen years after operation this patient had 25° 
flexion and 15° extension of wrist and was work­
ing as furniture mover.
Fig. lb
be obtained. If possible, the biopsy wound 
should be placed so that the subsequent 
operation will extirpate the site and tract 
of the wound. If the diagnosis can be made 
accurately by frozen section, the wound 
should then be sutured, the skin sterilized 
and the wound excluded from the operative 
field; there should be a change of drapes, 
gowns, instruments and gloves before recon­
struction is done.
2. En bloc excision to include the biopsy 
wound should be performed.
3. The tumour should not be entered.
There are many bones or portions of
bone that can be resected leaving little 
residual functional disability so that no re­
construction is necessary. These include the 
clavicle, scapula, ribs and portions of the 
fibula, ulna and pelvis.
R esection
A number of major factors must be con­
sidered to reach a decision on the feasibility 
of resection for primary bone tumours.
Choice of Cases for Resection
Giant cell tumour, chondrosarcoma and 
fibrosarcoma may be resected if they are 
of low-grade malignancy,5- n .  13, i e  so 
may selected cases of adamantinoma and 
parosteal osteogenic sarcoma.17- 18 Patients
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with benign aggressive tumours that have 
recurred, such as desmoplastic fibroma, 
chondrosarcoma, chondromyxoid fibroma 
and aneurysmal bone cyst, and patients with 
benign tumours located in bones in which 
excision will not cause functional impair­
ment are also candidates for resection. Oc­
casionally an osteogenic sarcoma or a fibro­
sarcoma or chondrosarcoma of high-grade 
malignancy that is confined within a bone, 
or is in a bone that can be excised without 
appreciable functional disability, may be re­
sected.4- 3
Choice of Cases for Resection and
Bone Graft
Consideration must be given to the loca­
tion of the lesion, its size and its relation 
to important soft tissue structures. Tomo­
graphy, computed tomography, arteriography 
and other radiographic and scanning pro­
cedures are sometimes helpful in deline­
ating the margins of the lesion. The joint 
surfaces and structure of the bone that is 
to remain following resection are important. 
As already mentioned some bones can be 
excised totally without impairing function; 
in others local excision of the tumour leaves 
a cavity or defect that can be simply filled 
with grafted bone. The large defect remain­
ing after a massive resection can be satis­
factorily bridged by an autograft taken from 
the tibia,7- n- 10 pelvis3- 13 or fibula,12 or 
by a well-fitted allograft (Fig. 1). When a 
joint is involved it can be bridged by an 
autograft (arthrodesis) or preserved, albeit 
altered, by use of an allograft.3- 41- 13
Choice of Graft
Consideration should be given to the 
quality of the bone in deciding between the 
use of autograft and allograft and to the 
amount and contours of cortical and can­
cellous bone required to ensure strength and 
osteogenesis.3- 6- 7- 1213 In filling a
cavity such as that left after curettage of 
a solitary bone cyst, insertion of autografts 
or allografts gives good results. In filling 
large defects following massive segmental 
resections, I have preferred large autografts 
taken from the posteromedial surface of the 
proximal end of the tibia. Serious complica­
tions have been few3- 7- 13- 1(i and with a 
combination of cortical and cancellous bone
there has been excellent union, replacement 
and remodelling of the transplant.
In an attempt to preserve the joint the 
use of cadaver bone and cartilage allo­
grafts3- 41- 14 is being investigated. This 
method has been successful for lesions about 
the knee joint and is being used for the 
shoulder, wrist and ankle. The fairly high 
rate of complications, including joint in­
stability, and the precarious state of the 
articular cartilage mean that this method 
will require careful analysis for many years 
before the final results can be ascertained. 
Defects have been remedied with artificial 
material such as metal or plastic held in 
place with methylmethacrylate cement. Al­
though these materials give immediate struc­
tural stability and often excellent joint func­
tion in the young, active person, they are 
likely to loosen, fracture, or otherwise fail. 
Nevertheless they are the most successful 
replacement for defects of the hip. Whole- 
bone resection for osteogenic sarcoma with 
a total femur and full-joint prosthetic re­
placement has been done, but the resulting 
morbidity, complications and functional sta­
tus of the limb need further scrutiny.4
In the selection of surgical management 
for primary sarcomas of bone each patient 
should be treated individually. The location 
of the tumour, its pathology and biologic 
behaviour, and the effects of any drugs used 
in its control are extremely important. One 
must also consider the patient’s functional 
needs, the psychologic impact on the patient 
of the proposed operation, the length of 
time required for rehabilitation, the family 
setting and the patient’s financial status be­
fore arriving at a decision. Expertise in 
diagnosis, treatment and rehabilitation 
should be available in any institution where 
patients with primary sarcomas of bone are 
treated.
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EN BLOC RESECTION FOR OSTEOGENIC SARCOMA*
RALPH C. MARCOVE, MDt
Preservation of a limb without sacrifice of the 
principles of cancer surgery is desirable in young 
people with osteogenic sarcoma. At present am­
putation is generally regarded as the only well- 
established curative treatment for this condition. 
To determine whether en bloc resection with 
intensive chemotherapy is a realistic alternative 
to radical amputation and chemotherapy, 43 pa­
tients who underwent en bloc resection for 
osteogenic sarcoma of the distal femur (20 pa­
tients), proximal tibia (11 patients), shoulder 
girdle (11 patients) and fibula (1 patient) were 
studied.
After tumour resection, chemotherapy and 
pulmonary resection 32 (74%) of the 43 patients 
are alive and 29 (67%) have no evidence of dis­
tant disease. Of the 38 patients without metasta­
tic disease at the time of admission (5 were ad-
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(Chief, bone tumor service, Hospital for Joint 
Diseases, and clinical associate professor of sur­
gery, Cornell University Medical Center, New 
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Reprint requests to: Dr. Ralph C. Marcove, 517 
E 71 St., New York, NY 10021, USA.
mitted with pulmonary metastases) 24 (63%) 
are alive without evidence of disease and with­
out having had postoperative metastases.
Chez les personnes jeunes souffrant de cancer 
osteogenique il est souhaitable de conserver le 
membre sans toutefois sacrifier les principes 
de la chirurgie anticancereuse. Presentement 
I'amputation est generalement consideree com- 
me le seul traitement curatif bien etabli de 
cet etat pathologique. Afin de determiner si la 
resection “en bloc" associee a une chimiothe- 
rapie intensive constitue une alternative rea- 
liste a I’amputation radicale et a la chimiothe- 
rapie, on a etudie 43 patients qui ont subi une 
resection “en bloc” d’un sarcome osteogenique 
du femur distal (20 patients), du tibia proximal 
(11 patients), de la ceinture scapulaire (11 pa­
tients) ou du perone (1 patient).
Apres resection de la tumeur, chimiotherapie 
et resection pulmonaire, 32 (74%) des 43 pa­
tients sont vivants et 29 (67%) ne presentent 
aucun signe de maladie disseminee. Des 38 
patients exempts de metastase au moment de 
I'hospitalisation (5 avaient des metastases pul- 
monaires), 24 (63%) sont vivants sans mani­
festation de I? maladie et sans avoir eu de 
metastase postoperatoire.
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Preservation of a limb without sacrifice of 
the principles of cancer surgery is desirable 
in young people with osteogenic sarcoma. 
At present amputation is generally regarded 
as the only well-established curative treat­
ment for this condition, 1-6 When the tumour 
is close to a joint, amputation usually in­
cludes excision of a part of the adjacent 
joint bone as well as the involved bone to 
include both the area of potential capsular 
local spread and possible intraosseous skip 
areas of tumours. In cases of lesions of the 
distal femur, which have the lowest rates 
of cure, the whole bone is usually removed.7
To determine whether en bloc resection 
with intensive chemotherapy is a realistic 
alternative to radical amputation and chemo­
therapy,8 14 43 patients who underwent en 
bloc resection for osteogenic sarcoma were 
studied. The femur was the site of the tu­
mour in 20 patients, the tibia was affected 
in 11, the shoulder girdle in 11, and the 
fibula in 1. This paper is a preliminary re­
port of the results obtained.
M aterials and M ethods
In all patients the following investigations 
were carried out: routine physical examina­
tion and laboratory determinations, standard 
anteroposterior and lateral radiographs of 
the involved bone as well as skeletal survey, 
bone scanning and chest tomography, and 
biplane arteriography of the area of osteo­
genic sarcoma (Fig. l) .ir>* 1(i The findings 
were evaluated to determine size, location 
and resectability of the tumour and the soft 
tissue component, as well as the presence of 
metastatic disease or skip areas. In children 
with lesions of the distal femur, orthoroent- 
genographic scanning of the lower extremi­
ties and other appropriate studies deter­
mined the degree of skeletal maturity and 
projected growth curves. The objectives and 
potential risks of the protocol were care­
fully explained to the patients and their 
families. The presence of pulmonary meta- 
stases was not necessarily a contraindication 
if the lesions were considered surgically re­
sectable17’20 or responsive to chemothe­
rapy, or both.14’ 21' 22 The advisability of 
use of an ischial weight-bearing brace post- 
operatively was discussed with the parents 
and patient before operation. Upon com-
Fig. lb
Fig. 1.—Osteogenic sarcoma of (a) distal fe­
mur and of (b) scapula. Arteriograph demon­
strates resectability of lesions.
pletion of these investigations we proceeded 
with the resection of the sarcoma.
■ 4 
A 4
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L esions o f  the D istal F em u r
Twenty-six patients with lesions of the 
distal femur were considered for replace­
ment surgery.23 Amputation was required 
in five because of the size of the tumour, 
and in one because a tumour pseudocapsule 
was encountered at operation. There re­
mained 20 patients (age range, 11 to 21 yr) 
who underwent en bloc resection of the 
tumour and replacement with a metal total 
femur-knee prosthesis; 3 had pulmonary 
metastases at the time of admission.
About 8 weeks were needed for con­
struction of the prosthesis. During this time 
the patient received chemotherapy consist­
ing of vincristine, doxorubicin (Adriamycin) 
and high-dose methotrexate with citrovorum 
factor rescue. Our regimen for the admini­
stration of chemotherapy has been described 
elsewhere.14' 21’ 22 When the prosthesis 
was ready the patient was re-evaluated; if 
the protocol criteria were still valid, replace­
ment was performed. Immediately after re­
placement the patient was placed in a long-
Fig. 2.—Ischial weight-bearing brace with pel­
vic band used after total femur and knee replace­
ment.
leg ischial weight-bearing brace (at first 
with a pelvic band). An active range of 
movement and ambulation was started as 
the clinical situation allowed. The pelvic 
band was removed after about 6 weeks (Fig. 
2). Then, after sufficient postoperative 
wound healing, adjuvant chemotherapy was 
resumed. The regimen consisted of biweek­
ly cyclophosamide, vincristine and high-dose 
methotrexate with citrovorum factor rescue 
for five cycles. 14> 21* 22
O perative  T echniqOe
In performing the biopsy in previously 
untreated patients a lateral approach had 
been selected to correspond with the pro­
posed site of the subsequent surgical inci­
sion. The biopsy scar and tract are excised 
and, through a long Gibson skin incision, 
posterior and anterior approaches are made 
to the hip. The incision is carried along the 
greater trochanter and the lateral aspects of 
the femur distal to the knee and then curved 
slightly anteriorly over the lateral tibia to 
a point 4 cm distal to the tibial tubercle. The 
incision is deepened and as the area of 
tumour is approached an ample margin is 
left on the femur, so that the tumour is 
never made visible. If a tumour pseudocap­
sule is seen the operation is discontinued and 
with fresh instruments amputation is per­
formed at a higher level. The knee is re­
moved en bloc with the distal femur. The 
patellar tendon is left intact and the patella 
is split coronally so that the inner half is 
removed with the specimen and the outer 
half remains in continuity with the remain­
ing quadriceps mechanism. The tibia is 
reamed to accept the stem of the total knee 
prosthesis and methyl methacrylate is in­
troduced into the tibia after a trial insertion 
of the prosthesis. The gluteal muscles are 
attached with heavy silk through preformed 
holes to the prosthetic shaft proximally, and 
the groups of medial and lateral thigh mus­
cles are attached to each other.. The distal 
hamstrings are often transferred anteriorly to 
act as knee extensors and to provide a deep 
layer below the skin incision. The wound is 
carefully checked for hemostasis (cautery is 
generally not used). Hemovac suction en­
sures drainage. The wound is flushed with 
antibiotic solutions during and immediately
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after surgery and antibiotics are prescribed 
before and after operation. The legs are 
kept elevated postoperatively (Fig. 3).
Results
Duration of follow-up in these 20 patients 
ranged from 2 to 35 months. At the time of 
writing 13 of the 20 patients are alive and 
free of disease; 1 is alive with disease.
Nine of the 17 patients admitted without 
metastases are still free of disease.
Of the three patients admitted with pul­
monary lesions, one is alive with no appa­
rent metastatic disease 24 months after re­
placement (she had a second pulmonary me­
tastasis and thoracotomy 7 months after re­
placement surgery); the remaining two pa­
tients died with widespread metastases 21 
and 30 months after replacement.
Six patients underwent thoracotomy; three 
are alive without disease. In one patient 
chemotherapy reduced the size of the pul­
monary nodule so that it was not found at 
subsequent exploratory thoracotomy.
Seven patients had amputations: three for 
infection, two for local recurrence, one for 
breakage of the prosthesis and one for ra­
diation necrosis (a dose of 6600 rad had 
been administered before replacement). Of 
this group three are alive and free of disease; 
one had infection, one had local recurrence 
and one had breakage of the prosthesis.
Range of motion usually improved with 
time; ankle and foot motion usually was 
quite good. At first, walking was possible 
only with crutches, but patients could man­
age later with a cane. Without the use of a 
cane a gluteus maximus limp was evident 
unless an ischial weight-bearing brace was
v
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used. Patients were instructed to wear the 
ischial weight-bearing brace with quadrila­
teral socket and to treat the extremity much 
the same as a “polio leg”.
L esio n s  o f t h e  § h o u l d e r  G irdle
Eleven patients (age range, 8 to 63 yr) 
who had osteogenic sarcoma of the upper 
portion of the humerus, scapula or clavicle 
underwent a Tikhoff-Linberg procedure; one 
had pulmonary metastases at the time of 
admission.24
The Tikhoff-Linberg procedure (en bloc 
upper humeral interscapulothoracic resec­
tion) is an alternative to radical ablation for 
neoplasms of the shoulder girdle.25'31 It 
is indicated mainly when the neoplasm does 
not involve the axillary artery or the brachial 
plexus, lymph nodes are negative and the 
tumour is not fixed to the chest wall. Primary 
tumours of bone, as well as soft tissue tu­
mours adjacent to bone, can be treated by 
this method. A forequarter amputation5’ 31 
is a better operation if lymph nodes are in­
volved. Only five patients received chemo­
therapy, including the patient who had three 
thoracotomies. Chemotherapy was begun 3 
weeks after operation, and was administered 
according to our protocol.14- 21> 22
Operative Technique
The initial incision is made over the 
medial two thirds of the clavicle; it is ex­
tended from the region of the coracoid 
process distally along the medial border 
of the arm overlying the neurovascular 
bundle. The incision is so placed that the 
biopsy scar and tract are excised with the 
specimen. Providing it is free of tumour, 
the neurovascular bundle is mobilized. The 
musculocutaneous and radial nerves can 
be identified and usually preserved. If the 
lesion involves the soft tissue at the level 
of the proximal humerus in the vicinity of 
the nerves the radial and musculocutaneous 
nerves may have to be sacrificed. In one 
patient even the ulnar nerve was removed. 
The posterior skin incision originates at 
the junction of the lateral and middle thirds 
of the clavicle and is carried distally over 
the middle of the scapula to its angle- The 
inferior angle of the scapula is mobilized 
and the vertebral border is dissected from
the chest wall in much the same way as 
for a forequarter amputation. If the lesion 
involves the scapula, a wide soft tissue 
margin must be preserved. The skin flap 
from the initial incision is raised over the 
proximal humerus, leaving the deltoid muscle 
intact with the specimen in upper humeral 
lesions. When much of the humerus is re­
moved, excessive shortening can be avoided, 
and better elbow power for flexion provided, 
by a humeral prosthesis or Kiintscher nail 
replacement fixed into the proximal soft 
tissues or the clavicle stump (Fig. 4). Some 
patients are more comfortable if a greater 
amount of clavicle is removed and the nail 
is fixed into the soft tissue. Closure is rou­
tine; hemovac suction is used. A postoper­
ative sling and swathe or Valpeau dressing 
is applied- Hand and elbow movement is 
encouraged early postoperatively.
Results
Follow-up ranged from 2 to 37 months. 
Of the 11 patients 7 are alive without evi­
dence of disease.
The patient who was admitted with pul­
monary metastases underwent subsequent 
thoracotomies at 2, 7 and 13 months after 
resection. He has no apparent disease 3 
months after his last operation.
Four patients died. One was admitted 
with pulmonary metastases (radiation osteo­
genic sarcoma from previous Hodgkin’s dis-
Fig. 4.—(a) Preoperative radiograph of osteo­
genic sarcoma of humerus in 11-year-old. (b) 
Postoperative radiograph showing Kiintscher nail 
inserted after resection to maintain length of arm.
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ease) and died of widespread metastatic dis­
ease 6 months after resection. Surgery in 
this patient was palliative only. Another pa­
tient died 7 months after resection with 
widespread disease and a local recurrence. 
The remaining two patients died of wide­
spread metastases.
The result in the one patient with local 
recurrence could not have been improved 
by a forequarter amputation since the same 
tissue planes at the insertion of the levator 
scapulae muscle would have been disturbed.
Six (66%) patients never had evidence of 
metastatic disease.
One patient, who is alive without disease, 
received vaccine (lysed cell) therapy post- 
operatively 3 years ago.
Of the five patients who received chemo­
therapy all are free of disease.
Wrist and hand function was normal in 
patients who underwent operation. In pa­
tients with radial nerve palsy, a cock-up 
splint was used and tendon transfers were 
done 2 years later. The surgical deformity 
was usually corrected by a small amount of 
shoulder padding under clothing, but a plas­
tic filler is better.
Lesions of the Proximal T ibia
Eleven patients (age range, 11 to 24 yr) 
with osteogenic sarcoma of the proximal 
tibia underwent en bloc resection and total 
long-stem knee replacement. One patient 
had metastatic disease on admission. After 
resection and replacement the patients were 
started on the chemotherapy protocol.1114.21
Operative Technique
A posterior medial incision is made and 
the neurovascular bundle identified. The 
anterior tibial artery and other interosseous 
perforating vessels are ligated at their orig­
in. The vessels of the popliteal fossa are 
also ligated, preserving the main arterial 
trunk. The fibula is removed en bloc along 
with the upper tibia. The total knee and 
distal femur are also removed en bloc, keep­
ing a margin of normal tissue around the 
tumour. Care must be maintained to 
preserve cutaneous nerves. If a tumour of 
the upper tibia has extended into the skin, 
this area, of course, must be sacrificed. 
The long-stem Guepar knee (with solid
shafts) is cemented into the distal tibia and 
proximal femur.
Results
The follow-up in this group ranged from 
4 to 23 months. Eight (72) patients never 
had evidence of metastatic disease. Two pa­
tients are alive with disease after thoraco­
tomy, one at 16 and one at 20 months after 
resection. One patient died 3 months after 
resection with pulmonary metastases and 
local recurrence. In retrospect she should 
not have undergone resection because her 
lesion was too large. Amputation was done 
in one patient at his request because of ex­
cessive numbness of his foot (too many 
cutaneous nerves had been sacrificed).
Lesions of the F ibula
One patient, a 15-year-old girl, had osteo­
genic sarcoma of the right fibula. She had 
received a direct blow below the right knee, 
resulting in continued mild discomfort and 
swelling, 3 weeks before admission. The 
right knee joint had a full range of motion. 
Clinically, the lateral popliteal nerve was 
intact. Arteriography demonstrated that the 
tumour was resectable. She was started on 
the chemotherapy regimen14’ 21’22 and 
after a frozen section biopsy confirmed the 
presence of osteogenic sarcoma, she under­
went en bloc resection of the fibula.
Because of persistent fluid collection, re­
sumption of chemotherapy was delayed until 
2 months after operation. Vincristine and 
methotrexate with citrovorum factor rescue 
were administered according to our adju­
vant chemotherapy protocol,14- 21* 22 for 1 
year.
Operative Technique
A long skin incision is made from above 
the knee joint to the ankle, leaving a seg­
ment of skin directly overlying the tumour. 
Skin flaps are developed anteriorly and 
posteriorly. The tumour is not exposed and 
a 2-cm layer of healthy tissue is left over 
the tumour. The lower fibula is disarticulated 
at the ankle mortice. Using an osteotome, 
a section of tibia above and medial to the 
tibiofibular joint that includes part of the 
lateral tibial condyle, is removed en bloc 
with the specimen. Thus the whole of the 
fibula is removed together with the tumour.
i
%
November 1977 THE CANADIAN JOURNAL OF SURGERY 527
tibiofibular joint and a wide surrounding 
zone of muscles; the common peroneal 
nerve and two of the three lower limb ar­
teries are ligated. A long-leg plaster cast is 
applied with the ankle in the neutral posi­
tion for 6 weeks.
Results
The patient was free of disease for 2Vi 
years and walked without a limp with the 
use of a drop-foot brace. Stress films showed 
no instability of the ankle joint. Then a 
nodule developed inside the upper tibia. 
The remainder of the upper tibia was re­
moved en bloc and a Guepar total knee with 
long-stem prosthesis was inserted. She con­
tinues well and there is good stability of 
the ankle joint, contributed to by the resi­
dual capsule as well as the lateral ligaments.
Summary
In all, 43 patients were treated for osteo­
genic sarcoma of the extremities by en bloc 
resection and chemotherapy. Of this group 
32 (74%) are alive after tumour resection, 
chemotherapy and pulmonary resection and 
29 (67%) have no evidence of disease.
Of the 38 patients without metastatic dis­
ease at the time of admission 24 (63%) are 
alive without evidence of disease and with­
out having had postoperative metastases. 
Compared with published survival rates, 
these results are considerably better than 
those of previously described treatment 
plans.7, 32-35
The ultimate test for this method of man­
agement is the control of tumour. The mean 
time for development of pulmonary meta­
stases after amputation for osteogenic sarco­
ma has been reported to be 7.9 months.3 ’' In 
a recent study at Memorial Sloan-Kettering 
Cancer Center, when radiographs were taken 
at 1-month intervals, the mean time for de­
tecting pulmonary metastases was only 5.5 
months.10 Poor survival rates in children 
with osteogenic sarcoma, despite adequate 
radical ablation of the primary tumour site, 
are probably due to the presence of distant 
microfoci of disease, mainly pulmonary, at 
the time of operation.36' 37 Hence pul­
monary resection and systemic chemothe­
rapy using drugs with demonstrated efficacy 
are needed for optimal treatment of this
radioresistant tumour. If these means are 
utilized, en bloc resection for osteogenic sar­
coma appears to be a feasible alternative to 
radical amputation.
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RADIATION TREATMENT OF EWING’S SARCOMA AND 
OSTEOGENIC SARCOMA*
R. D. T. JENKIN, MB, FRCP[C]t
At the Princess Margaret Hospital, Toronto, dur­
ing the period 1960 to 1975, radiation therapy 
was given to 59 patients with Ewing's sarcoma 
without overt metastases. Over this period 
treatment was modified to include, as well as 
irradiation to the primary tumour, total body ir­
radiation (TBI) and chemotherapy according to 
various regimens. The 5-year survival rate of 38% 
in 26 patients who received TBI suggests that 
this may be of value.
In patients with osteogenic sarcoma preoper­
ative irradiation was not found to be of value. 
Recently the resection of pulmonary metastases 
combined with chemotherapy has increased the 
survival rate. When the primary site makes 
resection impracticable, the response to ir­
radiation and chemotherapy is encouraging. 
Three cases so treated are described.
Entre 1960 et 1975, au Princess Margaret Hos­
pital de Toronto, de la radiotherapie a ete ad- 
ministree a 59 patients souffrant de sarcome 
d'Ewing sans signe de metastases. Durant cette 
periode le traitement a ete modifie pour inclu- 
re, avec I'irradiation de la tumeur primaire, 
I'irradiation corporelle totale (ICT) et divers 
regimes chimiotherapeutiques. Le taux de sur- 
vie a 5 ans de 38% chez 26 patients qui ont 
recu I'lCT suggere que ce mode de traitement 
peut etre valable.
Chez les patients souffrant de sarcome osteo- 
genique I'irradiation preoperatoire n’a pas ete 
trouvee de valeur. Recemment la resection des 
metastases pulmonaires associee a la chimio- 
therapie a augmente le taux de survie. Quand 
le foyer primaire rend la resection impossible, 
la reponse a I’irradiation et a la chimiotherapie 
est encourageante. Trois cas traites de cette 
maniere sont decrits.
*From the department of radiation oncology, The 
Princess Margaret Hospital, Toronto, Ont.
Presented at the conference “Modern Concepts of 
Bone Tumor Treatment”, Ottawa, Ont. May 12, 
13, 1977
tAssociate professor of radiology, University of 
Toronto.
Reprint requests to: Dr. R. D. T. Jenkin, Depart­
ment of radiation oncology, The Princess Marga­
ret Hospital, 500 Sherbourne St., Toronto, Ont. 
M4X 1K3.
I n both Ewing’s sarcoma and osteogenic 
sarcoma, control of the primary tumour is 
the first requirement if adjuvant drug treat­
ment is to fulfil its potential to increase the 
rate of cure by eradication of occult meta­
static disease. In Ewing’s sarcoma irradia­
tion of the primary tumour will provide 
rapid complete control initially. In osteo­
genic sarcoma response to irradiation alone 
is slow and often incomplete, so that re­
section is the treatment of choice, irradia­
tion being reserved for the small number 
of patients in whom the tumour site makes 
resection impracticable.
This report will update and extend the 
experience at the Princess Margaret Hos­
pital, Toronto (PMH) with radiation therapy 
for Ewing’s sarcoma1’3 and osteogenic sar­
coma.
E w ing ’s Sarcoma
During the period 1960 to 1975, 77 
consecutive patients with Ewing’s sarcoma 
who had not been treated previously were 
registered at PMH; 17 had overt metastatic 
disease at the time the diagnosis was made. 
In all 77 patients the primary tumour was 
treated by irradiation. Treatment methods 
evolved during the study period, and they 
will be analyzed for each of four periods 
of uniform treatment policy (1960 to 1964, 
1965 to 1969, 1970 to 1972 and 1973 to 
1975).
Treatment Groups
1960 to 1964.—During these years 
treatment consisted of irradiation of the 
primary tumour alone, careful follow-up 
and, in the metastatic phase of the disease, 
single-agent chemotherapy and local irra­
diation of symptomatic sites.
The 16 consecutive patients without me­
tastases at the time of diagnosis, so treated, 
formed the base line for our subsequent 
experience. The 5-year survival rate in these 
16 patients was 25% and the 5-year re­
lapse-free survival rate was 12% (Fig. 1).
November 1977 THE CANADIAN JOURNAL OF SURGERY 531
Years
Fig. 1.—1960 to 1964. Ewing’s sarcoma. Survi­
val (------) and relapse-free (— ) survival rates
in 16 patients whose initial treatment was local 
irradiation only. Results at 1, 3 and 5 years are 
indicated.
At 1 year from diagnosis only 44% were 
relapse-free.
The primary tumour was treated with a 
dose of 4500 to 6000 rad in 3 to 6 weeks;2 
5000 rad in 25 fractions over 5 weeks be­
came our standard dose, employed to the 
present time. The tissue volume irradiated 
included the whole tumour and a margin 
of not less than 5 cm. Ewing’s sarcoma, 
while arising in bone, is mostly a large soft 
tissue mass. Therefore, if the tumour was 
located in a limb, the irradiated volume 
included not only the whole involved bone 
but all the soft tissues of that segment of 
the limb. In the pelvis it is difficult to de­
lineate the soft tissue mass precisely by 
palpation, bone and soft tissue radiography, 
or bone scanning, even when complemented 
by intravenous pyelography or angi­
ography. Recently computerized tomography 
(CT) has proved valuable in delineating the 
soft tissue mass at this site and has re-em­
phasized the large fields required to pro­
vide adequate irradiation (Fig. 2).
1965 to 1969.—Experience with irra­
diation of the primary tumour as the only 
treatment indicated that most patients with 
Ewing’s sarcoma have occult metastases at 
the time of diagnosis, which subsequently 
become overt, usually within 18 months. 
This is illustrated by the shape of the re­
lapse-free curve in Fig. 1.
Impressed by the effectiveness of irradia­
tion in the treatment of the primary tumour
Fig. 2 b
Fig. 2.—(a) Radiograph and (b) computerized 
tomography scan of Ewing’s sarcoma of left ilium. 
Note large soft tissue mass identified on scan.
we developed a protocol in which the occult 
systemic disease was also treated by irra­
diation. Thirteen patients were treated ac­
cording to this protocol during the years 
1965 to 1969. Upon completion of primary 
tumour irradiation they underwent total 
body irradiation (TBI) (300 rad given in a 
single treatment).2- 2 Three of these 13 pa­
tients had evidence of metastases at the 
time of diagnosis, although in 2 patients only 
a solitary site was identified.
The 5-year survival and relapse-free 
survival rates were 38 and 23% , respective­
ly (Fig. 3). Among the four patients alive at 
5 years were the two with a solitary meta­
static site (one in bone, one in lung).
While these were relatively good results 
for this tumour, 10 of the 13 patients had 
relapsed within 24 months of diagnosis, so 
that the initial steep slope of the relapse- 
free survival curve was not altered (Fig. 3).
During this period adjuvant chemo-
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Fig. 3 .— 1965 to 1969. Ewing’s sarcoma. Survi-
vival ------ ) and relapse-free (-—) survival rates
in 13 patients whose initial treatment was local 
irradiation followed by total body irradiation 
(TBI).
therapy, under study elsewhere, had shown 
promising early results.4 10 A new protocol 
was therefore designed in which elective 
systemic treatment was with TBI, cyclo­
phosphamide and vincristine.
1970 to 1972.—Thirteen patients with­
out evidence of metastatic disease at the 
time of diagnosis received, initially, a dose 
of 5000 rad in 25 fractions to the primary 
tumour, 300 rad TBI on completion of lo­
cal irradiation and then combination chemo­
therapy, which began on recovery from the 
pancytopenia induced by TBI and continued 
for 12 months. Cyclophosphamide (15 
mg/kg) and vincristine (0.05 mg/kg to a 
maximum dose of 2.0 mg) were given as 
alternating weekly intravenous injections. 
Nine of these patients were treated more 
than 5 years ago and four more than 4 
years ago.
The actuarial 5-year survival and re­
lapse-free survival rates were 38 and 11%, 
respectively (Fig. 4). These results were not 
obviously different from our former ex­
perience; in particular, the 1-year relapse- 
free rate (46%) was not improved.
During this period TBI precluded the 
use of chemotherapy until approximately 2 
months after diagnosis. Since the initial 
slope of the relapse-free survival curve re­
mained steep (Fig. 4) we elected to discon­
tinue TBI and to introduce early combina­
tion chemotherapy.
1973 to 1975.— Seventeen patients with-
Fig. 4.—1970 to 1972. Ewing’s sarcoma. Sur-
val (------ ) and relapse-free (— ) survival rates
in 13 patients whose initial treatment was local 
irradiation. TBI and 1 year of cyclophosphamide 
and vincristine.
out demonstrable metastases at the time 
of diagnosis received irradiation of the 
primary tumour as before, although chemo­
therapy was given concurrently. A number 
of chemotherapy regimens were used. In 
particular, nine patients received a four- 
drug program including various combina­
tions of cyclophosphamide, actinomycin D, 
vincristine and doxorubicin (Adriamycin), 
which was planned to be of 24 months’ 
duration.
Results have been disappointing. The 
actuarial 3-year survival and relapse-free 
survival rates were 32 and 19% although 
the respective 1-year rates of 100 and 70% 
represented an improvement (Fig. 5).
Primary Tumour Control
All 59 patients included in the four treat­
ment groups described above had an ap­
parently adequate initial response to irra­
diation at the primary site as determined 
by symptomatology, clinical and radiologic 
examination.
The true effectiveness of local irradiation 
is indicated by the rate of recurrence at 
the primary site. An isolated first relapse at 
the primary site or a synchronous first re­
lapse at both the primary and distant sites 
are the forms of primary recurrence that 
are clearly definable and obviously repre­
sent inadequate irradiation control, so that 
their incidence may be used to monitor the 
effectiveness of irradiation. Recurrence at
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Fig. 5.-1973 to 1975. Ewing’s sarcoma. Actu­
arial survival (------) and relapse-free (—-) sur­
vival rates in 17 patients whose initial treatment 
was local irradiation followed by 18 to 24 months 
of chemotherapy with various combinations of 
cyclophosphamide, vincristine, actinomycin D and 
doxorubicin.
the primary site may also be seen after one 
or more systemic relapses, but its impor­
tance at that time is uncertain with regard 
to the differentiation between true tumour 
recurrence and reseeding to the primary 
site. At autopsy, diffuse skeletal involve­
ment is common and microscopic tumour at 
the primary site is generally found. While 
the incidence of a first relapse at the primary 
site is clearly definable and of major clinical 
importance, the true rate of irradiation 
failure, while not precisely definable, will 
be higher.
A first relapse, which included recurrence 
of the primary tumour, was seen in 15 
(25%) of the 59 patients. In 4 patients the 
first relapse was at the primary site alone 
whereas the other 11 patients had synchro­
nous relapse at both primary and distant 
sites. The prospect for relapse at the primary
site was not dependent on the site of the 
primary tumour, at least when sites were 
divided simply into those of limb or trunk 
(Table I). Neither did the specific treatment 
protocol appear to influence the incidence 
of recurrence at the primary site, although 
the patient numbers were small (Table II).
Among 35 patients with a limb tumour, 
overt metastatic disease did not develop in 
10. Only 1 of these 10 patients had a relapse 
at the primary site, and he was subsequently 
cured by resection. But of the 25 patients in 
whom metastatic disease developed, the first 
relapse was at the primary site in 8, although 
this was synchronous with metastatic disease 
in 7 of them. The greater effectiveness of 
primary tumour irradiation in the patient 
without occult metastases may simply reflect 
a selection of patients with smaller primary 
tumours, that is, with a smaller number of 
tumour stem cells to be eradicated or with 
less malignant tumours, rather than an indi­
rect influence of the occult malignant cell 
population on primary tumour radiosensitiv­
ity. Our patient numbers were too small to 
provide useful data on this point.
Conclusions
In Ewing’s sarcoma irradiation of the
TABLE II.—Incidence of P rimary Recurrence 
of E wing’s Sarcoma Related to the T reatment 
Received
Treatment
No. of 
patients
Primary
recurrence
Irradiation to tumour 
alone................................ 16 4
Irradiation to tumour and 
total body irradiation 
(TB I).............................. 13 2
Irradiation to tumour, 
TBI and chemotherapy. 13 3
Irradiation to tumour and 
chemotherapy................ 17 6
T otal........................... 59 15
TABLE I.—Incidence of P rimary Recurrence of E wing’s Sarcoma R elated to the Site of Origin
Site
Trunk—  
Limb.......
Total
Recurrence
No. of Primary Primary and
patients site alone distant sites Total (%)
24 2 4 6 (25)
35 2 7 9 (26)
59 4 11 15 (25)
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primary tumour remains the treatment of 
choice. Return of normal function is rapid 
and primary recurrence is uncommon un­
less overt metastatic disease appears syn­
chronously or earlier. A dose of 5000 rad 
in 25 fractions over 5 weeks is considered 
appropriate in that local morbidity is ac­
ceptable even when combination chemothe­
rapy is given for protracted periods. All 
available methods of investigation should 
be used to delineate the extent of the pri­
mary tumour. Very generous tissue vol­
umes should then be irradiated.
It is unclear from our experience whether 
TBI is an effective systemic treatment. The 
5-year survival rate of 38% for 26 patients 
who received this treatment, with or with­
out cyclophosphamide and vincristine, sug­
gests that it may be of value. The elective 
irradiation of tissues likely to be involved 
with micrometastases at diagnosis therefore 
remains an active area of investigation.
O st e o g e n ic  Sarcoma
Historical Considerations
Extensive experience with preoperative 
irradiation for osteogenic sarcoma demon­
strated that tumour response was slow and 
frequently incomplete, even at high dosage. 
For example at the PMH from 1958 to 
1970, 27 patients less than 30 years of age 
were treated by initial irradiation of a 
peripheral tumour to a dose of 5000 to 
6000 rad in 25 to 30 fractions. Response 
was judged to be complete in 3, partial in 
17 and absent in 7. The primary tumour 
recurred in all 27 patients within a median 
time of 3.6 months.11 Therefore, this did 
not prove to be a useful palliative man­
euver, while we sought to select for delayed 
amputation patients in whom the risk of 
development of pulmonary metastases was 
small. Irradiation of the peripheral primary 
tumour has therefore been abandoned, at 
least in North America.
Massive irradiation immediately preoper- 
atively has also had adequate trial. The ra­
tionale was that this might be a tumour- 
specific immunologic stimulus and also that 
viable tumour cells would not be liberated 
at the time of resection. Results were un­
equivocally negative.12
Recent Advances
Until recently the mortality rate for osteo­
genic sarcoma was about 80%. Failure of 
treatment was due almost entirely to the de­
velopment of, and the failure to control, 
pulmonary metastases. Two advances have 
changed this situation. First, it became ap­
parent that multiple pulmonary resections 
could salvage some patients with overt pul­
monary metastases.13 In as many as 50% 
of patients in whom pulmonary metastases 
eventually appear, only a small number of 
foci exist, so that cure by resection is prac­
tical. Second, effective adjuvant chemothe­
rapy with either doxorubicin or high-dose 
methotrexate with citrovorum factor rescue 
was developed, with a 50% chance of era­
dicating micrometastases present at the time 
of diagnosis.14’ 13
The combination of adjuvant chemothe­
rapy with pulmonary resection when neces­
sary has markedly increased the survival 
rate, in osteogenic sarcoma. For example, at 
the PMH the 2-year survival rate increased 
from 18 to 81% when 31 patients, less 
than 30 years old, treated during the period 
1958 to 1970, were compared with 16 
treated during 1974 and 1975 (Fig. 6).
Current Indications for Irradiation
The success of doxorubicin and high-
Fig. 6.—Comparison of survival rates for 16 patients with osteogenic sarcoma, less than 30 years old, referred postoperatively to Princess Margaret Hospital, Toronto (PMH) during 1974 and 1975 for elective systemic therapy and for 38 patients treated during 1958 to 1970 at PMH.
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dose methotrexate in the adjuvant context 
required that the effectiveness at the pri­
mary site of irradiation combined with 
these drugs be evaluated. Since in some 
patients the tumour site makes resection 
impracticable, experience with this bimodal 
approach is accumulating. Three patients 
with primary osteogenic sarcoma in the 
sacroiliac region have been treated at the 
PMH in this manner.10
Case 1.—A 12-year-old girl had both a 
primary tumour in the sacroiliac region and a 
single secondary in the os calcis. The primary 
tumour was irradiated with 6000 rad (in 30 
fractions) and the secondary with 2500 rad 
(in 5 fractions). This was followed over a pe­
riod of 8 months by a course of doxorubicin 
to a cumulative dose of 550 m g/m 2 and subse­
quently by intermittent high-dose methotrexate. 
She continued in complete remission more than 
39 months from the time of diagnosis. The 
hypoxic cell sensitizer, metronidazole, was 
given during irradiation. Evidence of late 
toxicity included major bone degeneration in 
the irradiated area and soft tissue fibrosis.
Case 2.— A 16-year-old girl had a primary 
tumour at the sacroiliac joint and a small 
shadow, assumed to be a metastasis, in the left 
lower lung. The primary site was irradiated 
with 5000 rad (in 24 fractions). Doxorubicin 
was given concurrently followed by combina­
tion treatment with doxorubicin and high-dose 
methotrexate. Doxorubicin given after she had 
received 4200 rad caused acute enteritis. The 
patient remained in complete remission more 
than 11 months from the time of diagnosis. 
Late toxic manifestations included an episode 
of small bowel obstruction requiring laparo­
tomy.
Fig. 7.—Case 3. Extent of left sacroiliac chon- 
droblastic osteogenic sarcoma is demonstrated. 
Note soft tissue pelvic component of mass and 
direct invasion of, and seeding within, spinal canal.
Case 3 .— In this 23-year-old woman a 
primary osteogenic sarcoma of the sacroiliac 
area was recently diagnosed. Seeding within 
the spinal canal was evident (Fig. 7). Local ra­
diation was given to 4750 rad in 23 fractions 
combined with high-dose methotrexate in the 
1st and 3rd weeks of irradiation. Metronidazole 
(1 to 3 g/d) was given 4 hours before irradia­
tion. A severe skin reaction required that treat­
ment be discontinued before 5000 rad was re­
ceived as planned. It is too early to assess this 
patient’s response to irradiation.
It is possible that irradiation control of 
the primary tumour may have been enhanced 
in these patients by the chemotherapy, since 
in our earlier experience with 27 irradiated 
patients less than 30 years old only 3 pa­
tients had a “complete” response and this 
response was of only 3 to 6 months’ dura­
tion. However, the toxicity has been high.
Control of primary osteogenic sarcoma 
with irradiation at high-dose-per-fraction 
megavoltage combined with the radiosensi­
tizer, 5 -bromodeoxyuridine, and systemic 
therapy with high-dose methotrexate, doxo­
rubicin, cyclophosphamide and vincristine 
has recently been reported.17 The high-dose 
fractions were used since there is a broad 
shoulder to the cell survival curve for osteo­
genic sarcoma irradiated in vitro.18
Metastatic Lung Disease
Whole lung irradiation alone to a dose of 
2000 rad in 20 fractions has little demon­
strable effect ^fcovert metastatic disease of 
the lung. Individual lung metastases may re­
spond to small-volume high-dose irradia­
tion.
Elective irradiation of the lung (1500 rad 
over 14 d) following control of the primary 
site has been subjected to prospective ran­
domized clinical trial. At the Mayo Clinic 
no observable effect was found, although at 
48 months approximately, 37% of all pa­
tients were without pulmonary metastases.10
Conversely, in a cooperative prospective 
randomized clinical trial, 41% of the elec- 
tively irradiated patients (1750 rad in 10 
fractions over 12 d) were free of metas­
tases at 48 months compared with 26% of 
those with no irradiation of the lung (P =  
0.08).20' 21
Since radiation is an active agent in osteo-
✓
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genic sarcoma, its elective use in combina­
tion with chemotherapy to eradicate occult 
pulmonary metastases is currently under 
active study.
Conclusions
Resection is the primary treatment of 
choice in osteogenic sarcoma. There are pro­
visional data indicating that, when resection 
is not practical, the primary tumour may be 
controlled by irradiation in combination 
with effective chemotherapeutic agents and 
possibly with radiosensitizers. The duration 
of medical control is uncertain but appears 
to be greater than that achieved with irra­
diation alone.
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CURRENT CONCEPTS IN THE MANAGEMENT OF DISSEMINATED 
MALIGNANT BONE DISEASE IN CHILDHOOD*
NORMAN JAFFE, MB, BCh, Dip Paed
Disseminated malignant disease should be ap­
proached with the intention of curing the patient. 
This requires a multidisciplinary approach. Es­
sential to the successful application of multi­
disciplinary treatment is the administration of 
effective chemotherapy, which may achieve re­
duction in both microscopic disease and overt 
tumour. In Ewing’s sarcoma, the latter should be 
treated also by irradiation. Limited areas of bulk 
tumour that have failed to respond or have re­
sponded only partially may be removed surgical­
ly. Chemotherapy and radiation therapy should 
be used extensively for palliation; surgery may 
be required occasionally for control of pain. The 
decision to treat palliatively should be reached 
only after patients have received multidisciplin­
ary consultation.
Les neoplasies disseminees devraient etre 
abordees avec I’intention de guerir le patient. 
Ceci requiert un apport multidisciplinaire. Line 
chimiotherapie efficace est essentielle au suc- 
ces d'un traitement multidisciplinaire. Elle peut 
permettre d’enrayer aussi bien les lesions mi- 
croscopiques que la tumeur macroscopique. 
Dans le sarcome d'Ewing, il y a lieu de recourir 
aussi a I’irradiation. Des regions limitees d'une 
masse tumorale qui n’a pas repondu au traite­
ment ou qui y a repondu partiellement peuvent 
etre enlevees chirurgicalement. La chimiothe­
rapie et la radiotherapie devraient etre fre- 
quemment utilisees comme traitement palliatif; 
la chirurgie peut etre necessaire a I’occasion 
pour controler la douleur. La decision d'entre- 
prendre un traitement palliatif ne devrait etre 
prise qu’apres que les patients aient repu une 
consultation multidisciplinaire.
D uring the past decade, major progress has 
been made in the management of several 
childhood tumours.115 This derives from 
the application of adjuvant chemotherapy to
*From the Sidney Farber Cancer Institute, Chil­
dren’s Hospital Medical Center, and Harvard 
medical school, Boston, MA.
Supported in part by a research grant (CA06516) 
from the National Cancer Institute and by grant 
RR-05526 from the division of research facilities 
and resources, National Institutes of Health.
Presented at the conference “Modern Concepts of 
Bone Tumor Treatment”, Ottawa, Ont., May 12 
and 13, 1977.
Reprint requests to: Dr. Norman Jaffe, Sidney 
Farber Cancer Institute, 44 Binney St., Boston, 
MA 02115, USA.
destroy clinically undetected micrometa- 
stases and the adoption of an integrated 
multidisciplinary approach to the treatment 
of established disease. This paper reviews 
current concepts in the management of dis­
seminated malignant disease in childhood 
with particular reference to osteogenic sar­
coma and Ewing’s sarcoma.
G eneral  Pr in ciples
Histologic Diagnosis
Meticulous histologic confirmation of the 
tumour is basic to planning an optimal 
course of therapy and will assist in differen­
tiating primary malignant tumours of bone 
from metastatic infiltration from other 
sources. Tumours that most frequently me­
tastasize to bone include neuroblastoma, 
rhabdomyosarcoma and soft tissue sarcomas. 
Occasionally Ewing’s sarcoma must be dif­
ferentiated from nonHodgkin’s lymphoma 
and early leukemia, and osteogenic sarcoma 
from fibrosarcoma and chondrosarcoma.
Assessment of Extent of Disease (Staging)
After confirmation of the existence of a 
neoplasm, its full extent must be determined. 
In bone diseases, investigation for this 
purpose includes radiographic examination 
of the chest, complete lung tomography and 
fluoroscopy if indicated. Radiographic ex­
amination of the skeleton has generally been 
replaced by bone scintigraphy, reserving the 
former for sites dictated by the scintigram. 
Bone marrow examination is frequently per­
formed in suspected cases of Ewing’s sar­
coma or nonHodgkin’s lymphoma of bone. 
Other examinations are carried out as indi­
cated.
Evaluation of Previous Treatment
A fujl assessment of the treatment pre­
viously administered is of critical impor­
tance. This applies particularly to chemo­
therapy. Occasionally patients considered 
unresponsive to a specific chemotherapeutic 
regimen may obtain a response when the 
dose and schedule of the identical agents 
are altered. This has been demonstrated
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in the weekly high-dose methotrexate pro­
gram (vincristine-methotrexate-citrovorum 
factor).3
Multidisciplinary Conference
Once the full extent of disease has been 
established, expertise from each discipline 
is elicited for the planning and strategy of 
further treatment. Each patient receives in­
dividual consideration, and invariably the 
approach should be with “an intent to cure” . 
Patients generally will fall into two major 
categories: those in whom cure is possible 
and those who cannot be cured.
Curable advanced metastatic disease. — 
Chemotherapy in these patients forms the 
vanguard of treatment. When administered 
in an aggressive and systematic manner, de­
struction of tumour may result in impressive 
responses and it may be possible to transfer 
the patient from a “palliation” treatment 
status to one of “potential cure”. If a satis­
factory response is achieved, one may reach 
a decision to ablate the primary lesion if 
this has previously not been performed. 
Foci that fail to respond or foci of residual 
disease, if limited, may be removed sur­
gically or treated by irradiation. After a 
complete remission, further treatment is with 
adjuvant chemotherapy.
Palliation. —  This form of treatment con­
stitutes the bulk of clinical practice in pa­
tients with disseminated disease since cure is 
usually not attainable when the disease is 
widespread. The decision to palliate should 
be made at the multidisciplinary consultation. 
Analgesics should then be administered judi­
ciously and without restriction. Chemothe­
rapy and radiation therapy are indispensable 
for treating patients in this category. Fre­
quently their application may reduce turnout- 
bulk and prolong useful life.8- »• 13 Surgery 
also has a definite role in palliation. In some 
instances cervical chordotomy may be 
recommended. Occasionally the pain in a 
swollen functionless limb is so intense that 
relief may be possible only through am­
putation. The family should be fully ap­
prised of the goals of treatment, and ade­
quate supportive care should be provided.
The general principles governing the man­
agement of disseminated disease in children 
are particularly applicable to osteogenic sar­
coma and Ewing’s sarcoma, in which the 
evolution of new treatment programs has 
produced a number of unusual complica­
tions. These have required more specific 
forms of management and will be discussed 
in greater detail.
Osteogenic Sarcoma
Effective chemotherapy has induced a 
change in the biologic behaviour of osteo­
genic sarcoma. In the majority of patients, 
micrometastases appear to have been de­
stroyed and in the minority who relapse, me- 
tastases of the lungs, the most frequent 
site of spread, have been reduced and de­
layed.2 0 This has prompted more aggres­
sive treatment to render additional patients 
free of disease.5 Essentially, attempts are 
made to achieve an NED (no evidence of 
disease) status by the administration weekly 
of a combination of vincristine and high- 
dose methotrexate with citrovorum factor 
(V-MTX-CF). Metastases that fail to re­
spond are removed surgically. Radiation 
therapy combined with V-MTX-CF weekly 
may be administered if the tumour has been 
incompletely resected. After an NED status 
has been achieved, V-MTX-CF is admin­
istered at 3-weekly intervals on the assump­
tion that this can still be effective against 
residual microscopic disease. Doxorubicin 
(Adriamycin) is also prescribed for patients 
who have not received this agent previously. 
With this approach, 12 of 24 patients have 
been rendered free of disease for periods 
varying from more than 7 to more than 
52 months (updated from original publica­
tion"’).
The alteration in metastatic pattern has 
not been limited to the pulmonary paren­
chyma- During the past 2 years in seven 
patients undergoing treatment with adjuvant 
programs, metastases developed in iliac 
nodes, ribs, femora, vertebrae or other bones. 
Surgical removal of metastatic tumour was 
attempted in most with gratifying results. 
Radiation therapy and V-MTX-CF weekly 
were also administered to some patients. In 
those with lesions of the femur, internal 
prostheses were used, permitting further 
ambulation.5
Involvement of the vertebral bodies by 
metastatic osteogenic sarcoma represents an
November 1977 THE CANADIAN JOURNAL OF SURGERY 539
emergency situation. It occurred in three 
patients who had been treated with V-MTX- 
CF for 20 to 24 months after the diagnosis 
had been made and treatment initiated. 
Pulmonary metastases had appeared approx­
imately 8 months earlier. In view of the 
limited number of pulmonary metastases, 
the potential for extended survival appeared 
excellent. In one patient, immediate neuro­
surgical decompression to secure viability 
of the spinal cord was undertaken. This was 
followed by radiation therapy (3500 rad), 
which was also administered to the other 
two patients. In all three symptomatic im­
provement and retention or restoration of 
neurologic function were achieved. The 
complication may be detected' incidentally 
on radiographic examination or may mani­
fest with pain, sudden onset of paralysis or 
paresis and inability to void urine. The site 
of obstruction is demonstrable by myelo­
graphy. The problem will probably be en­
countered with increasing frequency in the 
future and will represent a major challenge.
Metastases to bone may be particularly 
painful. Frequently such pain can be re­
lieved by irradiation and weekly treatments 
of V-MTX-CF. More recently we have ob­
tained similar gratifying results with cis- 
platinum (50 m g/m 2) administered on 2 
consecutive days every 3 weeks. In one pa­
tient objective and subjective responses were 
obtained. Further investigations with cis- 
platinum are in progress.
E w in g ’s Sarcoma
Various chemotherapeutic regimens are 
effective in Ewing’s sarcoma and several 
have produced complete remission.8’ •' This 
provides compelling support for the use of 
chemotherapy in patients with metastatic 
disease. Combinations of vincristine, actino- 
mycin D, doxorubicin and cyclophospha­
mide have prolonged survival. However, in 
most patients the responses were tempo­
rary.8’ !) Additional or alternative modes of 
therapy are indicated.
Radiation therapy is also effective in the 
treatment of Ewing’s sarcoma. This is gen­
erally administered as treatment of the pri­
mary lesion in association with chemothe­
rapy. Most investigators report a high degree 
of local control. Their experience indicates
that patients with metastatic disease should 
receive a combination of radiation therapy 
and chemotherapy. Chemotherapy should 
be administered principally to destroy mi­
croscopic tumour and, it is hoped, areas of 
bulk disease wherever possible. The latter 
should also be irradiated to achieve a more 
durable response. Surgical ablation of resi­
dual disease, if limited, or of isolated tu­
mours that have failed to respond, might 
also be considered.
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BONE SARCOMAS: CLINICAL EXPERIENCE*
JOSEPH G. SINKOVICS, MD, FACPt and CARL PLAGER, MD
Sarcomas of osseous origin form a heterogen­
eous group of tumours with great variability in 
their natural history. Irradiation is an established 
etiologic factor. The possibility of oncornaviral 
etiology offers a unifying concept. Patients with 
osseous sarcomas respond immunologically to 
their tumours. Immunotherapeutic measures 
have not as yet conferred more than marginal 
benefit when applied adjunctively with conven­
tional therapy. Chondrosarcoma is a surgically 
curable tumour still resistant to radiotherapy and 
chemotherapy. Adjuvant chemotherapy with 
doxorubicin or with high-dose methotrexate and 
citrovorum factor rescue can suppress or eradi­
cate the micrometastases of osteogenic sar­
coma. Ewing's sarcoma is highly sensitive to ra­
diotherapy and chemotherapy, and adequately 
treated patients can now survive, clinically free 
of tumour, for long periods.
Les sarcomes d'origine osseuse forment un 
groupe heterogene de tumeurs ayant une gran­
de variabilite dans leur etiologie naturelle. L’ir- 
radiation est un facteur etiologique reconnu. La 
possibility qu'ils originent d’un virus oncorna 
offre une notion d’unification. Les patients souf- 
frant de sarcome osseux reagissent immunolo- 
giquement a leur tumeur. Jusqu'a maintenant 
I’immunotherapie n'a confere que de faibles 
benefices lorsque administree en appoint au 
traitement conventionnel. Le chondrosarcome 
est une tumeur qui peut etre guerie par la chi- 
rurgie mais qui demeure resistante a la radio- 
therapie et a la chimiotherapie. Une chimiothe- 
rapie d’appoint avec de la doxorubicine, ou avec 
de fortes doses de methotrexate et du leucovo- 
rin au besoin, peut diminuer ou eliminer les mi­
crometastases du sarcome osteogene. Le sarco­
me d’Ewing est tres sensible a la radiotherapie 
et a la chimiotherapie, et les patients adequa- 
tement traites peuvent survivre, cliniquement 
exempts de tumeur, pour des periodes prolon- 
gees.
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The clinical behaviour of sarcomas of osse­
ous origin is highly variable. Ewing’s sarco­
ma may be multicentric in origin or may 
metastasize rapidly through hematogenous 
routes after its inception. The classic intra­
medullary osteogenic sarcoma is notorious 
for having produced pulmonary micrometas­
tases by the time of its diagnosis. In contrast 
the typical chondrosarcoma is characterized 
by slow and localized growth and a tendency 
to metastasize late in its clinical course.
E w in g ’s Sarcoma
There is no doubt that adequate therapy 
for Ewing’s sarcoma should not be directed 
to the primary tumour only.1' - At our clin­
ics, patients without clinically evident me- 
tastases presently receive radiotherapy 
(> 5000 rad megavoltage in > 5 weeks) to 
the primary tumour and systemic chemothe­
rapy with vincristine (1.5 mg/m- on day 1, 
intravenously), cyclophosphamide (200 mg/ 
d on days 3, 4 and 5, orally) and doxoru­
bicin (Adriamycin) (60 mg/m- on day 2, 
intravenously) at 28-day intervals until a to­
tal dose of 450 mg/m- of doxorubicin is 
reached. Thereafter doxorubicin is replaced 
with actinomycin D (0.3 m g/m -’d) on days 
1 to 5 within each course, but courses are 
given at 8-week intervals for a total treat­
ment time (including previous courses with 
doxorubicin) of 2 years. Patients with meta­
static disease receive radiotherapy to selected 
painful bone metastases and systemic chemo­
therapy with vincristine, cyclophosphamide, 
doxorubicin and dimethyl-triazeno-imida- 
zole-carboxamide (DTIC). Table 1 presents 
the clinical data for 16 patients we have 
treated in the past 2 years with a follow-up 
of approximately 2 years. No evidence of 
disease (NED) status was achieved at 2 years 
in five of six patients treated as cases of pri­
mary presentation. The new treatment regi­
men to be implemented in 1977 will consist 
of the same schedule for radio- and chemo­
therapy, but between courses of chemothe­
rapy immunotherapy will also be admin­
istered; that is, on days 13, 17 and 24 pa­
tients will receive live Chicago bacille Cal­
mette Guerin (BCG) by scarification and
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TABLE I.—Results in P atients with Ewing’s Sarcoma T reated with Radiotherapy and Chemo­
therapy, 1975 to 1977
E xtent o f disease at in itia tion N o. o f
Clinical evaluation  
at 8 — 30 mo
N E D  status Progression o f diseaseo f treatment patients
Primary*.................................. 6 5 1
Metastatic).............................. 10 3J 7§
“Received vincristine (VCR), cyclophosphamide (CTX) and doxorubicin (DXR) with actinomycin D
■(Received VCR, CTX, DXR, Act D and dimethyl-triazeno-imidazole carboxamide (DTIC).
J1 patient died of DXR cardiotoxicity. , .
§2 patients were inadequately treated (refused or could not take more than 1 to 3 courses of chemotherapy).
intracutaneous inoculations of “viral onco- 
lysates” prepared from an established cell 
line of Ewing’s sarcoma.3 Pseudomonas 
vaccine if available for this purpose will be 
given preference over BCG.
Osteogenic Sarcoma
The natural history of this tumour varies 
according to the cell type (fibroblastic being 
the least, and osteoblastic the most, malig­
nant, with chondroblastic tumours running 
an intermediate course) and the location and 
size of the primary tumour. Osteogenic sar­
coma of the facial bones carries a good prog­
nosis, there being approximately 50% survi­
vors at 3 years, and still over 40% survivors 
at 5 years. The most frequent primary site 
is the femur; primary tumours in the proxi­
mal femur follow a much more malignant 
clinical course than those located distally. 
At the M. D. Anderson Hospital there were 
no 5-year survivors among patients with 
primary osteogenic sarcoma of the proximal 
part of the femur, whereas the 3- and 5-year 
survival rates for patients with primary tu­
mours in the distal half were 23 and 12%, 
respectively.4 In addition to the classic in­
tramedullary osteogenic sarcoma, periosteal, 
parosteal, extraosseous and other variants 
of this tumour exist; the parosteal variant 
is the least malignant.
Death from osteogenic sarcoma is fre­
quent because of an extremely high (over 
80%) incidence of hematogenous pulmonary 
metastases. Two powerful treatment modali­
ties have recently reduced postamputation 
mortality and achieved remission in meta­
static disease; these are systemic chemothe­
rapy with doxorubicin or with high-dose 
methotrexate with citrovorum factor rescue.
These modalities can be applied in combina­
tion, and the methotrexate regimen aug­
ments the efficacy of low-dose radiother­
apy. 5-0
In addition to immunotherapy in the form 
of nonspecific immunostimulation, we and 
others (page 494) have applied sarcoma-spe­
cific immunization with x-irradiated alloge­
neic (or autologous) tumour cells, sarcoma 
cell lysates (including viral oncolysates), lym­
phocyte mediators (transfer factor and in­
terferon) and lymphocyte transfusions.10’ 11 
The overall results of immunotherapy have 
been disappointing, but not entirely with­
out promise. For example, both transfer 
factor and interferon appear to suppress 
subclinical micrometastases of osteogenic 
sarcoma.
The contrast between soft tissue sarcomas 
and osteogenic sarcoma in terms of response 
to active immunization remains unexplained. 
Modest benefits derived from nonspecific 
immunostimulation and sarcoma-specific 
immunization to patients with soft tissue sar­
comas; sarcoma-specific immunization was 
carried out with either x-irradiated sarcoma 
cells12 or viral oncolysates of sarcoma 
cells.13 In the latter trial, patients with me­
tastatic sarcomas received chemotherapy for 
5 days at 29-day intervals and on days 17 
and 24 they received Chicago BCG scarified 
in the skin and intracutaneous inoculations 
of lysed sarcoma cells prepared from estab­
lished allogeneic cultures infected with the 
harmless PR8 influenza A virus with the 
purpose of stabilizing antigens expressed at 
the cell membrane. The least number of 
progressors were found in the group receiv­
ing chemoimmunotherapy.13 Similar trials, 
that is, immunization of patients with clin­
ical or subclinical osteogenic sarcoma with
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TABLE I I —Therapy for Osteogenic Sarcoma After Amputation, 1975 to 1977
Vol. 20
Clinical status
No. of 
patients Treatment A t initiation of treatment A t 9 — 24 mo
4 VCR, CTX, DXR, DTIC NED NED > 24 mo
1* VCR, CTX, DXR, DTIC NED NED > 24 mo
1 VCR, CTX, DXR, DTIC Pulmonary metastases Progression
MeCCNU, Act D Pulmonary metastases PR, stable > 24 mo
1 VCR, CTX, TF, BCG, DXR, 
DTIC, VO
Pulmonary metastases Progression
M TX, XRT Pulmonary metastases Stable
1 VCR, CTX, DXR, DTIC Pulmonary metastases Dead
1 RBD, DTIC Pulmonary metastases Dead
5 COnPAdr NED Progression
DXR, DTIC Pulmonary metastases Progression in 4 (1 died) 
PR, then progression in If
MTX, XRT Pulmonary metastases PR, then progression in 1 
Stable, then progression in 2 
(1 died)
Progression in 1
1
GCB
L5 excision. Allograft, 1970 
2100 rad NED Recurrence 1972
4488 rad a t 22 MV Recurrence Progression
RBD, DTIC Stable, then progression, 1976
tAIso received bacille Calmette Guerin (BCG) and viral oncolysates (VO).
P CB “ 11 tumour of bone;MeCCNU = methylcyclohexyl-chloroethyl-nitrosourea; TF = transfer
factor; M TX = high-dose methotrexate with citrovorum factor rescue; XRT = radiotherapy; COnPAdr = 
cyclophosphamide, Oncovin (vincristine), phenylalanine mustard, Adriamycin (doxorubicin)- NED = 
no evidence of disease; PR = partial remission.
x-irradiated osteogenic sarcoma cells or with 
various osteogenic sarcoma cell lysates, 
failed to influence the course of this disease.
Table II summarizes our clinical experi­
ence in 15 patients with this tumour limited 
to the past 2 Vi years. It is evident that post­
amputation treatment with vincristine, cyclo­
phosphamide, doxorubicin and DTIC pre­
vented clinical manifestation of metastatic 
disease. The Southwest Oncology Group 
protocol has been applied successfully for 
the adjuvant treatment of postamputation 
osteogenic sarcoma and it will be presented 
elsewhere (unpublished data). Once meta- 
stases became evident, the same chemothe­
rapy, chemotherapy with high-dose metho­
trexate and citrovorum factor rescue with 
radiotherapy, and various modalities of im­
munotherapy failed to gain long-lasting con­
trol over the disease. One patient with 
malignant giant cell tumour of bone has been 
included. Brief, temporary tumour response
was noted to rubidazone, but it was less than 
that required to qualify for a partial remis­
sion. Of the 15 patients, 5 had no evidence 
of disease more than 2 years after postampu­
tation treatment, 2 were stable at 1 and 2Vi 
years, 4 had progression of their disease be­
tween 9 months and 2 years and 4 died dur­
ing that time.
Chondrosarcoma
In a previous review of 83 patients treated 
at our institution, the pelvis was the most 
common primary site.1 ^  This tumour differs 
substantially from osteogenic sarcoma in its 
natural history. The peak incidence is in the 
older age groups. Radical surgery has been 
curative for chondrosarcoma; decades of 
tumour-free survival follow for most patients 
who have undergone adequate operation. 
Another difference between osteogenic sar­
coma and chondrosarcoma is the relative
November 1977 THE CANADIAN JOURNAL OF SURGERY 545
TABLE III.'—P atients T reated for Chondrosarcoma, 1976 to 1977
Patient
no. Clinical status and location Treatment Clinical course
i Well-differentiated tumour of sternum 
Pulmonary metastases
Excision, 1973 
BCG, VO, 1976 
RBD, DTIC, 1976
Progression, 1977 
Progression, 1977
2 Myxoid tumour of chest wall Local immunotherapy, 1976 
RBD, DTIC, 1976
Brief remission, 
1976
Progression, 1977
3 Grade 2 tumour of humerus Disarticulation, 1973 NED, 1977
4 Myxoid tumour of sacrococcyx 
Pulmonary and abdominal metatases, 1976
VCR, CTX, DXR, DTIC, 
1976 Dead, 1976
5 Poorly differentiated tumour of left knee. 
Pulmonary metastases
5000 rad, 1973 
BCG, VO, RBD, DTIC, 
1976
Progression, 1976 
Progression, 1977
6 Myxoid tumour of right knee 
Pulmonary metastases
6000 rad, 1973. 
McCCNU, DTIC, 1976
Progression, 1976 
Progression, 1977
7 Grade 3 tumour of L4 Excision. 5000 rad, 1976 
VCR, CTX, DXR, DTIC, 
BCG, VO, 1976 NED, 1977
8 Dedifferentiated tumour of right femur 
Pulmonary metastases
Disarticulation, 1976 
VCR, CTX, DXR, DTIC, 
1976 Progression. 1977
radiotherapeutic and chemotherapeutic resis­
tance of the latter. While the response rate of 
osteogenic sarcoma to doxorubicin is almost 
30%, less than 15% of the chondrosarco­
mas are known to have responded. In pre­
dicting the clinical course of a chondrosar­
coma, grading is essential. Low-grade tu­
mours (those without mitotic cells) may re­
cur locally if inadequately removed, but they 
seldom metastasize. The 5- and 10-year sur­
vival rates for patients with these tumours 
are estimated to be 90 and 83%, respective­
ly. Grade 3 tumours (those with more than 
two mitotic cells per high-power field) dis­
play a high propensity for distant metastasis 
with estimated 5- and 10-year survival rates 
of 43 and 29%, respectively. The moderate­
ly malignant grade 2 tumours lie in between, 
with a local recurrence rate of about 50%, 
but their propensity for metastasis is still 
low (grading as practised at M. D. Anderson 
Hospital and Tumor Institute, unpublished). 
The dedifferentiated or spindle cell chondro­
sarcomas carry a poor prognosis. The preli­
minary impression at our institution is that 
poorly differentiated chondrosarcomas re­
spond better to doxorubicin than do the 
well-differentiated tumours.
At present we attend eight patients with
chondrosarcoma at our clinics (Table III). 
It is evident that metastatic disease in this 
group of patients has failed to respond to 
chemoimmunotherapy.
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EVALUATION OF INTRAOPERATIVE BIOPSY OF THE PANCREAS*
C. JAMIESON, MB, BS, FRCS[C], K. D. BURY, MD, FRCS[C1, FACS and 
N. D. COLAPINTO, MD, FRCS[C], FACS
The authors carried out a retrospective review 
of intraoperative biopsy of the head of pancreas 
in 47 patients. Vim-Silverman needle biopsy (32 
patients), or wedge biopsy (9 patients), or both 
(5 patients) were used. The correct diagnosis in 
the 34 patients with carcinoma was made in 
76%  by paraffin section and in 65%  by frozen 
section. Diagnostic accuracy was 77%  with 
needle biopsy and 38% with wedge biopsy. Com­
plications occurred in six patients and consisted 
of pancreatitis, fistula and hemorrhage. Two pa­
tients required reoperation because of hemor­
rhage. The case of one patient who died of a 
pancreaticoperitoneal leak at the biopsy site is 
described in detail. The overall complication rate 
was 15%. These results indicate that wedge 
biopsy carries significant risks and frequently 
does not detect carcinoma. Needle biopsy is 
relatively safe and is more likely to provide an 
accurate diagnosis of carcinoma.
Les auteurs ont realise une etude retrospective, 
chez 47 patients, des resultats de biopsies de la 
tete du pancreas prises lors d'une intervention 
chirurgicale. Une biopsie a I’aiguille Vim-Silver­
man (32 patients), ou une biopsie conique (9 
patients), ou les deux (5 patients), ont ete utili- 
sees. Le diagnostic correct chez les 34 patients 
souffrant de carcinome a ete obtenu chez 76% 
par coupe a la paraffine, et chez 65%  par coupe 
surgelee. La precision de diagnostic a ete de 77% 
avec la biopsie a I'aiguille et de 38%  avec la biop­
sie conique. Des complications, consistant en pan-
*From the departments of surgery, The Wellesley 
Hospital and St. Michael’s Hospital, University of 
Toronto, Toronto, Ont.
Reprint requests to: Dr. N. D. Colapinto, Ste. 503, 
55 Queen St. E., Toronto, Ont. M5C 1R6.
creatite, fistule et hemorragie, sont apparues 
chez six patients. Deux patients ont necessity 
une deuxieme intervention pour juguler une he­
morragie. On decrit en detail le cas d'une pa- 
tiente qui est decedee des suites d'une fistule 
pancreatoperitoneale au point de biopsie. Le 
taux global de complication a ete de 15%. Ces 
resultats indiquent que la biopsie conique com- 
porte des risques significatifs et souvent ne per- 
met pas de deceler un carcinome. La biopsie a 
I'aiguille est relativement sOre et elle est plus 
susceptible d'assurer un diagnostic precis de 
carcinome.
Intraoperative biopsy of the pancreas re­
mains controversial, with disagreement 
among surgeons as to the value and dangers 
of different methods of biopsy.1'" Often it 
is difficult at operation to distinguish be­
tween carcinoma and chronic pancreatitis 
when a hard localized mass is found in the 
head of the pancreas. Some experienced sur­
geons are prepared to resect such a mass 
without histologic confirmation that it is a 
carcinoma;1"'1- in less than 2% of such in­
stances do they mistakenly resect a benign 
lesion. Most surgeons would probably re­
sect benign lesions in error more often if 
they did not first obtain a biopsy. If a carci­
noma of the pancreas was considered unre- 
sectable at operation, the patient and his 
family would benefit from an accurate diag­
nosis and prognosis, but biopsy in this 
situation probably would not alter the 
method of management and therefore would 
be an unjustified risk. Some surgeons be-
>
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lieve that biopsy is never indicated.3
Because of this unresolved controversy 
we carried out a retrospective study of our 
recent experience with intraoperative biopsy 
of the head of the pancreas.
Patients and Methods
In this analysis we reviewed all intraoper­
ative biopsies of the head of pancreas per­
formed by different surgeons at two Toronto 
teaching hospitals during the 10-year period, 
1966 to 1975. Cases involving biopsy of 
surrounding lymph nodes, and lesions of the 
ampulla, tail or body of the pancreas were 
excluded.
In 35 of the 47 patients the indication for 
surgery of the pancreas was obstructive 
jaundice. The other patients underwent 
biopsy because carcinoma was suspected, an 
abdominal mass was present, or because a 
mass was found in the pancreas during an 
unrelated abdominal procedure.
The biopsy was taken either by needle 
(Vim-Silverman) or as an incisional wedge 
(Table I). Most patients had more than one 
biopsy. Some underwent repeated biopsy 
until a positive diagnosis was obtained; one 
patient required 10 needle biopsies. In those 
in whom the needle was used the average 
number of biopsies was 2.3. All material ob­
tained by biopsy was examined by frozen 
section at the time of the operation and by 
paraffin section later. Each biopsy specimen 
was interpreted by several different patho­
logists.
In addition to biopsy, 28 patients under­
went some type of biliary-enteric bypass, 
with or without gastrojejunostomy, and 7 
patients underwent pancreatectomy; 12 pa­
tients had biopsy only. One patient died as 
a result of biopsy. This case is reported in 
detail because it illustrates some of the prob­
lems that may occur with biopsy of the 
pancreas.
TABLE I.—B iopsy of Pancreatic Tumours
T y p e  o f  biopsy N o . o f  p a tien ts
Vim-Silverman needle 
biopsy (alone) 32 (7 transduodenal)
Wedge biopsy (alone) 9 (2 transduodenal)
Needle and wedge biopsy 5
Unknown 1
Total 47
Case R eport
A 63-year-old woman was admitted for in­
vestigation of obstructive jaundice and weight 
loss. Septic shock developed as a result of 
suppurative cholangitis. At laparotomy, the 
gallbladder was dilated and edematous, the 
common bile duct was dilated and anterior 
to it a discrete firm nodule was found in the 
head of pancreas. Purulent bile was drained 
from the duct and two small stones were re­
moved. The distal duct was patent. Biopsy of 
the pancreatic nodule was performed with a 
direct approach and a wedge ( 9 x 6  mm) was 
excised. Histologic examination of the speci­
men indicated only inflammation and fibrosis. 
Cholecystectomy and choledochoduodenosto- 
my were performed. The patient made an ex­
cellent recovery. Four weeks after operation 
she was readmitted with ascites, but she had no 
evidence of peritonitis and was otherwise in 
good health. We suspected there was a com­
munication between the pancreatic duct and 
the peritoneal cavity at the biopsy site. Our 
plan was to treat the patient with intravenous 
alimentation, to perform retrograde pancreato­
graphy followed by a pancreaticojejunostomy 
over the biopsy site. However, she deteriorated 
rapidly. In spite of peritoneal lavage she died 
3 days later of sepsis, peritonitis and respira­
tory failure. Peritonitis was confirmed at au­
topsy, but there was no evidence of pancrea­
titis. The biopsy site had not healed. When 
injected with radioapaque dye, the distal pan­
creatic duct appeared dilated and a proximal 
stricture was seen (Fig. 1). The biopsy site 
communicated with the pancreatic duct, distal 
to the stricture (Fig. 2). Histologic examination 
confirmed that this stricture was a small car­
cinoma. It is unlikely that this small deep 
lesion would have been identified by biopsy;
Fig. 1.—Postmortem pancreaticogram with am­
pulla cannulated. Proximal to stricture pancreatic 
duct is dilated.
548 THE CANADIAN JOURNAL OF SURGERY Vol. 20
Fig. 2.—Pancreas opened along duct displays 
stricture (lower arrow). Upper arrow indicates un­
healed biopsy site.
nevertheless, it was responsible for the sur­
rounding pancreatitis and probably contributed 
to the complication by obstructing the pan­
creatic duct.
R esu lts
Accuracy
Two of our 47 patients had probable car­
cinoma. If they are included with the 32 pa­
tients in whom pancreatic carcinoma was 
confirmed, the overall accuracy in diagnos­
ing carcinoma on paraffin section was 76%, 
compared with 65% by frozen section. 
Needle biopsy appeared to be more accurate 
than wedge biopsy (Table II). There were 
no false-positive reports.
Complications
Patients who underwent pancreatectomy 
following biopsy were excluded from those 
considered at risk from biopsy complica­
tions. Six patients had clinically significant 
complications that could be attributed to 
the biopsy itself, and all but one of these 
patients had multiple complications (Table
TABLE II.—Accuracy of Intraoperative Biopsy 
of Pancreas in 34 Patients with Carcinoma
Type of biopsy 
(iand no. of 
patients*)
Diagnosis made by
Frozen 
section, 
no. (and %)
Paraffin 
section, 
no. (and %)
Needle (30) 20 (67) 23 (77)
Wedge ( 8) 2 (25) 3 (38)
22 (65) 26 (76)
*Some underwent both needle and wedge biopsy.
III). Three patients had severe hemorrhage 
from the biopsy site; two required reopera­
tion to arrest the bleeding. Pancreatitis de­
veloped in these three patients; in one the 
condition was associated with pseudocyst 
and fistula, and in another with a subsequent 
fistula. Pancreatitis and cutaneous fistulas 
developed in two other patients. All fistulas 
eventually closed spontaneously, although 
one did not heal for 4 months. In another 
five patients, bleeding and enterocutaneous 
fistulas were probably caused by the asso­
ciated procedures rather than by the biopsy 
itself. The incidence of complications was 
low after needle biopsy alone (2 of 32), but 
was high after wedge biopsy alone (3 of 9). 
There were no complications in the nine 
patients who underwent transduodenal nee­
dle biopsy.
D iscussion
The diagnostic accuracy of pancreatic 
biopsy and the resulting complications vary 
widely in published reports. Errors in diag­
nosis are more often due to inaccurate sam­
pling than to mistaken interpretation. Inter­
pretation of small pancreatic biopsies is not 
easy. The pathologist must look for peri­
neural infiltration and subtle cytologic 
changes in order to recognize well-differen­
tiated lesions. When malignant tissue is 
obvious on the surface of the pancreas, only 
a small wedge is needed. Since wedge biopsy 
is usually used only in this situation, the 
relative accuracy and resulting complica­
tions of different biopsy methods may be 
influenced.
TABLE III.—Complications of Intraoperative 
Biopsy of Pancreas
Type of 
biopsy
No. of patients 
with
complications/ 
out of total
Type of 
complication
Vim-Silverman 2/32 Hemorrhage and
needle pancreatitis 
Fistula and 
pancreatitis
Wedge 3/9 Hemorrhage, 
pancreatitis 
and fistula 
Pancreatitis 
Fistula and 
pancreatitis
Both wedge 1/5 Hemorrhage,
and needle pancreatitis, 
fistula and 
pseudocyst
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Athough theoretically needle biopsy 
leaves only a small tract, our results suggest 
that there is still a small risk of subsequent 
development of fistula or pancreatitis. Such 
complications probably originate when the 
duct is obstructed by carcinoma and the 
needle establishes a pathway of escape for 
the pancreatic secretions. The secretions may 
leak into the gland parenchyma causing pan­
creatitis, and into the peritoneal cavity creat­
ing a fistula. A needle placed anywhere in 
the pancreas has an excellent chance of 
entering the ductal system at some point.3 
Although wedge biopsy resulted in a high 
incidence of complications in our series, 
George, Brown and Gilchrist8 reported 47 
successive wedge biopsies with no complica­
tions. They stressed the importance of avoid­
ing the main pancreatic duct when perform­
ing a wedge biopsy. Wedge biopsy was also 
found to be safe by Lightwood, Reber and 
Way;0 they reported a 3% morbidity rate 
and 87% accuracy with this method, but 
they reported three complications and two 
deaths after 22 needle biopsies, and their 
accuracy was only 50% . Fewer than half of 
the biopsies reported in that study were of 
the head of the pancreas, and the results 
therefore may not be comparable to ours. It 
is interesting that their complication rate 
with wedge biopsy was the same whether the 
biopsy was deep or superficial; this suggests 
that other factors such as dissection or mani­
pulation of the pancreas may be responsible 
for some complications. Hemorrhage is a 
danger with both techniques; although it 
may occur more often as a result of wedge 
biopsy, it is more easily recognized and con­
trolled. Another potential hazard of biopsy 
is traumatic implantation of tumour in an 
otherwise curable lesion, but this remains 
theoretical.
The operative findings in cases of carci­
noma of the head of pancreas may be similar 
to those of chronic pancreatitis. Features 
that are more typical of carcinoma are a 
dilated common bile duct, a discrete mass 
that is firm or hard, and a palpable dilated 
pancreatic duct.1".!* These findings, sup­
plemented by biopsy, will usually give a 
definitive diagnosis. An additional diag­
nostic technique is injection of the pan­
creatic duct with radiopaque dye; in pa­
tients with carcinoma, a typical gap be­
tween the smoothly dilated duct and the 
duodenum is revealed.12
Each situation must be dealt with indivi­
dually. If there are no hepatic or lymph- 
node metastases to biopsy, a decision must 
be made as to whether biopsy of the pan­
creas is justified. If there are unquestionable 
features of carcinoma there is no point in 
attempting to obtain a histologic diagnosis, 
since the lesion would be resected regardless 
of the results of biopsy. Material from a 
large superficial tumour may be obtained 
safely by taking a wedge biopsy with a scal­
pel, carefully avoiding the main ducts. A 
deeper mass is more safely biopsied with a 
needle. Tru-Cut (Travenol Laboratories 
Inc.) disposable biopsy needles are sharper 
than Vim-Silverman needles and easier to 
use in hard masses. If the mass is appro­
priately located, the needle should be in­
serted through both walls of the duodenum 
to reduce the risk of fistula.
Recent reports13' 13 of needle aspiration 
biopsy with immediate cytologic interpreta­
tion have shown a high degree of accuracy 
with no complications. A standard dispos­
able 20-mL syringe with a 21-gauge needle 
is used, and the needle is gently moved up 
and down in the mass while suction is ap­
plied. The suction is then released and the 
needle withdrawn. The syringe is detached 
from the needle, filled with air, reattached 
and used gently to blow the collected fluid 
and cells in the needle onto a glass slide. 
After fixing and staining, interpretation can 
be made in the same time it takes to perform 
a standard frozen section. The needle may 
be reinserted several times, without danger, 
to sample different areas.
In assessing the value of pancreatic biop­
sy there are other considerations. Cure is 
rare, and the operative mortality after resec­
tion of pancreatic carcinoma is high. There­
fore the benefits of a positive biopsy leading 
to resection are minimal. In comparison, 
death following pancreatectomy, without 
biopsy, for a lesion that is found to be benign 
is a tragedy. On the other hand, relatively 
curable lesions such as a penetrating carci­
noma of the ampulla may not be resected if 
a biopsy is not obtained because they are 
mistakenly thought to be pancreatic carci­
noma.
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C o n c l u s io n
In a retrospective review of 47 patients, 
intraoperative pancreatic biopsy success­
fully identified 76%  of the patients with 
carcinoma of the head of pancreas. The over­
all complication rate was 13% . Complica­
tions included pancreatitis, pseudocyst, fis­
tula and hemorrhage. One patient died after 
a wedge biopsy during which the pancreatic 
duct was entered resulting in a pancreati- 
co-peritoneal leak. Vim-Silverman needle 
biopsy was more accurate and safer than 
wedge biopsy; further improvement could 
probably be obtained by the use of aspira­
tion needle biopsy. Pancreatic biopsy at 
operation, if applied with discretion, is a 
valuable procedure in the management of 
pancreatic masses.
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RUPTURE OF THE DIAPHRAGM RESULTING 
FROM BLUNT TRAUMA IN CHILDREN*
LALIT K. SHARMA, MB, MS, FRCS.t RICHARD F.
and WALTER D. HENEGHAN, MB,
KENNEDY, MD, 
BCh, FRCP[C]§
CM, FRCS[C]t
Rupture of the diaphragm due to blunt trauma is 
rare in the pediatric age group. This article de­
scribes six such cases. This life-threatening con­
dition should be suspected in the case of any 
serious thoracoabdominal trauma, even in the 
presence of negative radiographic findings on 
initial evaluation. In the very sick child, horizon­
tal beam, lateral radiographs of the chest and 
abdomen have been extremely useful in estab­
lishing the diagnosis. The suspicion and investi­
gation of associated diaphragmatic injury will 
result in earlier diagnosis and treatment.
La rupture du diaphragme consecutive a un 
traumatisme contondant est rarement observee 
chez les patients d'age pediatrique. Cet article 
decrit six tels cas. Cette atteinte menagant 
le pronostic vital devrait etre envisagee dans 
tous les cas de traumatismes thoracoabdomi- 
naux serieuses, meme lorsque les resultats ra- 
diographiques sont negatifs a I'examen initial. 
Chez I’enfant tres malade les radiographies late- 
rales, par faisceau horizontal, du thorax et de 
I'abdomen ont ete extremement utiles a I'etablis- 
sement du diagnostic. Le doute et la recherche 
d’une blessure diaphragmatique associee en 
permettront le diagnostic et le traitement plus 
rapides.
R u p t u r e  of the diaphragm due to blunt 
thoracoabdominal trauma is now a well- 
established surgical problem. While several 
large series of cases have been reported in 
adults.1' 2 there are few reports of cases in 
the pediatric age group.3'3
* Presented at the annual meeting of the Canadian 
Association of Pediatric Surgeons, Quebec City, 
P.Q. Jan. 21, 1976.
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Analysis of 106 cases of blunt thoracoab­
dominal trauma admitted to the Dr. Charles 
A. Janeway Child Health Centre between 
January 1966 and December 1974, dis­
closed six cases of diaphragmatic rupture. A 
critical analysis of these cases forms the 
basis of this paper. To our knowledge this 
is the largest number of cases in the pedia­
tric age group to be reported in a single 
series.
Table I summarizes the age and sex of 
the six patients, the mode of trauma and 
clinical presentation, and the site of dia­
phragmatic injury.
Three types of presentation in adults with 
diaphragmatic rupture have been described 
in the literature; delayed, interval and acute. 
These types are also seen in children as illus­
trated by the following reports.
C ase  R epo r ts
Delayed Presentation
Case 1 .— A 9-year-old boy, while riding on 
a sleigh, ran into a slow-moving truck. On ad­
mission to a district hospital he was observed 
as a case of blunt abdominal trauma. N o ab­
normality was detected on the initial radio­
graphs. The possibility of diaphragmatic 
injury was not considered at this time and he 
was discharged apparently in good condition. 
One month after the accident he was read­
mitted with acute dyspnea and vomiting. Chest 
radiographs in the anteroposterior and lateral 
positions were taken, but the patient died be­
fore any treatment could be given. At autopsy 
a tear in the left dome of the diaphragm was 
found. The left pleural cavity was filled by a 
dilated stomach, which was twisted and gan­
grenous.
Interval Presentation
Case 2 .— A 13-year-old boy was knocked 
down by a car. On admission he was uncons­
cious, shocked, dyspneic and had multiple 
long-bone fractures. A supine radiograph of 
the chest led to the initial diagnosis of pul­
monary contusion with infrapulmonary pleural 
effusion and probable splenic injury. A trache­
ostomy was performed. For 4 days the pa­
tient’s condition was quite stable. On the 5th
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TABLE I. Age, Sex , M ode of T rauma and Clinical Presentation in  Six Patients with Rupture
of the D iaphragm
Patient
no.
Age,
yr Sex
Mode of 
injury
Presenting 
signs and 
symptoms
Interval from 
trauma to 
presentation
Site of 
rupture Result
i 9 M Sleigh riding, 
hit truck
Acute dyspnea, 
vomiting
1 mo Left Dead
2 13 M Pedestrian, 
hit by truck
Dyspnea, 
shock. Stable, 
then recurrent 
dyspnea and 
shock
2 h 
5 d
Left Alive
3 7 M Pedestrian, 
hit by truck
Shock. Stable, 
then vomiting
1 h 
3 d
Left Alive
4 F Pedestrian, 
run over by 
bus
Dyspnea,
persisting
shock
30 min 
5 h
Right Dead
5 14 M Pedestrian, 
hit by car
Dyspnea, 
shock, para­
plegia
? Left Dead
6 5 M Pedestrian, 
hit by truck
Dyspnea, 
shock, retinal 
hemorrhage
1 h Left Alive
over a 4 Vi year-old girl. On admission she was 
shocked, dyspneic and cyanosed, but she was 
fully conscious. Chest radiographs revealed 
multiple rib fractures and contusion of the 
right lung with pneumothorax but no evidence 
of pneumoperitoneum. Drainage through an 
intercostal tube relieved the cyanosis, but the 
shock persisted. Repeat investigation with 
horizontal beam lateral radiography of the 
chest and abdomen revealed a pneumoperito­
neum that had not been detected on the earlier 
films. It was concluded that the pneumoperi­
toneum was caused by pleural air entering 
through a rent in the right diaphragm, or by 
perforation of a hollow abdominal viscus. At 
laparotomy a large tear was found in the right 
dome of the diaphragm along with extensive 
laceration of the right lobe of the liver. This 
patient died 56 hours after admission. Death 
was attributed to extensive traumatic injury to 
the lungs and to respiratory failure.
It is interesting that this child sustained the 
rare injury to the right dome of the diaphragm. 
The value of repeated radiographs, particularly 
the use of horizontal beam lateral radiography 
of the chest and abdomen, in the diagnosis of 
diaphragmatic injury in a seriously ill child 
is apparent from this case.
D iscussion
When blunt diaphragmatic injury is caused 
by an automobile accident in an adult the 
patient is usually the driver of a vehicle or
day he again became suddenly shocked and 
dyspneic. A radiograph of the chest indicated 
diaphragmatic injury on the left side (Fig. 1). 
At laparotomy a tear was discovered in the left 
dome of the diaphragm; the lacerated spleen 
was lying in the left hemithorax along with the 
splenic flexure of the colon. The patient made 
an uneventful recovery.
In this example of interval presentation the 
patient suffered severe multiple injuries, but 
injury to the diaphragm was not initially de­
tected. It was only on the 5th day that acute 
cardiorespiratory symptoms led to the dis­
covery of the extent of his injuries.
Acute Presentation
Case 3 .—The rear wheels of a bus passed
Fig. 1.—Case 2. Anteroposterior chest radio­
graph on 5th day after injury reveals collapsed 
left lung with colonic shadow in left chest and 
shift of mediastinum to right.
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the front-seat passenger. It is striking that 
five of our six patients were pedestrians. 
Most had sustained major crushing injury to 
the thoracoabdominal region (Table II). 
Therefore we do not concur with Radha- 
krishna, Dickinson and Shaw4 that raised 
intra-abdominal pressure is the sole cause 
of diaphragmatic tear. Our own experience 
is in agreement with that of Hill6 that any 
major blunt thoracoabdominal trauma can 
cause a diaphragmatic tear.
Five of our six patients sustained injury 
to the left diaphragm. The close proximity 
of the large right lobe of the liver may dis­
tribute the force evenly on the diaphragm 
and thus protect the right dome. 7 Lucido 
and Wall8 believe that the common site of 
injury (the left posterolateral leaflet) is a 
potentially weak area owing to embryologic 
fusion. Others7 could not substantiate this 
theory. Bekassy and colleagues,!l using adult 
cadavers, subjected both leaves of the dia­
phragm to increasing pressure and con­
cluded that the left side was weaker than 
the right but that the difference was not 
statistically significant.
The diagnosis of diaphragmatic injury in 
cases of major thoracoabdominal trauma, 
especially in the presence of multiple in­
juries, is difficult. Carter, Guiseffi and Fel- 
son10 have described acute, interval and 
delayed presentations in adults. The acute 
phase is dominated by the associated in­
juries and damage to the diaphragm may 
escape notice unless the diagnosis is sus­
pected in every case. The possibility should 
be considered even when initial radiographs 
do not disclose such an injury. In three of 
our six patients there was no finding sug­
gestive of diaphragmatic injury at the ini­
tial clinical and radiologic examinations. In 
interval and delayed presentations the out­
standing signs and symptoms are those of
TABLE II.—Associated Injuries
Injury No. of cases
Central nervous system..............
Thoracic trauma (ribs and lungs)
Injury to abdominal viscera.......
Spleen...................................
Liver.....................................
Kidney.................................
Colon...................................
Fracture of long bones and pelvis 
Spine and spinal cord injury. . . .
2
1
1
1
3
4
5
2
1
gastrointestinal disease and strangulation. 
The physical findings as outlined by Bow- 
ditch11 are still applicable — “prominence 
and immobility of the left chest, displace­
ment of the cardiac dullness to the right, 
diminished or absent breath sounds on the 
left and tympanic percussion noted over the 
left chest”.
The essential radiologic indications of 
diaphragmatic injury as summarized by Car­
ter, Guiseffi and Felson10  and Arbulu, Read 
and Berkas,1- are as follows: elevation of 
the left diaphragm, arch-like shadow above 
the diaphragm, shifting of the mediastinal 
structures and presence of fluid levels in the 
affected hemithorax. Peck1:! has described 
the radiologic features present in the rare 
injury to the right leaf of the diaphragm. We 
suggest that supine radiographs of the chest 
and abdomen and a horizontal beam lateral 
radiograph of chest and abdomen are essen­
tial in all cases of blunt thoracoabdominal 
trauma in children. Barium meal, induction 
of pneumoperitoneum14  and liver scan­
ning15 are all helpful in the diagnosis of 
diaphragmatic injury. Laparoscopic evalua­
tion is not practical in these sick patients.
The treatment of diaphragmatic disrup­
tion is surgical repair at the time of diagnosis. 
The choice between a thoracic and abdomi­
nal approach should be decided on the basis 
of the associated injuries in each case.
In children who have sustained blunt tho­
racoabdominal trauma, the suspicion of 
associated diaphragmatic injury, whether it 
arises early or late, will lead to earlier diag­
nosis and treatment for these seriously in­
jured patients.
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EPIDERMOID CYSTS OF THE SPLEEN*
S LAN, MD, FRCS[C], L.-P. LEJEUNE, MD, FRCS[C], D. DILENGE, MD, FRCP[C] 
and P. MADARNAS, MD, FRCP[C]
The authors report three cases of epidermoid 
cyst of the spleen. A squamous cell lining was 
found in all three. One patient had a history of 
antecedent trauma, and in the surgical specimen 
the gross and histologic features were compati- 
ible with splenic damage. No hematologic alter­
ation was recognized on presentation. Angio­
graphy and spleen scanning were valuable aids 
in the diagnosis. All three patients were well 1 
year after operation.
Les auteurs signalent trois cas de kystes epi- 
dermoides de la rate. Dans les trois cas on a 
retrouve un revetement de cellules squameuses. 
Un patient presentait des antecedents de trau- 
matisme, et les caracteristiques macroscopiques 
et histologiques du prelevement a la chirurgie 
etaient compatibles avec une lesion splenique. 
Aucune modification hematologique n’a ete ob- 
servee. L’angiographie et la scintigraphie de 
la rate ont contribue au diagnostic. Les trois 
patients se portaient bien 1 an apres I'operation.
B e t w e e n  Jan. 1, 1969 and Dec. 31, 1975, 
259 splenectomies were performed at the 
Centre Hospitalier Universitaire in Sher­
brooke. In three cases from this series the 
pathological diagnosis was epidermoid cyst. 
The relative rarity of this entity and its 
debatable pathogenesis and clinicopathologic 
significance justify this report.
Splenic cysts lined by squamous epithe­
lium constitute a variable proportion of the 
different pathologic types of cyst found in 
the spleen, depending on the geographic area 
of their occurrence. In parts of the world 
where hydatid disease has a high prevalence, 
the hydatid cyst is the predominant lesion. In 
the United States and Canada, the propor­
tion of cysts lined by squamous epithelium 
is relatively high although such cysts are un­
common. Ferris, Dockerty and Heldon1 
found only one case in the Mayo Clinic se­
ries from 1911 to 1956. Cave, Garvin and 
Doohen2 discovered 51 cases in an extensive 
review of the literature. Five additional
♦From the departments of surgery, radiology and 
pathology, faculty of medicine, University of 
Sherbrooke, Sherbrooke, PQ.
Reprint requests to: Dr. P. Madarnas, Department 
of pathology, Centre Hospitalier Universitaire, 
Sherbrooke, PQ J1H 5N4.
cases were reported in a 32-year review of 
the surgical specimens from the University 
of Minnesota hospitals.3
In the cases we describe the diagnosis of 
splenic cyst was made preoperatively by 
means of plain radiographs, angiograms or 
spleen scans.
C ase  R e p o r t s
Case 1.—A 3 3-year-old woman had a his­
tory of recurrent urinary tract infection, and a 
2-month history of polyuria, polydipsia and 
weakness. She was admitted for investigation 
and control of diabetes. On routine physical 
examination the spleen was palpable 2 cm 
below the left costal margin. The liver was not 
palpable and no other mass was felt. The 
spleen scan indicated the presence of a cyst 
(diameter, approximately 7 cm) in the supero­
lateral half of the organ. Angiography (Fig. 
1) revealed hypovascularity in this region. The 
regularity of the surrounding splenic tissue 
further supported the diagnosis of a cystic le­
sion. Laboratory data on admission included 
the following: hemoglobin value 10.9 g/dL, 
hematocrit 34.3%, leukocyte count 4.9 x 
109/L  (normal differential), platelet count 250 
x 109/L, erythrocyte sedimentation rate 10 
mm/h and blood glucose value 350 mg/dL.
An uncomplicated splenectomy was per­
formed from which the patient made a straight­
forward recovery. The patient’s diabetes was 
controlled by insulin.
The enlarged spleen was deformed by a uni­
locular cystic structure (Fig. 2a). The wall 
varied from paper-thin to 0.4 cm in thickness 
in the trabeculated areas. After evacuation of 
the clear fluid content, the specimen weighed 
225 g. The inner lining of the cyst was made 
up of keratinized stratified squamous epithe­
lium with prominent intercellular bridges 
(Fig. 2b). Hemosiderin-laden macrophages and 
iron deposits were identified in the outer wall 
and the adjacent splenic tissue, which was un­
dergoing atrophy. Germinal centres and thy­
mic-dependent lymphoid hyperplasia were 
prominent in the white pulp. The red pulp was 
unremarkable.
Case 2.—A 19-year-old woman was admitted 
complaining only of an occasional sharp pain 
in the left shoulder. She had had one previous 
hospital admission 1 year earlier when she 
had had mild jaundice 1 month after an in-
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Fig. 3a
Fig. 3b
Fig. I .—Case 1. (a) Selective arteriography of 
celiac axis (2) permits good visualization of 
splenic artery (1), which appears elongated and 
pushed downward by displacement of spleen 
whose inferior limit reaches L4 level (arrows). 
This displacement is caused by hypovascularized 
mass, which seems to occupy upper portion of 
spleen (3=right hepatic artery; 4=gastroduodenal 
artery), (b) Regularity of lower contours of mass 
(arrows) is displayed; it appears embedded within 
the splenic parenchyma.
fluenza-like episode. At that time an enlarged 
spleen was detected. She was discharged with­
out medication after 2 weeks. The jaundice 
was presumed to be due to hypersensitivity to 
an oral contraceptive agent (norgestrel-ethinyl- 
estradiol). For the 7 months before the present 
admission she had been aware of a mass in
Fig. 2. Case 1. (a) Cross-section of spleen 
and of uniloculated cystic mass. Inner surface 
shows hyalinized trabecular bands, (b) Stratified 
nonkeratinizing squamous epithelium with promi­
nent intercellular bridges, (hematoxylin and eosin, 
reduced by 50% from x 400).
the left upper quadrant, particularly when she 
was in the erect position, and 6 months before 
admission she had experienced an episode of 
epigastric pain lasting 1 day.
On physical examination two spider angio­
mas were noticed. On palpation the liver was 
not enlarged but the spleen was palpable 7.5 
cm below the left costal margin. Angiography 
indicated a possible cystic lesion. The spleen 
scan was normal. The hemoglobin value was 
13.2 g/dL, hematocrit 40.4%, leukocyte count 
7.5 x 109/L , and platelet count 226 x 10VL.
Splenectomy was performed from which 
the patient made a smooth recovery.
The spleen was enlarged and severely de­
formed by a lobulated but unilocular cystic 
mass. The thickness of the wall varied from 
0.1 to 0.4 cm in the irregularly trabeculated 
areas. The cyst contained clear colourless 
fluid with small amounts of white flaky ma­
terial. The inner surface was lined by squa­
mous epithelium with focal areas having a 
prominent stratum granulosum and showing 
superficial keratinization. The adjacent splenic 
pulp contained hemosiderin deposits and 
showed evidence of pressure atrophy. Hyper­
plasia of the white pulp with prominent ger­
minal centres and thymic lymphoid hyper­
plasia were evident. The red pulp was normal.
Case 3 .— A 35-year-old man was seen in 
the outpatient department with a 6-month his­
tory of dry cough. In a motor vehicle accident 
13 years before he had sustained fractures of 
the left 6th and 7th ribs; no visceral trauma 
was detected and he had been treated conser­
vatively.
On physical examination, the blood pres-
M*i
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sure was 110/80 mm Hg, and the pulse was 
60/min. No abnormality was found on chest 
examination. The spleen was not palpable. A 
chest radiograph disclosed a calcified mass 
(diameter, 7 cm) in the left upper abdominal 
quadrant. The hemoglobin value was 16.2 g/ 
dL and the leukocyte count was 6.1 x 109/L  
(normal differential). The platelet count was 
310 x 107L, and the SMA 12 biochemical 
profile was normal. Angiography revealed the 
opacity to be situated at the splenic hilum 
(Fig. 3); the spleen itself did not appear en­
larged.
When splenectomy was performed dense ad-
Fig. lb
Fig. 3.—Case 3. (a) Routine chest radiograph re­
veals calcified cystic mass (arrows) in area of 
spleen, (b) Selective arteriography shows elon­
gated splenic artery (arrows) with displacement 
of its branches, which seem to enwrap calcified 
mass. Spleen does not appear enlarged or de­
formed.
hesions were found between the spleen and 
the parietal peritoneum. The postoperative 
course was uneventful.
The intact spleen weighed 217 g. It was de­
formed by a spherical, rigid, calcified cyst 
(Fig. 4) whose wall was up to 0.6 cm in thick­
ness. It contained a clear colourless fluid. The 
decalcified sections showed a scanty cellular 
lining which, in focal areas, appeared as stra­
tified squamous epithelium (Fig. 4b). Within 
the splenic tissue, remote from the cyst, there 
were several irregular fibrous areas with pro­
minent hemosiderin deposits and siderotic 
impregnation of the collagen resembling that 
seen in Gamma nodules. The white pulp dis­
played a noticeable thymic lymphoid hyperpla­
sia with inconspicuous germinal centres. The 
red pulp was unchanged.
D iscussion
Epidermoid cysts, by definition, are lined 
by stratified squamous epithelium.4, 3 Since 
many of these cysts are found in children 
without a history of antecedent trauma, 
their origin from embryonic rests is strongly 
favoured.5 The embryologic situation of the 
spleen within the dorsal mesogastrium sug­
gests a possible origin from ectopic esopha­
geal epithelial tissue. An alternative sug­
gestion is that the squamous epithelium rep­
resents a metaplastic change of endothelium 
or mesothelium.2’ 7' 8
The pathological changes in the three spe­
cimens described here are similar. All three 
cysts had a stratified squamous epithelial 
lining. The scanty lining in the third speci­
men may have been the result of pressure
Fig. 4.—Case 3. Cross-section of normal-sized 
spleen, with focal whitish scars, showing thick and 
calcified hilar cystic mass, (b) Area of nonkera­
tinizing stratified squamous epithelium resting on 
collagenized fibrous tissue (hematoxylin and eosin, 
reduced by 58% from x 400).
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atrophy. The origin of this cyst may have 
been the cavitation of a previous hematoma 
as suggested by the history of trauma. Ex­
cept in this case, where hemosiderin deposits 
and broad bands of irregular fibrous tissue 
within the spleen suggested an earlier trau­
matic episode, no intrinsic splenic pathology 
was found.
The patients were kept under observation 
for at least 1 year and had no evidence of 
the development of hematologic abnormali­
ties other than those expected after splenec­
tomy. Thus, for alleviation of symptoms, 
avoidance of complications and accurate 
histologic diagnosis, splenectomy is the pro­
cedure of choice in all cases of epidermoid 
cyst of the spleen.9,10
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INTESTINAL OBSTRUCTION DUE TO A DEFECT IN THE OMENTUM
JOHN A. McCREDlE, MB, MCh(Belf), FRCS(Edin), FRCS[C], FACS*
An unusual cause of instestinal obstruction is 
described in a 46-year-old woman thought be­
fore operation to have Crohn’s disease. The 
right colon and terminal ileum had passed 
through a defect that had developed sponta­
neously in the greater omentum and had re­
mained in that position for at least 1 year. 
The bowel was reduced and the multiple defects 
in the omentum were repaired.
On decrit chez une femme de 46 ans une cause 
inhabituelle d’obstruction intestinale. Avant 
I operation la maladie de Crohn etait suspectee. 
Le colon droit et I’ileon terminal avaient fait 
saillie a travers une dechirure apparue spontane-
* Associate professor of surgery and therapeutic 
radiology, University of Western Ontario, London, 
Ont.
Reprint requests to: Dr. J. A. McCredie, Depart­
ment of surgery, Victoria Hospital, 375 South 
St., London, Ont. N6A 5A5.
ment dans le grand epiploon, et etaient demeu- 
res dans cette position depuis au moins 1 an. 
L’intestin a ete remis en place et la region de 
I'epiploon presentant des defauts multiples a 
ete reparee.
I n t e r n a l  hernias are an uncommon cause 
of intestinal obstruction. They may occur 
in the paraduodenal and paracecal regions, 
at the root of the mesentery of the sigmoid 
colon and in the pelvis and diaphragm.1 
Bowel has also passed through the foramen 
of Winslow into the lesser sac2 and through 
defects in the mesentery of the terminal 
ileum3 and transverse mesocolon.4 We re­
port a case of recurrent subacute intestinal 
obstruction due to passage of bowel through 
a hole that developed spontaneously in the 
greater omentum. The patient was con­
sidered preoperatively to have Crohn’s 
disease.
November 1977 THE CANADIAN JOURNAL OF SURGERY 561
Fig. 1.—Radiograph shows narrow segment in 
terminal ileum considered before operation to be 
due to Crohn’s disease.
Fig. 2.—Right colon and terminal ileum have 
herniated through hole in greater omentum. Bowel 
is firmly adherent to stretched-out margins of 
defect.
Fig. 3 .“ After reduction of hernia, thickened 
margins of defect are visible.
Fig. 4.—Specimen resembles doughnut in shape 
and size. Diameter of defect was larger when 
occupied by herniated bowel.
Fig. 6.—Greater omentum after repair of trans­
lucent thinned-out regions.
Fig. 5.—Attentuated regions can be seen in 
greater omentum. Intestinal obstruction was due 
to passage of bowel through one of these regions.
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C a se  R e p o r t
A 46-year-old woman was admitted to hos­
pital in July 1975 with a clinical diagnosis of 
small bowel obstruction. Radiographic studies 
included a flat plate of the abdomen and gas­
trointestinal series with follow-through; the re­
sults were normal. She continued over a period 
of 1 year to have recurrent bouts of colicky, 
midabdominal pain associated with nausea and 
distension. The attacks lasted for 1 to 2 days. 
She was re-admitted to hospital in June 1976 
with a similar attack that settled spontaneous­
ly. The gastrointestinal series now showed a 
narrow segment in the terminal ileum consis­
tent with that seen in Crohn’s disease (Fig. 1). 
The patient had not had any abdominal injury 
or abdominal operations. At laparotomy an 
8-cm hole was found in the right of the greater 
omentum and through this defect had passed a 
mobile cecum, ascending colon, right half of 
the transverse colon and the terminal 12 cm of 
ileum (Fig. 2). The omentum at the circum­
ference of the defect was thickened to form a 
rolled edge about 3 cm in thickness. There 
were firm adhesions between the bowel that 
had herniated through the opening and the 
margins of the defect. The adhesions were 
divided and the bowel was retracted (Fig. 3). 
The defect in the greater omentum was excised, 
furnishing a specimen that resembled a dough­
nut in appearance and size (Fig. 4). On hold­
ing up the greater omentum several attenuated 
translucent regions were seen (Fig. 5). Sutures 
were inserted to obliterate these defects (Fig. 
6). The patient has not had any recurrence of 
symptoms.
D isc u ssio n
In this patient the right colon and termi­
nal ileum herniated through a defect that
developed spontaneously in a thin greater 
omentum. The bowel must have occupied 
this position for at least 1 year because the 
patient had symptoms during this time and 
there were firm adhesions between the 
margins of the defect and the bowel. The 
margins at the circumference of the defect 
had become thickened (up to 3 cm) prob­
ably as a reaction to the repeated trauma 
from powerful peristalsis of the bowel with­
in the ring.
The occurrence of a defect in the rela­
tively avascular part of the mesentery of 
the terminal ileum (Treves’ field) is well 
documented. The defect is thought most 
often to be congenital in origin and less 
frequently due to injury, spontaneous atro­
phy or chronic inflammation.3 One that 
occurs in the transverse mesocolon, general­
ly to the left of the middle colic vessels, 
is considered by Tanner4 to result from 
atrophy in most instances. In one case 
described by Tanner where there was a 
hole in the transverse mesocolon, the bowel 
left the lesser sac through a defect in the 
lesser omentum; in another patient the 
bowel passed through a defect in the great­
er omentum. The literature contains no 
report of intestinal obstruction due to a 
defect in the greater omentum alone.
References
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Another surgeon 
is about to use one of 
the wor cfe finest 
surgica blades....
... .this happens
thousands of times 
everyday!
It happens because the blades are by Swann-Morton,
the people who meet the highest requirements in surgical knives.
We need say very little about our superiority.
The world's surgeons have proved it for us!
dWtUvKrllloi&Vv
SWANN-MORTON LIMITED 
PENN WORKS, OWLERTON GREEN. 
SHEFFIELD S6 2BJ. ENGLAND.
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1977 DAVIS & GECK SURGICAL ESSAY AWARD
Dr. A. G. de la Rocha received the 1977 Davis & Geek Award at the Victoria Hospital, London, 
Ont. on Sept. 27.
The award was presented by Mr. John W. Ployart (second from left) of the Cyanamid Corpo­
ration on behalf of Davis & Geek. Dr. C. Barber Mueller (left), co-editor of the Canadian 
Journal of Surgery and Mr. John Stavroff. (right), local representative for Davis & Geek, 
were also present.
The editorial board and the editors of the Journal wish to thank Davis & Geek for providing 
this award, and extend their congratulations to Dr. de la Rocha and their thanks to all those 
who participated in the competition.
(Requirements for the 1978 award appear on page 556 of this issue.)
November 1977 THE CANADIAN JOURNAL OF SURGERY 565
CORRESPONDENCE
SIMPLE DEVICE TO PREVENT DISRUPTION OF CENTRALLY 
PLACED INTRAVENOUS CATHETERS
To the editor: The earliest observation of 
the fatal potential of intravenous air was de­
scribed by the Italian naturalist Redi in 
1667.1 Recently the use of central venous 
lines in the care of critically ill patients has 
increased.2- 3 The period of greatest risk, 
which occurs during the insertion of the 
catheter, can be reduced by placing the pa­
tient in the Trendelenburg position.
Air embolism has been reported following 
accidental disconnection of the central ven­
ous pressure (CVP) catheter at the hub.4' 6 
In the past 3 years we have experienced at 
least three instances of this mishap, despite 
attention to precautionary measures to se­
cure the connection. This prompted the in­
vention of a simple device to prevent such 
disruption of CVP catheters. The device can 
be used with any intravenous catheter con­
nection.
In our hospital, using aseptic technique 
and subclavian puncture, we insert the 
catheter (length, 20 cm) through a 14-gauge 
needle. The needle is then connected to the 
manometer by intravenous (IV) extension 
tubing (Fig. 1). Fig. 2 shows the site of dis­
ruption of the central line.
Fig. 3 illustrates the simple device, which 
is constructed of stainless steel so that it 
can be repeatedly sterilized and used. At 
one end of the device is an orifice into which 
is fitted the needle end of the connection. At 
the other end is an orifice of smaller diame­
ter to accommodate the IV extension tubing.
Fig. 1.—Standard intravenous line.
Fig. 2.—Disruption of line at connection.
Fig. 3.—Device for securing connections, (a) 
Orifice for intravenous (IV) needle, (b) Orifice 
for IV extension tubing.
Fig. 4.—Device in position, (a) Entry site of IV 
tubing, (b) Exit site of IV needle.
The IV extension tubing must be compressed 
in order to place it in its orifice, thereby se­
curing it in position (Fig. 4) and preventing 
disruption of the IV connection. It can be 
modified both in length and diameter of 
orifices to fit different connections. If de­
sired, tapes can be used to make the con­
nections even more secure.
Brian P. D. Colquhoun , m b , frcs(ed in ),
FACS
Department of surgery,
University Hospital,
Saskatoon, Sask.
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TOTAL REPLACEMENT ARTHROPLASTY OF ELBOW IN 
RHEUMATOID ARTHRITIS
To the editor: The painful, stiff and unstable 
rheumatoid elbow poses a therapeutic dilem­
ma that has not yet been resolved, and, for 
this reason, the article by Harder and Beau­
champ (Can J Surg 20: 234, 1977) at first 
glance appears timely. Their early results 
with complete synovectomy and total pros­
thetic replacement were good; in eight of 
nine elbows mobility was improved and pain 
relieved. But nine cases from which to draw 
valid conclusions are rather few and may 
give a falsely optimistic view of the diffi­
culties of surgery and the possibility of 
postoperative complications.
W. A. Soutar, in reporting 30 total elbow 
replacements ( / Bone and Joint Surg [Br] 
59: 99, 1977), noted that although the early 
results were good, there was a slow dete­
rioration over 5 years, the major problems 
being instability due to loosening of the 
humeral stem, severe comminuted fractures 
of eroded bone and gross instability of the 
elbow if ever the prosthesis had to be re­
moved. Hinge prostheses are especially 
prone to these complications, because the 
hinge itself has no means for absorbing ro­
tational movement or movement in the co­
ronal plane, and these stresses are trans­
mitted to the bone-cement interface. Soutar 
no longer recommends this type of arthro­
plasty. In Harder and Beauchamp’s series 
of cases, the longest interval from operation 
to final evaluation of their patients was 
only 2Vi years and the shortest was 2 
months. One is reminded of Harold Crowe’s 
remark that his feeling about this was that 
the authors hadn’t yet had time enough to 
find out what trouble they could get into.
The painful, stiff and unstable rheuma­
toid elbow defies efforts to find a definitive 
solution. Pending the development of a 
more satisfactory prosthesis, synovectomy 
is still the best that the surgeon can offer, 
and it has the additional advantage that 
further surgery is possible, should it become 
necessary.
Jo h n  V. F o w l e s , m b , f r c s[c ]
CARE/MEDICO
18, ave docteur Conseil,
Tunis,
Tunisia.
To the editor: Dr. Fowles’ comments are 
timely. Of our initial group of patients 
treated by total elbow replacement of the 
hinge type as reported in the Canadian 
Journal of Surgery, none has yet required re­
exploration of the elbow because of loosen­
ing or fracture. At present the interval from 
surgery ranges from approximately 2Vi to 
5 years. One patient has clinical evidence 
of loosening of the humeral component, but 
function of the arm remains satisfactory.
It is my unsubstantiated impression that 
attention to two details at the time of the 
procedure may be particularly important: if 
removal of cancellous bone in the medullary 
canal is thorough, permitting intimate con­
tact of the methylmethacrylate cement with 
cortical bone, and if the methylmethacrylate 
is inserted well beyond the tip of the stem 
of the prosthesis, the considerable stress 
exerted on this area may be sufficiently well 
distributed to reduce the danger of the toggle 
effect, which causes eventual breakthrough 
at the tip of the stem.
It is recognized that, as in the case of knee 
hinge prostheses, a fully constrained joint 
is far from ideal. We therefore continue to 
restrict the hinge arthroplasty to a small 
number of patients with extensive elbow- 
joint destruction.
It is hoped that a semiconstrained pros­
thesis, perhaps one along the lines of that 
designed by F. C. Ewald, will prove suffi­
ciently superior that fully constrained elbow 
joints with their inherent limitations will 
need to be used only in cases in which soft 
tissue supporting structures and inadequate 
bone stock allow no alternative.
D. H. H ar der , m d , f r c s [c ]
Department of orthopedic surgery,
Royal Columbian Hospital,
New Westminster, BC.
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O B I T U A R Y
HOMMAGE AU DOCTEUR JACQUES TURCOT
C’est avec peine que nous apprenions le 
deces subit du docteur Jacques Turcot, sur- 
venu en ce samedi saint, le 9 avril 1977. 
Tous ceux qui connurent Jacques Turcot, 
pour avoir oeuvre a ses cotes soit comme 
resident, soit comme patron, ne pouvaient 
faire autrement que d’etre atteres par le de­
part inattendu d’un collegue estime. La 
condition physique remarquable du docteur 
Turcot en trompa plus d’un; seuls ses pro- 
ches purent depister l’atteinte lethale quel- 
ques jours seulement avant l’echeance.
Pour tous les chirurgiens qui se sont 
entraines a l’Hotel-Dieu de Quebec, le sou­
venir du docteur Jacques Turcot restera 
comme un monument. II n’avait pas son 
pareil et aucun autre patron ne lui ressem- 
blait. De contact exigeant, le docteur Turcot 
s’imposait cependant par sa force de carac- 
tere, sa competence et son dynamisme. Chi- 
rurgien minutieux et habile, anatomisme 
par formation, le professeur Turcot ne pou- 
vait accepter la mediocrite ou le laisser- 
aller. II n’etait satisfait que par l’excellence 
du geste chirurgical.
Tout au long de sa carriere d’ailleurs, sa 
chirurgie se caracterisa par la precision du 
geste, la delicatesse anatomique et le savoir- 
faire chirurgical. L’assurance de son juge- 
ment se doublait d’une sagacite acquise par 
l’experience.
Forme a l’ecole de l’Hotel-Dieu par les 
chirurgiens Vezina, Roy et Petitclerc, au 
Memorial Hospital for Cancer and Allied 
Diseases de New York, puis a la Mayo 
Clinic de Rochester, Jacques Turcot ne mit 
que tres peu de temps pour s’imposer. Sa 
reputation depassa rapidement les limites 
hospitalieres. Ses debuts furent marques a 
l’enseigne de la science et de l’innovation.
Fils et petit-fils de medecins, le docteur 
Jacques Turcot suivit les traces que ses pe- 
res souhaitaient et rarement il a du les 
decevoir. En 1946 le service de chirurgie 
organisa un cours de chirurgie a l’Hotel- 
Dieu de Quebec et le docteur Turcot en fut 
l’un des fondateurs et Fame directrice. Cette
ecole de chirurgie a forme plus de 80 chi­
rurgiens generaux.
Le chirurgien se doublait d’ambition uni- 
versitaire, et rapidement il gravit les echelons 
academiques, devint secretaire du departe- 
ment de chirurgie, puis directeur en 1972. 
Pour lui, l’enseignement et le soin au patient 
etaient deux entites inseparables.
Sur les scenes nationale et internationale, 
Jacques Turcot represente surement le chi­
rurgien canadien-fran§ais le plus connu et 
le plus estime. La liste des nominations ac- 
ceptees par le docteur Turcot, au niveau 
des divers organismes professionnels tant 
provincial que canadien et americain, te- 
moigne de ses qualites exceptionnelles. 
Parrni plusieurs, je n’en mentionnerai que 
trois: gouverneur de l’American College of 
Surgeons, membre de la James IV Associa­
tion of Surgeons et president du College 
royal des chirurgiens et medecins du Canada 
(1968-70). C’est a cette periode que sa car­
riere atteint son apogee.
Son influence sur Involution de la me- 
decine canadienne s’est egalement faite 
sentir particulierement au niveau du Centre 
R- Samuel McLaughlin, centre de dosime- 
trie mis sur pied par le College royal pour 
l’enseignement et les examens de specialites.
C’est en temoignage de son oeuvre que 
!e Gouvernement canadien lui decemait, en 
1974, le titre d’officier de l’Ordre du Ca­
nada. C’etait reconnaitre, en la personne 
du docteur Jacques Turcot, un chirurgien 
universitaire de grande classe et un huma- 
nisme de grande tradition.
Jacques Turcot n’est plus. Les chirur­
giens de l’Hotel-Dieu de Quebec et les 
anciens residents du cours de chirurgie gar- 
deront toujours de lui le souvenir d’un 
chirurgien exigeant, competent et fier d ’etre 
ce qu’il etait. Son contact permit, a plus 
d’un, une remise en question dans l’appren- 
tissage du role de chirurgien et de profes­
seur. Jacques Turcot restera a plus d’un 
titre un exemple a suivre.
Louis D ionne, md
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B O O K  R E V I E W S
THE ANAESTHESIOLOGIST’S HAND­
BOOK. 2nd ed. Donald G. Catron. 201 pp. 
IHust. University Park Press, Baltimore, 
1976. $8.95, paperbound. ISBN 0-8391- 
0956-3.
This handbook is aptly named since it fits 
very conveniently into the pocket of most 
operating room gowns.
In his preface Catron describes the book as a 
collection of references “intended for use by 
busy practitioners and students as an on-the- 
spot review of problem situations” and I be­
lieve it fulfils its stated purpose.
It is not a “how to” handbook, rather it is 
a “why”. It lists the basic fundamentals of 
knowledge that any competent anesthetist must 
understand. Cross-references are given and, in 
general, the reader will find answers to most 
questions in a straightforward and systematic 
manner.
The doses given are somewhat confusing 
because the author has not been consistent, but 
has used metric and imperial measures inter­
changeably. Some important areas are not 
given sufficient emphasis; for example, the 
treatment of hypertension is not brought up 
to the standards of 1975 — the year of the 
most recent reference quoted. In fact, the 
references are rather limited in number.
Despite these minor criticisms, the reader 
will find this a useful book to have at hand 
when a few spare moments are found to re­
fresh the mind. A comprehensive index is 
provided.
P. Goodhall
Associate anesthetist-in-chief,
Department of anesthesia,
Women’s College Hospital,
Toronto, Ont.
THE BLOOD SUPPLY OF THE VERTE­
BRAL COLUMN AND SPINAL CORD IN 
MAN. H. V. Crock and H. Yoshizawa. 130 
pp. Illust. Springer Verlag New York Inc., 
New York, 1977. $38.50. ISBN 0-387- 
81402-7.
This book is an atlas of colour and black-and- 
white photographs, and a few radiographs, of 
dissections of the blood supply to the spine 
and spinal cord. The authors did their dissec­
tions on cadavers in which the arterial and 
venous systems were injected. They emphasize
the difficulties encountered in arterial and 
venous injections of human cadavers and 
briefly describe how they have overcome these 
problems. The technical detail, however, is in­
sufficient to guide others with similar in­
terests.
The book is technically of good quality. The 
text is brief; the bibliography is scanty. The 
legends to the illustrations are clear and well- 
written. The dissections are excellent, the vessels 
clearly shown, and the photography is very 
good.
Although it is intended for orthopedic sur­
geons, neurosurgeons and neurologists, the 
book has certain drawbacks which will limit 
its appeal to clinicians. It is entirely devoted 
to descriptive anatomy; there is no attempt to 
relate the anatomical distribution of vessels to 
vascular disease as a clinical problem. Al­
though the intramedullary arterial and venous 
patterns are well shown, they are not correlated 
with the ascending and descending pathways 
and the various spinal nuclear groups. The au­
thors illustrate the variation in size of radicular 
arteries at different segments, but they do not 
analyze the variety of patterns they must have 
found in their numerous dissections.
Despite its excellent technical quality, this 
book will only be of limited use to the readers 
for whom it was intended.
D. M. Robertson
Department of pathology,
Queen’s University,
Kingston, Ont.
CAHIERS D’ENSEIGNEMENT DE LA 
S.O.F.C.O.T. 4. Conferences d’Enseigne- 
ment. Sous la direction de J. Duparc. 186 
pp. Illust. Expansion Scientifique Franyaise, 
Paris, 1976. $24.84, broche. ISBN 2-7046- 
0875-X.
L’impression generate qui se degage de ce 
cahier de conference d’enseignement d’ortho- 
pedie nous parait tres favorable. Sa publica­
tion semble s’adresser au niveau post-gradue 
des residents a l’entrainement en orthopedie 
et represente possiblement un attribut comple- 
mentaire pour d’autres residents se dirigeant 
dans des disciplines chirurgicales connexes a 
l’orthopedie impliquant la traumatologie. Cette 
revue peut, a la fois, s’appliquer a des etu- 
diants de l’ecole de Medecine s’interessant
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particulierement a la traumatologie; soit a des 
orthopedistes desirants a la fois rafratchir leurs 
connaissances fondamentales ou faire revalua­
tion, a leurs termes, de leur technique chi- 
rurgicale. Nous avons note que ce volume est 
tres bien documente sur la litterature inter- 
nationale tout en degageant une vaste expe­
rience personnelle de la methodologie fran- 
gaise. Cependant il est a noter que cette revue, 
tout en recouvrant en detail une forme de trai- 
tement, une hypothese de travail ou une revue 
d’un systeme, ne couvre qu’en partie le pro- 
bleme mentionne et, de ce fait meme, ne peut 
etre consideree que complementaire a un texte 
de base fondamentale faisant l’etude compa­
rative de toutes les autres possibilities de trai- 
tement.
Plus particulierement, nous aimerions discu- 
ter l’article ecrit par Y. Gerard du service 
de clinique d’orthopedie et traumatologique 
de Reims sur l’enclouage percutane des frac­
tures diaphysaires des membres. Les principes 
ainsi que la technique de l’enclouage a foyers 
fermes de la diaphyse femorale nous semblent 
tres bien ecrits, d’une precision et d’un appli­
que qui font certes preuve d’une experience 
clinique en traumatologie des plus excellentes. 
Le tout est fait de fagon concise et precise, 
montrant a la fois les indications, les contre- 
indications et les dangers d’une telle technique 
au cours des diverses phases de la procedure 
ainsi que les moyens d’eviter toute complica­
tion. Quant aux resultats, nous notons qu’ils 
sont comparables a toutes les autres series pu- 
bliees, soit sur le continent Nord Americain, 
soit en Europe, se servant de techniques simi- 
laires. Nous remarquons avec satisfaction un 
taux d’infection tres minime dans toutes les 
series mentionnees, ce qui denote un jugement 
clinique et une technique qui est a la hauteur 
de la reputation de ce centre. Pour ce qui est 
des indications de l’enclouage intra-medullaire 
de fagon fermee, nous posons certaines reti­
cences lorsqu’il s’agit d’une fracture multi- 
fragmentaire ou, selon nous, il n’y a pas pro­
duction d’une fixation interne rigide, et dans 
certains cas qui, selon notre experience, neces- 
sitent une exposition de trait de fracture avec 
encerclage du fragment isole, en evitant toute- 
fois une devitalisation exageree des tissus mous. 
Cependant il est a noter que les resultats men- 
tionnes sont tres acceptables. Pour ce qui est 
des cas particuliers, lorsqu’il s’agit d’une frac­
ture poly-fragmentaire, nous favorisons plu­
tot un traitement orthopedique pur par ex­
tension continue. Selon nous un enclouage 
fait par un petit tuteur metallique intra-me­
dullaire ne nous semble pas essentiel pour main- 
tenir une angulation adequate des fragments.
Une immobilisation dans un appareil de Tho­
mas, apres avoir mis celui-ci dans une posi­
tion adequate dependant du niveau du trait de 
fracture et de la deformite qui peut etre pre- 
vue a cause de l’attachement musculaire, nous 
permet de conserver un alignement adequat 
ainsi qu’un raccourcissement minime. Nous 
abondons dans le meme sens que l’ecole fran- 
gaise au fait qu’une reduction ouverte par 
plaque et vis peut produire une devitalisation 
exageree de l’os, incitant ainsi a la pseudar- 
throse et aux incidences septiques, sans toute- 
fois permettre une fixation interne assez rigide 
pour rendre le patient immediatement ambu­
lant. Nous favorisons plutot, des que la con­
solidation est partiellement amorcee apres en­
viron 5 ou 6 semaines, l’application d’un pla- 
tre prothese qui, a la fois, permet de conserver 
la mobilite du genou amorcee dans l’appareil 
de Thomas et une mise en charge plus rapide 
de fagon a augmenter l’osteogenese. Ceci nous 
semble un compromis tres acceptable permet- 
tant a la fois un bon controle de l’alignement 
et de la rotation, une preservation de la mo- 
tilite du genou et de la cheville, un taux d’in­
fection nil, un raccourcissement minime du a 
l’amorce deja avancee de la consolidation, un 
retour de la fonction beaucoup plus rapide que 
le traitement conservateur, et un taux de con­
solidation plus rapide par le fait de la mise 
en charge.
En ce qui a trait aux fractures ouvertes un 
taux d’infection de 6% nous semble prejudi- 
ciable au patient. Nous abondons dans le sens 
de l’article qui montre un taux de complica­
tions septiques comparables pour l’enclouage 
secondaire. La methode par plaques vissees 
rajoutant la devitalisation des tissus mous aux 
traumatismes initiaux nous semble aussi pre- 
judiciable au patient. Comme alternative, nous 
suggerons plutot la methode orthopedique pure 
par extension continue, pour une periode li- 
mitee d’environ 4 a 6 semaines, jusqu’a for­
mation d’un cal osseux assez abondant pour 
pouvoir placer le patient dans un platre pro­
these par la suite.
La discussion sur I’enclouage percutane in- 
tra-musculaire du tibia nous semble aborder un 
probleme excessivement controverse; bien que 
la technique ait ete abondamment discutee, 
nous ne favorisons que tres rarement cette 
methode vu l’incidence relativement elevee de 
pseudarthrose, soit 2.5% dans les cas de frac­
tures fermees et 4% dans les cas de fractures 
ouvertes, avec un taux d’infection de 8% dans 
les fractures ouvertes. Le traitement conser­
vateur par la methode du platre de Sarmiento 
nous semble une alternative des plus valables 
avec une mise en charge presque immediate, un
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taux d’infection nil et des taux de pseudar- 
throse certainement comparables aux resultats 
obtenus dans cette serie.
Pour l’enclouage de l’humerus, nous abon- 
dons dans le sens de cet article demontrant 
que l’humerus est un os qui se prete beau- 
coup mieux a un traitement orthopedique 
simple. L’osteosynthese cependant est possible 
et tres efficace, surtout lorsqu’il s’agit de frac­
tures pathologiques, avec un retour de la 
fonction des plus adequates.
Nous aimerions souligner en terminant l’ar- 
ticle du Theomine qui revoit avec une tres 
grande precision les fractures de la main et 
leur traitement a la fois conservateur et chi- 
rurgical; nous ne pouvons que souscrire avec 
enthousiasme a ce magnifique document de 
precision, concision et realisme. Notre expe­
rience montre aussi le peu d’indication de la 
fixation interne par ce systeme de plaques et 
vis tel que decrit dans le systeme Suisse.
P. O. N adeau
Chirurgien-orthopediste,
Hopital du Saint-Sacrement,
1050 Chemin Ste-Foy,
Quebec, PQ.
CEREBRAL DURAL SINUSES AND THEIR 
TRIBUTARIES. Jefferson Browder and 
Harry A. Kaplan. Edited by Robert H. 
Wilkins. 120 pp. Illust. Charles C Thomas, 
Publisher, Springfield, IL, 1976. Price not 
stated.
The authors of this book are highly respected 
for their contributions to the understanding of 
the vascular system of the brain. This mono­
graph, although small in size, is a treatise on 
the anatomy of the cerebral venous circula­
tion; Browder and Kaplan have provided a 
meticulous anatomical description of normal 
specimens and their variants. The book is 
written in a clear, concise style and is easily 
understood.
The book is organized into 12 chapters; each 
chapter deals with a different region and 
structure within the cerebral venous system. 
Old and new anatomical concepts are con­
trasted and presented in appropriate places 
throughout the text. Chapter 12 is especially 
interesting; it deals with recently recognized 
tumours of the cerebral dural sinuses and their 
possible association with benign increased in­
tracranial pressure. The finding of 68 such 
lesions gathered from their 950 specimens is 
of special interest.
Most of the illustrations are photographs of 
vinylite casts taken from selected parts of the
sinuses and their tributaries; the quality is 
excellent. The remaining illustrations are in 
the form of schematic drawings; these are 
clear but of only average quality.
This book is highly recommended, especially 
for neurosurgeons; it will also be of value to 
residents, medical students and practising 
physicians in all of the neurologic specialties.
E. Ventureyra
Department of surgery,
Children’s Hospital of Eastern Ontario,
Ottawa, Ont.
COUPES SERIEES DU CORPS HUMAIN. 
Anatomie-radiologie-Scanner. G. Guerinel, 
L. Chevrot et M. Mattel. 287 pp. Illust. 
Masson, Paris, 1977. $108.90. ISBN 2-225- 
46464-2.
11 s’agit d’un atlas presentant les dessins de 
coupes seriees du corps humain obtenues par 
serigraphie (“scanner”) et comparees avec la 
realite anatomique controlee sur cadavre. Voici 
un magnifique volume cree tout specialement 
pour les radiologistes de pointe et pour les 
medecins interesses a ce nouveau moyen d’in- 
vestigation. Dans une premiere partie les au­
teurs font une etude theorique de la tomoden- 
sitometrie (TDM), (computed tomography, CT) 
depuis la prise de I’image jusqu’a sa concre- 
tisation par l’ordinateur, en exposant quelque 
peu les indications de la technique; dans la 
seconde partie de l’ouvrage ils cofnparent en 
couleur et en noir et blanc l’image des coupes 
obtenues par TDM et la realite anatomique 
de la tete, du tronc et des membres.
L’illustration est excellente et la nomencla­
ture est en fran?ais et selon l’appellation in- 
ternationale.
Ce serait le premier volume frangais du 
genre, ce qui temoigne de la clairvoyance de 
ses auteurs.
Bien que le livre soit destine a une clientele 
de radiologistes, il apporte aux anatomistes une 
dimension de variabilite individuelle associee a 
une precision mathematique.
G. Marceau
Faculte de medecine,
Universite Laval,
Quebec, PQ.
CLOT. James J. Tullis. 572 pp. Illust. Charles 
C Thomas, Publisher, Springfield, IL, 1976. 
$39.50.
The subject of blood coagulation is reputedly 
difficult and contentious. The obfuscation in 
some of the current books and review articles
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on the subject has unfortunately helped to 
promote this viewpoint.
This book is well produced; it is of modest 
size and contains excellent, current references. 
Apart from two chapters, the book is written 
by one author.
The first section deals with the physiology 
and biochemistry of coagulation; subsequent 
sections deal with defects of clotting and 
hemostasis and the clinical implications of 
such defects. The author properly gives equal 
emphasis to bleeding disorders and conditions 
associated with hypercoagulability; too fre­
quently, in other books, this information is 
fragmented. He has wisely included only 
limited details of specific technical procedures. 
The controversial areas of theory and practice 
in coagulation have been presented in a bal­
anced manner.
Throughout the book the reader is left with 
the impression that the author is fully aware 
of his subject; he has not merely garnered the 
impressions of other workers. The author’s 
stated intent was to bridge the gap between 
research and practice; he has achieved his 
goal. This book will be useful to residents and 
specialists in either laboratory or clinical medi­
cine. The reading will bring profit and pleasure 
to those who choose to look into it.
T. G. J ones
Department of laboratory medicine,Ottawa Civic Hospital,Ottawa, Ont.
ENDOCRINE SURGERY. A HANDBOOK 
OF OPERATIVE SURGERY. Edward Pa- 
loyan and A. M. Lawrence. 269 pp. Illust. 
Year Book Medical Publishers, Inc., Chica­
go, 1976. Price not stated.
The busy surgeon is in need of a short author­
itative account of endocrine surgery. The ob­
jective of the authors, an endocrine surgeon 
and a medical endocrinologist, was to meet this 
need; they have succeeded.
The book covers the subjects of parathyroid, 
thyroid, pancreatic and adrenal gland surgery. 
The current state of the art in each field is 
clearly and dogmatically presented by two 
workers who are actively engaged in the field. 
In each section the embryology, anatomy and 
physiology are described; this is followed by a 
discussion of the pathology associated with 
specific clinical syndromes, and their medical 
and surgical treatment. There are many clear 
line drawings illustrating anatomical points 
and details of surgical procedures. The careful 
arrangement of the text and illustrations, the
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clear print and the convenient size of the book, 
make it a pleasure to read. In addition, specific 
topics are easily found.
There are no references in the book and only 
a brief summary of controversial points is in­
cluded. Nevertheless, considering the overall 
economy of words, the text is surprisingly 
complete.
Few surgeons have a sufficient volume of 
endocrine surgery to restrict themselves to this 
subspecialty. General surgeons who, from time 
to time, are confronted with these problems, 
will find this book a source of much useful 
information.
H. T. G. Williams
Professor and chairman,
Department of surgery,
University of Alberta,
Edmonton, Alta.
HISTOPATHOLOGIE O.R.L. ET CERVICO-
FACIALE. F. Leroux-Robert et J. de Brux.
390 pp. Illust. Masson, Paris, 1976. $50.71.
ISBN 2-225-45793-X.
Dans l’avant-propos, les auteurs attirent l’atten- 
tion sur l’importance de la clinique dans l’in- 
terpretation histopathologique d’une lesion. II 
s’ensuit que chaque pathologie est accompa- 
gnee d’une partie clinique, dans laquelle nous 
trouvons frequemment un rappel embryologi- 
que; puis, l’histopathologie nous est expliquee. 
Les pathologies les plus courantes et, quelques 
fois meme les plus rares, y sont discutees et 
illustrees de photos histologiques. Comme les 
auteurs le mentionnent, les references les plus 
importantes y sont rapportees; leur choix dans 
l’ensemble m’apparait juste.
Les discussions cliniques sont interessantes 
pour l’anatomopathologiste, mais la pathologie 
y est souvent trop courte; il est probable aussi 
que le chirurgien prefererait y trouver plus de 
details cliniques. Les microphotographies a 
petit grossissement sont de mauvaise qualite; 
la majeure partie des photos sont cependant a 
moyen et fort grossissement et de bonne qua­
lite. II n’existe pas suffisamment de macropho­
tographies ou de photographies cliniques; le 
detail clinique ayant sa place dans le livre, il 
me semble que certaines microphotographies 
auraient dues etre sacrifices.
Dans l’ensemble, il s’agit d’un livre honnete 
et agreable a lire; le tout resulte probablement 
d’un habile dosage de clinique d’histopatholo- 
gie. Le livre se veut l’experience de deux 
pcrsonnes et les discussions apparaissent done 
plus comme le resultat de l’experience que 
comme une revue de la litterature. Le livre
nous apparalt surtout oriente vers le clinicien 
qui aimerait revoir son histopathologie.
G . P. D io n n e
Pathologiste,
National Defence Medical Centre,
Ottawa, Ont.
LE TRAITEMENT DES METASTASES OS- 
SEUSES. Rapport Presente au 78e Congres 
Frangais de Chirurgie. Edited by J. Duparc 
and J. Decoulx. 274 pp. Illust. Masson, Pa­
ris, 1976. Price not stated, paperbonnd. IS­
BN 2-225-45529-5.
Most publications on cancer deal with the treat­
ment of primary malignant neoplasms. But the 
management of patients with metastases re­
mains the most common problem facing the 
practising physician. Bone metastases are dis­
abling; they are the source of the most severe 
pain, they compromise integrity of the skeletal 
system resulting in serious loss of function 
and are often responsible for neurologic com­
plications that arise when vertebral metastases 
impinge on the cord.
This book is oriented to surgeons. It sup­
ports and emphasizes the need for a more posi­
tive and enterprising approach to the treatment 
of bone metastases since far too often a pessi­
mistic attitude prevails in relation to the sur­
gical treatment of such metastases. One impor­
tant chapter deals with vertebral metastases; 
both operative and nonoperative management 
are discussed, for the most part from the sur­
geon’s viewpoint.
The first few chapters deal with oncologic 
generalities as they relate to bone involvement. 
Diagnosis and nonsurgical treatment are well 
summarized and presented in an informative 
but not exhaustive manner. The most important 
part of the book describes the different forms 
of surgical treatment with details on the new 
advances of cement fixation and prosthetic re­
placements. It is interesting to read about the 
attempt to standardize prosthetic hardware re­
placements. In this type of surgery many dif­
ferent types and sizes of prostheses are neces­
sary. Often they must be custom made and it 
is unrealistic to expect most general hospitals 
to store them.
The authors describe the various surgical 
techniques required to deal with bone meta­
stases in various locations. The reader is re­
ferred to an excellent bibliography for accu­
rate details of the technique. The authors have 
summarized the clinical results from several 
centres and the advice in every chapter is 
substantiated in this way.
This book is an excellent reminder that in
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medicine, it is as important to improve the 
quality of life as to prolong it.
A. T rias
Department of orthopedic surgery,
University of Sherbrooke,
Sherbrooke, PQ.
LA HANCHE EN CROISSANCE. Jean Ga­
briel Pous, Alain Dimeglio, Jose Adrey and 
others. 216 pp. Illust. J. B. Bailliere, Paris, 
1976. $30.00. ISBN 2-7008-0009-5.
“The growing hip” is a basic textbook on or­
thopedic problems of the hip in children; it is 
designed for specialists including the ortho­
pedic surgeon, pediatrician, physiatrist and 
physiotherapist who are confronted with these 
problems.
After a short introduction, the growth of the 
hip is described from its embryology to com­
plete maturation. In the following sections the 
authors describe congenital, developmental and 
traumatic conditions. The final chapter illus­
trates surgical techniques currently employed 
in the management of orthopedic problems in 
children.
This book fulfils its aim as an excellent 
teaching text. The problems are discussed 
clearly and completely; the discussion is up to 
date. The authors include most current tech­
niques and methods —  not only ones they 
favour. Chapters are well introduced; impor­
tant points are emphasized in heavier print, 
in order to draw the attention of the reader. 
Sketches and radiographs are plentiful and are 
of excellent quality.
This book is an important contribution to 
the field of disorders in the growing hip; it 
is highly recommended to those working in 
this area.
R. Gallien
La Clinique de Chirurgie Orthopedique 
du Qu6bec,
220 est, Grande-Allee,
Quebec, PQ.
LA MALADIE DE CROHN RECTO-COLI- 
QUE. M. Julien et J. Vignal. 141 pp. Illust. 
Masson, Paris, 1976. $12.83, broche. ISBN 
2-225-45210-5.
Cette monographie est une etude anatomo- 
clinique retrospective de 192 dossiers de ma- 
lades presentant une maladie de Crohn recto- 
colique, traites dans differents hopitaux fran- 
gais. Les diagnostics histologiques et topogra- 
phiques ont tous ete verifies. Le traitement 
de tous ces malades fut chirurgical. Les dif-
ferentes donnees furent analysees sur ordina- 
teur.
Les grands chapitres comportent une etude 
pathologique, epidemiologique, clinique radio- 
logique, endoscopique, therapeutique et pro- 
nostique de la maladie. Les complications, 
particulierement les complications ano-rectales 
et le diagnostic differentiel font l’objet de cha­
pitres particuliers. Toutes les donnees ainsi 
recueillies sont comparees a celles de grandes 
series publiees dans la litterature anglo-saxonne 
et scandinave. La bibliographic est d’ailleurs 
tres abondante. Certains points particuliers 
demandent quelques remarques. Les auteurs 
affirment la place preponderante de la patho- 
logie dans le diagnostic. Ils ne se prononcent 
pas sur l’existence de colites granulomateuses 
differentes de la maladie de Crohn et de la 
colite ulcereuse. L ’examen macroscopique per- 
operatoire aurait plus de valeur que l’histologie 
des tranches de section pour determiner 
l’extension de la resection. Les auteurs preco- 
nisent la conservation du rectum le plus pos­
sible. Leurs resultats therapeutiques apres chi­
rurgie sont difficilement comparables, a cause 
du jeu de recul. Finalement, ils insistent, avec 
raison sur la valeur de l’hyperalimentation 
parenterale comme nouvelle therapie adju- 
vante.
Le volume comporte de plus, de bonnes 
reproductions de cliches radiologiques, des 
photos de pieces pathologiques et histologi­
ques et de nombreux tableaux. II s’agit done 
d’un resume des travaux presentes au 78e 
congres frangais de chirurgie. Ces resumes sont 
plus complets que ceux que l’on publie avant 
les congres des associations nord-americaines. 
Cependant, l’ouvrage n’a de valeur que comme 
etude prealable a 1’assistance a ce congres.
R. Cote
Hopital du St. Sacrement,
1050 Chemin Ste-Foy,
Quebec, PQ.
THE IMMUNOLOGY OF MALIGNANT
DISEASE. 2nd ed. Jules E. Harris and Jo­
seph G. Sinkovics. 606 pp. Illust. The C. Y.
Mosby Company, Saint Louis, 1976. $45.90.
This book fulfils two roles: first, it presents a 
comprehensive review of the latest advances in 
the area of immuno-oncology and second, it 
provides an excellent source (more than 5600) 
of pertinent references. The complex subject 
matter is dealt with in depth, but it is clearly 
presented. The book is not concise and is not 
recommended for bedtime reading. It demands 
the reader’s complete attention. But it is an
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excellent reference textbook and, as such, 
should have broad appeal.
The book is divided into five chapters; each 
leads logically to the next. The first chapter is 
devoted to a review of the current state of hu­
moral and cellular immunology and the role 
that T and B cells play in the regulation, mod­
ulation, suppression and enhancement of the 
humoral and cell-mediated immune responses. 
I imagine that the authors felt compelled to in­
troduce the reader to the entire breadth of im­
munology before leading him or her into the 
more forbidding and less understood areas of 
clinical and immuno-oncology. Although to­
day it is not possible to cover the whole field 
of immunology in a single chapter, the authors 
have, with some success, attempted to do this. 
An immunologist would have no trouble fol­
lowing the sequence of topics and train of 
thought developed in this chapter. However, 
nonimmunologists may find it rather heavy 
reading.
Chapter 2 deals at length with the immuno­
logy and tumours in experimental animals. The 
data are presented in great detail and the casual 
reader may at times feel lost. Certain basic 
concepts, such as immunologic surveillance, 
are discussed here and in several other chap­
ters. It would seem reasonable to repeat im­
portant concepts as they apply to a variety of 
topics.
Chapters 3 and 4 deal with the immune de­
ficiency states associated with malignant dis­
eases and the methods used to suppress the 
immune response. The immune states are dis­
cussed in great depth. Special emphasis is 
placed on the subjects of Hodgkin’s disease, 
the leukemias and multiple myeloma. Parts of 
chapter 4 deal with the chemical suppression 
of the immune response in patients undergoing 
organ transplantation and the immunosup­
pressive therapy for autoimmune diseases; these 
subjects might, at first glance, appear to be 
out of place in this book. However, several of 
the chemotherapeutic drugs used in the treat­
ment of allografted patients and patients with 
autoimmune diseases are identical to those 
used in patients with malignant disease. I sus­
pect that these subjects were included to em­
phasize this fact.
The fifth and final chapter of the book con­
sists of a systematic presentation of the various 
human malignant diseases, their etiology, patho­
genesis and clinical picture and the role of 
immunotherapy in modifying the natural 
course of these diseases.
I have two minor reservations about this 
book. First, the authors have not included 
enough of their own subjective but expert
analysis of the data and second, the bibliogra­
phies appended to each chapter, while com­
prehensive, are too long. The majority of read­
ers who are less familiar with the field would 
appreciate a short list of important references 
at the end of each chapter.
In summary, Harris and Sinkovics have tried 
to condense all of contemporary immunology 
and present it in a form comprehensible to 
clinical oncologists. They have included in their 
discussions the role of viruses in oncogenesis 
and the evidence in favour of immunotherapy 
as a form of treatment. This book should be on 
the highly recommended reading lists of all 
clinical oncologists and basic scientists work­
ing in the field. Unfortunately the price of this 
book may deter medical students and residents 
from purchasing it; the prevailing attitude is 
that the half-life of any medical textbook is 
shorter than the time required to read it.
The reader should not expect to wade 
through this book in short order. However, 
the rewards in terms of information gleaned 
from it are directly related to the effort put 
into reading it. I believe that the book will 
serve as a primary standard reference book for 
a good number of years.
M. Richter
Department of pathology,
Ottawa Civic Hospital,
Ottawa, Ont.
MOTOR DISORDERS OF THE ESOPHA­
GUS. Robert D. Henderson and John O.
Godden. 231 pp. Illust. The Williams & Wil­
kins Company, Baltimore; Burns and Mac-
Eachern Limited, Don Mills, Ont., 1976.
$24.75. ISBN 0-683-03947-4.
With the development of modern manometric 
techniques much new information on normal 
and abnormal esophageal function has accu­
mulated in the medical literature. This mono­
graph is a timely presentation of this knowledge 
and its application to clinical practice. After a 
brief review of the structure and function of 
the esophagus, the authors describe the ap­
proach to investigation and management of 
common motor disorders.
The presentation is well balanced including 
sections on hiatus hernia and achalasia that 
take up more than half the text. The informa­
tion is well classified and is easily read. Case 
histories are used frequently to illustrate im­
portant points and a large number of good- 
quality radiographs and sketches are used to 
correlate structure and function. Although 
much of the material is from Henderson’s own 
data (both published and unpublished), an ade-
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quate review of the literature and an accom­
panying bibliography are presented with each 
chapter. On the various controversial issues 
Henderson clearly states his personal prefer­
ences.
There are some minor criticisms. In attempt­
ing to develop an orderly concept of patho­
physiology the issues have sometimes been 
oversimplified. In chapter 2, for example, sec­
ondary and tertiary peristaltic activity of the 
normal variety is confused with that associated 
with disordered motor activity. Cinefluorogra- 
phy, generally regarded as an important diag­
nostic tool, is mentioned only briefly. Undue 
emphasis is placed on the role of the abdominal 
segment of esophagus in preventing reflux. The 
authors believe that a long intra-abdominal 
tube prevents reflux in the absence of a lower 
esophageal sphincter; this view is contradicted 
by the available data and is certainly not shared 
by workers in the field.
On the whole, in attempting to describe a 
rational approach to the investigation and 
management of esophageal problems, the auth­
ors have achieved their objective. Anyone in­
terested in esophageal disease will find the 
book both interesting and useful.
T. A. K han
Assistant professor of surgery,
University of Manitoba,
Winnipeg, Man.
CRITIQUE OF ITEM 609 (SESAP II)
The roentgenogram is typical of osteogenic 
sarcoma. There has been a great effort to 
improve the survival rate of patients with 
osteogenic sarcoma by using various forms 
of irradiation and chemotherapy alone or 
in combination with a variety of surgical 
procedures. No such methods or combina­
tion of methods have proven to be as suc­
cessful as radical surgical ablation, such as, 
in this case, hip disarticulation in order to 
remove the entire femur. Hemipelvectomy 
offers no advantage over hip disarticulation 
but does add significantly to operative risk 
and complications. pB]
Reference
609/1 . Friedman MA, Carter SK; The the­
rapy of osteogenic sarcoma: Current status 
and thoughts for the future. J Surg Oncol 
4:482-510, 1972.
OUTLINE OF ORTHOPAEDICS. 8th ed. 
John Crawford Adams. 472 pp. Illust. 
Churchill Livingstone, Edinburgh; Longman 
Canada Limited, Don Mills, 1976. $13.50, 
paperbound. ISBN 0-443-01167-2.
This book is a classic in the field of medical 
summaries. It is another text in the tradition 
set by Bailey’s “Short Practice of Surgery” 
that so many of us relied on in the anxious 
days before the final examinations. Unfortu­
nately the subject of fractures is not included, 
but a companion volume by the same author 
entitled “Outline of Fractures” is available.
The subject of orthopedics is developed from 
a historical introduction. The language is clear 
but not clipped; it is interesting but brief. 
Simple diagrams are used to explain the patho­
genesis of conditions such as osteomyelitis. 
Diagrammatic presentations, line drawings and 
radiographs are used effectively to explain, 
in a step-wise fashion, subjects that other­
wise would be complicated for the novice. 
Normal and abnormal radiographs are pub­
lished side by side to illustrate the lesion under 
consideration. Subheadings are in bold type 
and less important information is presented 
in small print. References and the bibliogra­
phy are appropriately left to the end of the 
book.
Vacation Rental
H A W A I I  B E A C H  
C O T T A G E
•  The blue of the Pacific
•  Scent of Polynesian 
blossoms
•  Whisper of the coconut 
palms
•  Oahu
•  Sleeps four
•  Tennis
•  Beach - Swimming Pool
$320 —  (U.S.) per week, 
plus tax
C O N D O M I N I U M  
P.O. Box 129 - a, 
Pleasantville, N.Y. 10570 
U.S.A.
576 THE CANADIAN JOURNAL OF SURGERY Vol. 20
IN DEX TO ADVERTISERS
ABBOTT LABORATORIES
Ensure ............................ 484, 485
AYERST LABORATORIES
Hibitone .................................  482
Injectables .............................. 552
BOEHRINGER INGELHEIM (CANADA) LTD.
Trasylol ..........................  528, 529
C A L M IC  LTD.
Polybactrin ......................  540, 541
DAV IS & GECK
Dexon ..............  Outside Back Cover
Surgilon .................................  488
ETHICON SUTURES LTD.
Prolene ..............  Inside Front Cover
Vicryl ........... 492, Inside Back Cover
HOLLISTER LIM ITED
Draining Wound Management
System ................................... 509
SW A N N -M O RTO N  LIM ITED 563
SEARLE C O M PA N Y  OF CANADA, G. D.
Metamucil ....................... 550, 551
W IN TH RO P LABORATORIES
This text is accurate, clear and to the point. 
It will continue to be of special value to the 
medical student and to those who are un­
familiar with the field of orthopedics.
E. M. Cooperman
Books Received
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